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3ABSTRACT
PP2A is a major serine/threonine phosphatase in eukaryotic cells which
dephosphorylates many of the proteins involved in signal transduction. Alterations in
PP2A activity have been implicated in a number of diseases including cancer, which has
led to the suggestion that PP2A is a tumor suppressor. PP2A exists in a number of
holoenzyme forms. The core dimer (PP2AD) consists of a structural (PR65) and a
catalytic (PP2Ac) subunit, and can be associated with one of several regulatory B
polypeptides (B, B', B'' and B'''). Interaction with these B subunits probably controls
both the subcellular location and substrate specificity of the phosphatase activity. The
ST antigen of SV40, and ST and MT antigen of the polyoma tumour virus interact with
the PP2A dimer, competing with the B subunits for binding. This interaction has been
shown to be required for the full transforming actions of each virus. In addition to the
trimeric nature of the holoenzyme, it now clear that many more proteins interact with
individual subunits of the PP2A complex, influencing its regulation and activity.
Consequently, to understand how viruses affect the regulation and diverse functions of
PP2A, it is important to study not only its trimeric state, but also its complex
composition. To achieve this, a series of monoclonal antibodies have been generated
against the structural subunit of PP2A and two of the regulatory subunits. The
characterisation of these antibodies and their use in studying PP2A associated proteins
are described in this thesis. In a complementary approach, a novel TAP tagged PR65
subunit has been constructed and used to isolate proteins interacting with PP2A.
Associated proteins have been indentified by MS approaches. Interestingly, the
deubiquitinating enzyme, USP28, has been shown to interact with PP2AD, in
4immunoprecipitation experiments. This association appears to affect the ubiquitin status
of PP2A.
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6ABBREVIATIONS
AKT β-analyl-α-ketagluterate transaminase
AD Alzheimer’s Disease
AMPK AMP-activated protein kinase
APS Ammonium Persulphate
ATP Adenosine Triphosphate
Bcl-2 Integral membrane protein
BGG Bovine gamma globulin
BMCH1 BM-Condimed Hybridoma Cloning Supplement
BRET Bioluminescence resonance energy transfer
BSA Bovine Serum Albumin
CAK Cdc activating kinase
CBP Calmodulin binding peptide
cdc Cell division cycle protein
CDK Cyclin dependent kinase
CF Cystic Fibrosis
CFTR CF transmembrane conductance regulator
CIP2A Cancerous Inhibitor of PP2A
DMSO Dimethyl Sulfoxide
DMEM Dulbecco’s Modified Eagle Medium
dNTP Deoxynucleotide Triphosphate
Dsh/Dvl Dishevelled
DTT Dithiothreitol
DUB Deubiquitinating enzyme
E. coli Escherchia coli
EDTA Ethylenediaminetetraacetic Acid
EF3 Elongation factor 3
ERK Extracellular – regulated kinase
FBS Foetal Bovine Serum
Fz Frizzled
GANP Germinal centre-associated nuclear protein
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GRB2 Growth-factor-receptor-bound protein 2
HAZ Hypoxanthine Azaserine
HEAT Huntington, EF3, A subunit of PP2A, TOR1
HRP Horseradish peroxidase
Hsp72 Heat-Shock related 70 kDa protein 2
Hsp90 Heat shock protein 90
IF Immunofluorescence
IG Immunoglobulin
IMAC Immobolised Metal Affinity Chromatography
IP Immunoprecipitation experiments
IPTG Isopropyl β-D-1-Thiogalactopyranoside
JNK c-Jun NH2-terminal kinase
kDa Kilodalton
Leu Leucine
7LRP Low-density-lipoprotein-related protein
LT Large T Antigen
Q-ToF Quadruple Time of Flight
mAb Monoclonal antibodies
MAPK Mitogen-activated protein kinase
MEK1,2 Mitogen-activated protein kinase kinases
MS Mass Spectroscopy
MT Middle T Antigen
NFT Neurofibillary tangles
NP40 Nonylphenyl Polyethylene Glycol
OA Okadaic acid
OPI Oxaloacetate, Pyruvate and bovine Insulin
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PCR Polymerase chain reactions
PIP2 Phosphatidylinositol phosphatase 2
PI3K Phosphatidylinositol 3-kinase
PK Protein kinase
PLCγ1 Phospholipase Cγ-1
PPs Protein phosphatases
PP2A Protein Phosphatase type 2A
PP2Ac 35 kDa catalytic subunit of PP2A
PP2AD Dimer of PP2A
ProtA Staphylococcus aureus protein A
PR65 Structural/scaffolding subunit of PP2A
PTPA Phosphotyrosyl phosphatase activator of PP2A
PyV Mouse polyoma virus
Ras Rat sarcoma (signalling molecule in MAPK pathway)
Rb Retinoblastoma protein
RISC RNA-induced silencing complex
RNAi RNA interference
R2 Rat2 fibroblasts
SAPK Stress activated protein kinase
SCA12 Spinocerebeller ataxias 12,
SDS Sodium Dodecyl Sulfate
SG2NA Striatin and S/G2 nuclear autoantigen
Ser Serine
SHCA SRC-homology 2 (SH2) domain- containing transforming protein A
ShRNA Small hairpin RNA
siRNA Short interfering RNAs
SMPR65 Strep III- myc PR65 human tag
SMPR65r Strep III- myc PR65 rat tag
ST Small T antigen
Src Member of the sarcoma family kinase
SV40 Simian Vacuolating Virus 40
TAP Tandem affinity purification
Tap42 Two A phosphatase-associated protein
8TCF Tissue culture fluid
tEF1α Translation elongation factor 1-alpha
TGF-β Transforming growth factor beta
Thr Threonine
TOR Rapamycin-sensitive signalling pathway
Tyr Tyrosine
USP28 Ubiquitin specific protease
UV Ultra-Violet
v/v Volume/volume
WEE1 Nuclear kinase that inhibits cdc2
w/v Weight/volume
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CHAPTER 1. INTRODUCTION
1.1 Reversible Phosphorylation
Phosphorylation is a post-translational modification used to alter the activities of
regulatory proteins fundamental for normal cell growth, survival and death [1].
About a third of total eukaryotic proteins are regulated by phosphorylation [2]. This
post-translational modification is reversible, as proteins are controlled by the
opposing actions of protein kinases and protein phosphatases (Figure 1.1.).
Figure 1.1. Reversible Protein Phosphorylation.
An essential regulatory mechanism in many cellular processes, involving the
opposing actions of the protein kinases and protein phosphatases.
P=Phosphate group
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Protein phosphorylation plays a vital role in regulating many cellular processes, and
phosphorylation of a protein can change its function. Disruption in this controlled
action affects cell growth and cell death and has therefore been implicated in many
diseases such as cancer and Alzheimer’s disease [1, 3-6]. Studies into these precise
activities are required to reveal potential targets for therapeutic agents in the
treatment of human diseases.
Initially much of the research was undertaken on protein kinase (PK) regulation and
substrates, rather than the protein phosphatases (PPs). This is probably explained by
the fact that the kinases were the first to be discovered, due to the large number of
PK  genes  present  in  the  eukaryotic  genome.  It  is  now  apparent,  however,  that  the
number  of  assembled  functional  PP  complexes  are  similar  to  the  number  of
expressed PKs, and are of equal importance in determining the overall occupancy of
a phosphorylated site. At the very least, the level of phosphatase activity directed
towards a specific phosphorylation site determines the degree of kinase activation
required to produce an increase in the overall phosphorylation state of a site.
The phosphorylation of proteins can occur on several amino acids. Serine residues
are the most common site, followed by threonine. Tyrosine phosphorylated sites are
relatively rare, but easy to purify using antibodies, and therefore the few
phosphotyrosine sites are well defined [5]. The serine/threonine specific protein
phosphatases show a broad overlap in substrate specificity in vitro and probably
account for dephosphorylation of all known cytosolic or nuclear substrates
phosphorylated by the corresponding protein kinases [7]. This group of protein
phosphatases can be divided into different classes categorised by their sequence
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homology and biochemical properties; the PP1-like, PP2A-like, PP5 and PP7
families (reviewed in [8]). All of these are structurally related and have a similar
catalytic mechanism. PP4, PP6, PP2A, PP2B and PP2C phosphatases can be grouped
in the PP2A-like family due to the very high similarity within their subunits [9]. The
discovery of many phosphatase inhibitors, which can penetrate living cells,
facilitated the study of serine/threonine phosphatases [10]. The most widely used has
been Okadaic acid (OA), a non competitive inhibitor of PP2A, PP1, PP4 and PP5.
Treatment  of  the  cells  with  OA  causes  the  phosphorylation  of  many  proteins,  and
induces diverse cellular processes as a consequence of inhibiting the phosphatases.
Other toxins such as calyculin A, tautomycin, dinophysistoxin, nodularin and
microcystin have also been described to inhibit protein phosphatases but with
varying potencies [11].
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1.2 The structure of PP2A
1.2.1 General overview
Protein Phosphatase type 2A (PP2A) is a major serine/threonine phosphatase in
eukaryotic cells and is involved in regulating many processes including the cell cycle,
apoptosis, transcription, translation, replication and signaling pathways (reviewed in
[4]).  PP2A  exists  as  a  number  of  holoenzyme  forms;  the  core  enzyme  is  a  dimer
(PP2AD) consisting of a structural/scaffolding subunit (PR65) of 65kDa and a 35kDa
catalytic subunit (PP2Ac). A third regulatory B subunit can be associated with the
core enzyme to form the holoenzyme [6, 12]. The presence of PP2AD in vivo was an
area of uncertainty for a number of years because some researchers believed its
presence was due to degradation and dissociation of the B subunits during PP2A
purification [13]. The dimer has since been shown to represent at least one-third of
the total PP2A present in the cell [14].
Molecular  cloning  showed  two  distinct  mRNAs  (α and  β)  encoding  PR65  with  an
87% amino acid sequence identity [15]. In addition, two isoforms of the PP2Ac
subunit have been identified (α and β), which have a 97% identity to each other. As
with PR65 both isoforms of PP2Ac are ubiquitously expressed; however, PP2Acα is
ten times more abundant than PP2Acβ due to transcriptional regulation [16-18].
There  have  been  four  B  subunit  families  identified:  B,  B’,  B’’  and  B’’’,  all  with
multiple isoforms (Figure 1.2.). In theory, the combination of all the known subunits
could produce more than 80 different holoenzymes which potentially may spatially
and functionally target PP2A to diverse cellular processes at different cellular
locations [19].
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Figure 1.2. PP2A holoenzyme composition.
The structural or scaffolding A subunit (PR65) and the catalytic C subunit (PP2Ac),
both  of  which  exist  in  two  isoforms  α-  and  β-  are  known  as  the  core  dimer.  This
associates with one of the regulatory B subunit families (B, B’, B’’ and B’’’) to form
the holoenzyme.
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1.2.2 PR65
PR65  exists  in  two  forms,  α and  β,  and  although  these  share  86%  homology  they
display quite unique functions. For example, in early Xenopus development, a switch
from PR65β to PR65α expression is observed, suggesting these isoforms are
involved in developmental programmes [20]. A 12 amino acid extension is present
on PR65β which is probably required for a specific function [21], potentially
involving RalA, a small GTPase that binds PR65β but not PR65α [22]. In addition,
PR65β demonstrates remarkably weaker binding capabilities to the regulatory B
subunits and PP2Ac than PR65α; and PR65β does not appear to associate with
PR55α, PR61α and PR61β at all [23, 24].
The deduced protein sequences of the α- and β- isotypes of PR65 are made up of 15
imperfect  repeating  units  of  39  amino  acids  [15].  A  similar  sequence  was  also
observed in a protein related to Huntington’s disease, elongation factor 3 (EF3) and a
lipid kinase, TOR1, which has lead to the tandem array of sequences being named
HEAT (Huntington, EF3,  A subunit of PP2A, TOR1) repeats or motifs [25].  This
structure has now been found in a variety of other proteins and is conserved between
species [15, 25, 26]. These HEAT repeats display a common structure; the repeats
occur in tandem, multiple times and a specific pattern of hydrophobic and
hydrophilic amino acids with a weak consensus sequence is present. Each sequence
repeat contains a pair of anti-parallel helices (A and B), which are tilted relative to
one another by ~15°, about an axis parallel to the helical axis. This forms the outer
(A), and inner (B) face. Most of the helices are kinked by up to 45° around the
middle of the structure and the hydrophobic residues are positioned to create a
hydrophobic core [27]. The 15 HEAT repeats in PR65 assemble to form an extended
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curved structure that consists entirely of tightly packed helices and connecting loops,
giving rise to an asymmetric hook shape (C- shape) [26]. The intrarepeat turns are
aligned to form a continuous ridge that provides a platform for mediating protein-
protein interactions between PR65, PP2Ac and one of the regulatory B subunits.
Binding of the B subunits to PP2AD is  mutually  exclusive  and  occurs  mainly  via
PR65 [28, 29].
The structure of PP2A co-crystallized with two of its inhibitors, OA and microcystin
[30] (Figure 1.3.), and a PP2A trimer containing one of the B’ subunits (PR61γ) [31,
32], have been solved to reveal important structural insights into PP2A holoenzyme
assembly. PR65 appears to be very flexible and a substantial conformational switch
from a hook shape to a more closed horseshoe shape is observed when PP2Ac and
PR61γ are associated (Figure 1.4.). This conformational change appears between
HEAT motifs 11-15, in particular between HEAT motifs 11 and 12, and 12 and 13
[30].
Mutations that disrupt the ability of PR65β to form holoenzymes have been detected
in several types of cancer, including 15% of primary lung and colon tumor-derived
cell lines [21], and the loss of function of PR65β has been shown to contribute to
cellular transformation [22]. More recently mutations have been discovered in
PR65α genes in human melanomas and breast and lung carcinomas [33]. These
cancer associated PR65 mutants are often compromised in their binding to PP2Ac
and  the  regulatory  B  subunits,  disrupting  the  overall  structure  of  the  PP2A
holoenzyme and hence altering PP2A’s activity.
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Scaffolding A subunit
Regulatory B subunit
Catalytic C Subunit
Figure 1.3. Crystal Structure of PP2A in complex with the toxin Microcystin.
Scaffolding A (PR65α) subunit is shown in green, the catalytic C (PP2Acα) subunit
in blue and the regulatory PR61γ1 subunit in yellow can be seen to interact with both
the PP2Acα and PR65α subunit. The structure of PR61γ1 is similar to that of PR65α
containing alpha helices and HEAT repeats although there is no homology in their
sequences [34]. Microcystin is shown in purple.
Figure 1.4. Structure of PR65.
PR65 subunit alone (grey), compared with PR65 in the trimeric complex (blue). In a
complex PR65 forms a more closed structure. This conformational change appears
between HEAT motifs 11-15, in particular between HEAT motifs 11 and 12, and 12
and 13 [31].
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1.2.3 The catalytic subunit: PP2Ac
Molecular cloning revealed PP2Ac to be highly conserved during evolution; the
sequences of yeast and human share an 86% identity [35]. All known PP2Ac
sequences have TPDYFL at the C-terminus, and even PP4c and PP6c terminate with
YFL sequence [36]. Therefore, it is not surprising that post translation modifications
occur at the C-terminal tail of PP2Ac, regulating this protein (see section 1.3.2). In
mammals  there  exists  two  isoforms  of  PP2Ac,  α and  β [17,  37,  38],  which  are
ubiquitously expressed with very high expression levels in the heart and brain [16].
Despite the 97% homology between the α and β isoforms, PP2Acα knockout mice
are embryonically lethal [39], indicating PP2Acβ can not compensate for the loss of
PP2Acα. This lack of redundancy suggests PP2Acα and PP2Acβ have distinct
functions [40], further supported by the finding that the two isoforms have different
subcellular localisations during development [41]; PP2Acβ was localised to the
cytoplasm and nucleus whereas PP2Acα is present mainly at the plasma membrane.
1.2.4 The regulatory B Subunits
The four families of B subunits termed the B/PR55, B’/PR61, B’’/PR72 and B’’’
families show little sequence similarity, except for two PR65 subunit binding motifs
involved in the interaction with PR65 HEAT repeats 1-10 [42]. The B/PR55 family
is encoded by four genes, termed α, β, γ and δ, [43] and splice variants of PR55β
have been identified [44]. PR55α and PR55δ are 89% similar and show widespread
expression in tissues, whereas the PR55β and PR55γ isoforms are highly enriched in
the brain [44]. A role for PR55β has been implicated in a neurodegenerative disorder
known as autosomal dominant spinocerebeller ataxias 12 (SCA12), due to an
expanded CAG repeat immediately upstream of this gene affecting PR55β
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expression [45, 46]. PR55α and δ, appears to be involved in targeting PP2A to the
cytosolic compartment, PR55β to the nucleus and PR55γ to the cytoskeleton,
illustrating how B subunits can confer varying subcellular localisation, of the PP2A
holoenzyme [47]. An interesting feature of the PR55 family is the presence of five
degenerate WD-40 (tryptophan-aspartic acid) repeats, a conserved sequence of
approximately 40 amino acids, thought to mediate protein-protein interactions [48].
The WD-40 repeats in the PR55α and PR55β subunits have been shown to interact
with the cytoplasmic domain of type I and type II TGF-β receptors [49], linking
PP2A to the functional regulation of members of the TGF-β family.
The most diverse B subunit family is the B’ group, also known as PR61 (B56) [19,
50]. Genes PPP2R5A-PPP2R5E encode subunit variants PR61α, β, γ, δ and ε, and
have been mapped to human chromosome regions 1q41, 11q12, 3p21, 6p21.1 and
7p11.2 à p12 respectively by fluorescence in situ hybridization [51]. As displayed
in Figure 1.5., the PR61 isoforms are highly homologous. The central region shows
more than 90% similarity between the different isoforms, whereas the N- and C-
termini diverge. This has led to the idea that it is the ends of the molecule that are
important for substrate interactions and subcellular localisation and the core domain
responsible for binding PP2Ac and PR65 [42, 52]. Several of the PR61 isoforms
contain a bipartite nuclear localisation signal in their C-terminus, suggesting these
subunits are located in the nucleus and target PP2A to nuclear substrates [19, 53].
Northern Blot analysis has revealed PR61α to be most prevalent in heart and skeletal
muscle, PR61β in the brain and PR61δ in the brain, embryo and ovary. Two isoforms
of PR61ε have been revealed with a high expression in the brain, embryo, ovary and
thymus. PR61δ and PR61ε also have a high tissue expression in 14-day old embryos,
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indicating a role in embryonic development [51]. Isolation of human and rabbit
cDNA clones have identified three different spliced transcripts from the PR61γ gene,
with two further variants predicted. γ1 is highly expressed in the thymus, spleen and
ovary, and γ2 and 3 transcripts are highly expressed in the thymus and ovary [51, 54]
(Table 1.1). PR61α containing PP2A complexes are involved in c-myc turnover, by
dephosphorylating ser-61 of this proto-oncogene and promoting degradation of it. c-
myc is  upregulated  in  many  human  cancers  [55],  which  implicates  PR61α as  a
tumour suppressor. In addition, PR61 isoforms have a role in Wnt Signalling (see
section 1.4.4).
Probably the least understood regulatory B subunits are those of the B’’ (PR72)
family. The diversity of this family arises from specific tissue distribution,
developmental expression and subcellular localisation [56]. A PP2A holoenzyme
containing PR72 was first purified from rabbit skeletal muscle [57] and the PR130
protein  was  isolated  from  a  human  heart  cDNA  library.  Six  isoforms  of  the  B’’
family have now been identified in mammals: PR72, PR130, mPR59, G5PR and two
PR48 variants, PR70 and PPP2R3L product. All of these have been shown to have
important roles in regulating the G1/S transition of the cell cycle and DNA
replication initiation at S phase. PR72 and PR130 share C-terminal sequence
similarity, as they arise from the same gene by alternative splicing [58]. High levels
of the 72kDa protein are expressed in the heart and muscle, whereas the 130kDa
protein is more ubiquitously expressed [58]. This family characteristically contains
two functional, conserved Ca2+ binding EF- hand motifs (termed EF1 and EF2) [59].
Proteins containing this Ca2+–binding helix-loop-helix motif could change their
conformation upon Ca2+ binding, possibly altering their ability to interact with
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secondary proteins. By a combination of experiments including mammalian double
hybrids and pull down assays, Ca2+ binding to one of the EF motifs in these subunits
can influence the assembly of PP2A holoenzyme and its catalytic activity [59, 60]. It
has also been shown that Ca2+ interaction with the EF1 motif regulates the ability of
PR72 to induce G1/S phase arrest [59]. PR72 and mPR59 share 65% sequence
similarity, but their expression patterns and functional properties differ [61]. mPR59
is a mouse specific B’’ subunit that was identified by its association with the
retinoblastoma (Rb) related protein, p107 [61]. Over expression of mPR59
dephosphorylates p107 causing cells to accumulate in G1, inhibiting progression
through the cell cycle. Identification of PR48 by a yeast two-hybrid screen approach
using cdc6, led to the suggestion of a role for PP2A in DNA replication initiation.
Cdc6, an essential protein in the formation of the pre-initiation complex required for
DNA replication, binds PR48 specifically and forms functional complexes with
PP2A, resulting in cdc6 dephosphorylation. This results in G1 arrest [62]. PR70 has
also been shown to be involved in cell cycle progression, due to an association with
cdc6 [63] and pRb [64]. The other PR48 isoform, PPP2R3L, is mainly expressed in
the heart and skeletal muscle, but its functional role remains unknown [65]. The
G5PR isoform was identified by yeast-two hybrid screening, and is a germinal
centre-associated nuclear protein (GANP). G5PR containing complexes exert a
phosphatase activity on proteins and enzymes involved in DNA replication [66].
More  recently  a  new  family  of  regulatory  B  subunits  has  been  identified,  B’’’,
consisting of two proteins containing a similar WD-40 repeat sequence homologous
to the B family. These subunits have been termed Striatin and S/G2 nuclear
autoantigen (SG2NA), (PR110 and PR93 respectively). PR110 and PR93 bind to
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PP2A in the absence of the regulatory subunits from the B, B’ and B’’ families and
can act as substrates for PP2A. Although the function and cellular localisation of this
family are dissimilar, they both bind calmodulin in a Ca2+ dependent manner [29, 67,
68].
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Figure 1.5. Alignment of the predicted amino acid sequence of murine PR61
isoforms and splicing variants.
Residues that are identical are shown in bold. The central region is the most similar
and the N- and C-termini diverge [17].
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Table 1.1. Nomenclature, subcellular and tissue distribution PR61 subunits.
GENE
SYMBOL
ISOFORMS SUBCELLULAR
LOCALISATION
TISSUE
DISTRIBUTION
PPP2R5A PR61α/B56α Cytoplasm Heart, skeletal
muscle
PPP2R5B PR61β/B56β Cytoplasm Brain
PR61β2 (cloning
artefact)
Not applicable
PPP2R5C PR61γ1/B56γ1 Cytoplasm and
nucleus (speckles),
focal adhesions
Thymus, spleen,
ovary
PR61γ2/B56γ2 Cytoplasm and
nucleus
Thymus, ovary
PR61γ3/B56γ3 Mainly nucleus Thymus, ovary
PPP2R5D PR61δ1/B56δ1 Nucleus, cytosol,
mitochondria,
microsome
Embryo, brain,
ovary
PR61δ2/B56δ2 Unknown
PR61δ3/B56δ3 Unknown
PPP2R5E PR61ε/B56ε Cytoplasm Embryo, brain,
ovary, thymus
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1.3 PP2A Regulation
As PP2A is vital in almost every cellular process, it is important that it is tightly
regulated. This is achieved by a number of mechanisms. Firstly, as already described,
a huge number of trimeric and dimeric holoenzymes can be generated [4, 69]. The
precise composition of these multimeric complexes gives rise to many possibilities
for regulation. Secondly, PP2Ac can undergo post-translational modifications such as
phosphorylation and methylation, which is necessary for sequestration of regulatory
B subunit binding. In addition, PP2A can be regulated by the phosphotyrosyl
phosphatase activator of PP2A, PTPA, and inhibited by interaction with cellular
inhibitory proteins. Finally, reversible ubiquitination has been reported to regulate
PP2Ac [70].
1.3.1 Holoenzyme composition
B subunits can compete for binding to PP2AD in vitro and can therefore replace one
another [71]. This behaviour is due to the different binding affinities of B subunits to
PR65α. Studies indicate that PR72 has a higher affinity for PR65 than PR61 which
has a higher affinity than PR55 [59]. These dynamic subunit exchanges suggests that
recruitable pools of B subunits exist and helps explain how regulatory B subunits are
fundamental to PP2As function, since they determine catalytic activity, substrate
specificity and subcellular localisation of the PP2A trimer.
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1.3.2 PP2A post-translational modification
Regulation of PP2A complex formation and function by post translational
modifications has largely been attributed to PP2Ac [72]. So far methylation and
phosphorylation of the TPDYFL sequence at the C-terminal tail have been
documented.
1.3.2.1 Phosphorylation
In vitro, PP2Ac is phosphorylated by tyrosine –specific protein kinases; pp60v-src,
pp56lck, epidermal growth factor and insulin receptors [73]. This occurs on Tyr307 at
the conserved C-terminal tail, resulting in inactivation of the enzyme [73]. Addition
of the phosphatase inhibitor OA enhances tyrosine phosphorylation of PP2Ac,
suggesting that PP2A can reactivate itself in an autodephosphorylation reaction [73].
Phosphorylation by an autophosphorylation-activated protein kinase has also been
reported on Thr304 and causes inactivation of the enzyme [74].
1.3.2.2 Methylation
Reversible methylation of PP2Ac occurs at the carboxyl group of Leu-309 at the C-
terminal tail [75]. This reaction is catalysed by a specific Leucine carboxyl
methyltransferase (LCMT1) [76] and reversed by a specific protein phosphatase
methylesterase (PME-1) [77, 78]. Approximately 70-90% of PP2Ac is methylated in
vivo [36, 79] and although methylation has no drastic effect on PP2A activity, it is
clearly of importance as the methylation of PP2Ac varies during the cell cycle [80].
Furthermore, methylation appears to be important in holoenzyme assembly, for
example methylation of PP2Ac is necessary in recruiting PR55 subunits to PP2A
[81-83].
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1.3.3 Regulation by PTPA
Regulation of the phosphotyrosyl phosphatase (PTPase) activity of PP2A involves an
activator protein, originally called PTPA [6]. This ubiquitous 37kDa protein is well
conserved from yeast to humans [84], and requires the essential cofactors ATP and
Mg2+ [85]. Results by Longin et al. [86] have concluded that PTPA is probably
essential for the peptidyl prolyl cis/trans isomerase activity of PP2A on Pro190 near
the catalytic centre of PP2Ac, to reactivate its Ser/Thr phosphatase activity. This has
lead to the naming of the protein, phosphotyrosyl phosphatase activator of PP2A.
The  inactive  form  of  PP2A  can  be  fully  activated  by  PTPA/ATP-Mg2+ and in the
absence of PTPA, PP2A will be converted into an inactive apoenzyme.
1.3.4 Inhibitory proteins
Two specific inhibitors of PP2A have been identified as I1PP2A and I2PP2A. These
proteins can bind to PP2Ac, inhibiting all holoenzyme forms. I2 has been shown to
have oncogenic properties by counteracting PP2As effect as a potent tumour
suppressor [87]. In addition, CIP2A (Cancerous Inhibitor of PP2A), has been
identified as an inhibitor of PP2A, also with oncogenic activities, by binding to
PR65α complexes and inhibiting c-myc associated activities [88].
1.3.5 Ubiquitination of PP2Ac
Another way PP2A can be regulated, is by the reversible process of ubiquitination.
This modification is a common mechanism for down regulating proteins [89].
Ubiquitination is an ATP-dependent process which results in the covalent attachment
of a 76 amino acids polypeptide known as Ubiquitin [90, 91], to the substrate. This
generally  serves  as  a  molecular  tag  that  marks  proteins  for  degradation  via  the
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proteasome. Ubiquitin is attached to proteins by a cascade of enzymes [92]. The final
step of this cascade is facilitated by E3 Ubiquitin ligases. Ubiquitination of PP2A has
not been well documented, however Trockenbacher et al. [70] have observed the
transfer of Ubiquitin molecules onto PP2Ac, producing a polyubiquitinated chain,
which is then subject to degradation. This is achieved by the RING (really interesting
new gene) – finger domain of the E3 Ubiquitin ligase activity of protein MID1, as
elucidated by a yeast hybrid screen. The RING-finger domain has been shown to
mediate the addition of Ubiquitin, as a post-translation regulation of many proteins
[93, 94]. This interaction between microtubule-associated PP2Ac and MID1 is
thought to occur through the α4 protein, a regulatory subunit of PP2Ac [70].
Proteolytic degradation then takes place. Due to the need for such a tight control of
PP2A it seems probable that the actions of the ubiquitination of PP2A are reversed
by deubiquitinating enzymes (DUBs). However no associations between PP2A and
DUBs have yet been reported.
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1.4 Biological Role of PP2A
Many molecules have been shown to form complexes with PP2A, including protein
kinases, cytoskeletal, and structural proteins. Not only does PP2A reverse the effects
of protein kinases by dephosphorylating the substrates, it can also act to
dephosphorylate kinases themselves, so decreasing their activity and helping to
explain how one enzyme can have such pleiotropic effects. In fact, PP2A appears to
be the major kinase phosphatase in eukaryotic cells.
1.4.1 Signal transduction
PP2A plays important roles in the mitogen-activated protein kinase (MAPK)
pathways, involving a cascade of protein kinases that regulate a wide range of
cellular activities such as growth, differentiation and apoptosis. These signalling
pathways are tightly controlled and are switched on and off when required, hence
deregulation of MAPK activity has been implicated in cellular transformation [95].
Three MAPK pathways have been studied in detail; extracellular – regulated kinase
(ERK) pathway which is activated by a variety of mitogens and growth factors, and
the c-Jun NH2-terminal kinase (JNK)/stress activated protein kinase (SAPK) and p38
pathways which are stimulated by environmental stress and inflammatory cytokines
(reviewed in [96]). The ERK pathway is initiated through receptor activation of Ras
which then recruits Raf kinase, whose downstream substrate is mitogen-activated
protein kinase kinases MEK1,2. ERK1,2 is activated by phosphorylated MEK1,2
which can then translocate to the nucleus where it activates several transcription
factors [97, 98]. PP2A is described as a tumour suppressor because it acts to down-
regulate this signalling pathway, at multiple points. In vitro, PP2A dephosphorylates
and inactivates MEK1,2 and ERK1,2 [99, 100]. In the case of the ERK proteins this
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dephosphorylation occurs on both the serine and tyrosine residues in its activation
loop [101] by a PR55α/δ- PP2A complex [102]. Both ERK and MEK proteins can be
re-activated after addition of OA to the cells [103] and also when the T-antigens are
expressed (this will be described further in section 1.5). PP2A can also regulate the
ERK pathway by interacting with Shc and preventing its tyrosine phosphorylation,
hence the signal progression is inhibited [10]. Interestingly, PP2A has been
implicated in the positive as well as the negative regulation of MAP kinase pathways;
during Drosophila photoreceptor development [104] and in vitro by
dephosphorylating and hence activating one of the Raf proteins [105]. The actions of
PP2A on the ERK MAPK pathway is summarised in Figure 1.6. In addition, a
PR61γ- PP2A complex can induce ERK pathway activity [106]. Therefore, it appears
that specific holoenzyme PP2A composition is important to how the different MAPK
pathways are regulated. PP2A has also been shown to regulate the JNK pathway by
interacting with JNK and acting on the upstream kinases [107], and on the p38
pathway by associating and dephosphorylating upstream activator, MKK3 [108].
PP2A has been implicated at the cell membrane by preventing desensitisation of
epidermal growth factor receptor (EGFR) [109]. Upon ligand binding, the receptor
homo-or heterodimerizes with other EGFR receptors. This leads to activation of its
cytoplasmic tyrosine kinase domain and self phosphorylation on Tyr residues which
serve as docking sites for Shc and PI3K, initiating signally cascades [110]. Some Ser
and Thr residues also get phosphorylated on EGFR, which reduce ligand binding,
induce receptor desensitisation and promote receptor regulation [111]. OA has been
shown to induce EGFR phosphorylation on these serine residues, suggesting PP2As
role in this pathway [109].
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Figure 1.6. The role of PP2A in ERK pathway signalling.
PP2A both positively and negatively regulates components of the ERK-MAPK
pathway. PP2A dephosphorylates mitogen-activated protein kinase kinases
(MEK1,2,), extracellular – regulated kinase kinase (ERK1,2) and Shc to
downregulate the cascade and interacts with one of the Raf proteins to activate this
pathway.
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PP2A mediates the inactivation of PKBα following hyperosmotic stress by
dephosphorylating Thr308 and Ser473 on this protein kinase [112]. PR55α- PP2A
complexes dephosphorylate and hence inactivate PKCα in vitro [113, 114]. Other
protein  kinases  that  form  stable  complexes  with  PP2A  include:  Ca2+ /calmodulin-
dependent protein kinase I, II and IV, p70 S6 kinase, p21-activated kinase and casein
IIα (reviewed in [115]). PP2A also interacts with AMP-activated protein kinase
(AMPK) through PR65α, and a role in regulating the interaction between AMPKs α2
and γ1 subunits in a glucose dependent manner has been suggested [116].
1.4.2 Cell cycle
PP2A  has  been  implicated  in  cell  cycle  progression,  in  particular  in  the  G2/M
transition. These mitotic effects are mediated by negative regulation of CDK
complexes, by a PR55-PP2A holoenzyme [117, 118], identified using OA [119].
PP2A can regulate cdc2 and related kinases by inhibiting the pathway that results in
the phosphorylation of cdc2 at Thr161, rather than being involved directly in the
dephosphorylation [120]. This suggests that PP2A’s role lies in the control of CAK,
the kinase responsible for the phosphorylation of cdc2. In addition, PP2A could
control cdc2 activity by activating an inhibitor of cdc2 known as WEE1, which is
held in an inactive state in interphase. PP2A dephosphorylates and activates WEE1,
which in turn phosphorylates cdc2 at Tyr15, thus inactivating it [121]. Another
mechanism that PP2A can control G2/M transition is by the regulation of cdc25, the
phosphatase responsible for dephosphorylating the inhibitory Thr14 and Tyr15 sites
on cdc2 in the cdc2-cyclin B complex [122, 123].
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In a completely different role Voorhoeve et al. [124] have reported that UV
irradiation induces dephosphorylation of the pRb related p107 protein via activation
of PP2A, independently of p53 and p21. It is thought that the interaction between
p107 and the regulatory subunit PR59 targets PP2Ac to p107 resulting in
dephosphorylation of the protein, allowing p107/E2F complexes to form and
repressing some E2F dependent transcriptional activity. This is likely to be the
mechanism by which UV induces cell cycle arrest.
PP2A subunits have also been implicated in other cell cycle activities independently
of the holoenzyme. The PR61α and PR61β subunits form complexes with cyclin G1,
a transcriptional target of p53, both in vitro and in vivo [125]. An unconventional
cyclin, cyclin G2, is highly expressed independently of p53 in cells undergoing
apoptosis, and has been found to be directly associated with the catalytic subunit and
various B’ subunits of PP2A but not PR65 [126]. This G2-PP2A-B’-C complex acts
to inhibit cell cycle progression.
1.4.3 Translation, apoptosis and DNA damage
Tap42 (two A phosphatase-associated protein) of Sacch. cerevisiae can form a
complex with PP2Ac independently of PR65 and any B subunits. PP2Ac/Tap42
disruption upon nutrient deprivation leads to inhibition of the TOR signalling
pathway, a pathway involved in regulating translation initiation [127]. In addition,
TOR phosphorylated Tap42 seems to compete effectively with the yeast homologue
of PR65 and a 60kDa B subunit, for binding to PP2Ac [128]. The mouse homologue
of Tap42, α4 was found to bind to PP2Ac, at or near the substrate binding site of the
catalytic subunit also independently of PR65 and B subunits. However, further
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investigations need to be carried out to define the exact role of these complexes in
the initiation of translation [129]. In addition, PP2A is probably involved in the
termination of translation by an interaction with translation termination factor, eRF1,
again via PP2Ac [130].
A role for PP2A in apoptosis has been demonstrated by its interaction of the caspase-
3 enzyme, in a yeast two hybrid screen [131]. In cells undergoing apoptosis caspase-
3 is activated and cleaves PR65α. This generates a high amount of free PP2Ac,
which lowers the amount of the phosphorylated forms of MAP kinases. Thus,
providing  a  link  between  the  caspases  and  signal  transduction  pathways  and
highlights how useful the study of PP2A has been in providing insights into many
cellular processes. In addition, Bcl-2, an anti-apoptotic protein, becomes
phosphorylated on Ser70 to mediate the suppression of apoptosis. Through OA
experiments, PP2A was identified as the phosphatase which reverses this reaction
[132].
More recently, PP2A has been shown to facilitate DNA end-joining and double
stranded  break  repair  in  a  novel  mechanism  by  activating  Ku  and  DNA-PKcs  and
dephosphorylating γ- H2AX, the specific proteins involved in these pathways [133,
134].
1.4.4 Wnt Signalling
PP2A has been implicated at various stages of the canonical and non-canonical Wnt
signalling pathways. These pathways regulate cell-to-cell interactions during
development processes [135]. Canonical Wnt proteins bind to cell surface receptors
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of the Frizzled (Fz) and low-density-lipoprotein-related protein (LRP) families [136].
A signal  is  then  relayed  through the  cytoplasm via  a  number  of  proteins  including
Dishevelled (Dsh/Dvl). This leads to the stabilization and accumulation of β-catenin,
which can enter the nucleus and form a complex with TCF, activating transcription
of Wnt target genes. PR61-PP2A complexes interact with Axin, and APC, two of the
proteins responsible for Wnt-mediated β-catenin degradation and hence inhibiting the
canonical Wnt signalling pathway [137-139]. Over expression of PR61ε has been
shown to inhibit Wnt/β-catenin signalling in vitro and in Xenopus embryos [138-141].
This subunit has been shown to act upstream of Dsh/Dvl protein and downstream of
the Wnt ligand [142]. PR61ε regulates the Hedgehog pathway during eye induction
and eye field separation, two of the earliest events required for vertebrate eye
development [143].  In addition, a 48kDa truncated PR61ε has been shown to
regulate midbrain/hindbrain boundary formation during Xenopus embryonic
development [144]. PR61γ modulates PP2A action on the Wnt/β-catenin signalling
pathway during lung airway morphogenesis [145]. More recently, other regulatory B
subunits have been implicated in Wnt signalling, for example, PR55α has been
shown to control β-catenin phosphorylation and degradation [146]. PR61 isoforms
have also been implicated in non-canonical Wnt pathways. In Drosophila, PR61
impairs planar cell polarisation leading to the formation of multiple wing hairs and
abnormal hair polarity in the wing blade [147].
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1.5 DNA Tumor Viruses
Another class of proteins that can interact with PP2AD are polypeptides encoded by
DNA tumor viruses. Mouse polyoma virus (PyV) and the simian vacuolating virus
40 (SV40) were the first to be discovered [148, 149]. These two viruses have been
intensively studied and have provided a model system for the study of basic
eukaryotic processes such as DNA replication, transcription, signal transduction and
cellular transformation because they easily propagate, form well defined plaques,
have a short life cycle and a small genome. In addition, fundamental molecular
biological techniques were established during the study of SV40 and PyV. For
example, the use of restriction enzymes to generate precise DNA fragments to map
specific sequences [150, 151] and also the use of viruses to carry genetic information
into cells – genetic engineering [152, 153].
DNA tumor viruses do not encode replication proteins; they rely on the host cell
DNA replication machinery for their own DNA synthesis. Productive infection
depends upon the ability of the virus to drive cells out of the Go phase and into the S
phase of the cell cycle (reviewed in [154, 155]). The virus becomes absorbed by the
cell and transported to the nucleus, the genome is then uncoated and RNA
transcription of the ‘early’ region begins. The translated early proteins are known as
T-antigens (T-Ags). SV40 encodes Large T (LT) and Small T (ST) antigens and PyV
encodes LT, ST and Middle T (MT) antigens. LT promotes a transcriptional switch
to enable RNA synthesis from the ‘late’ region. The late proteins translated are the
viron proteins which assemble around the replicated genome to form the mature
virus.  Due  to  the  fact  that  PyV  and  SV40  replicate  their  genomes  by  a  similar
mechanism to that of eukaryotic genome, they have been important models for
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research into DNA replication [156-158]. When the virus enters permissive cells, the
virus is able to replicate and cell lysis occurs. However, when the virus enters non-
permissive cells, viral DNA replication is not supported and cell transformation
occurs, this could be due to a species-related block of the polymerases [159, 160].
The expressed T-antigens form multiple complexes with cellular proteins involved in
signalling pathways and cell growth, to change their normal functions. An important
role of the T-Ags is to interact with, and modulate the activity of PP2A [161, 162].
1.5.1 SV40
Cellular transformation by the SV40 virus has been shown to be the consequence of
the LT and ST forming complexes with a number of proteins involved in signal
transduction and growth control. The tumour suppressor protein p53 was first
identified as a cellular interacting protein of LT. Studies of p53 have revealed it to
serve as a sequence specific transcription factor, promoting the expression of many
genes that induce cell cycle arrest or apoptosis in the response to a variety of cellular
stresses [163, 164]. SV40 LT binds to the DNA binding domain of p53, which
stabilizes it and interferes with its ability to act as a transcription factor. SV40 LT has
also been shown to be associated with another tumour suppressor, Rb and two Rb
related proteins, p130 and p107. These three proteins repress the E2F transcription
factors, that regulate the expression of genes required for progression into the S
phase of the cell cycle. Binding of LT to Rb, p107 and p130, inactivate their normal
function, leading to cell proliferation [165-167]. Rb function is disrupted in nearly
every human cancer. In addition, SV40 LT has been found to be associated with
p300/CBP, Hsc70, Cul7, Bub1, TEF-1, Nbs1 and Fbxw7 (reviewed in [168]).
However, the function of these interactions is not as defined as p53 and Rb.
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An accumulation of studies have shown that whilst LT is required for morphological
transformation, ST has specific roles in the transformation process not performed by
LT  activity.  However,  SV40  ST  alone  can  not  transform  cells,  it  needs  the
cooperation with LT. ST has been shown to have positive effects on transcription by
transactivating cyclin A and D1 promotes [169, 170]. Immunoprecipitation
experiments revealed that PR65 and PP2Ac interact with SV40 ST antigen and also
PyV  ST  and  MT  [171,  172].  PP2A  appears  to  be  the  major  cellular  target  of  ST.
PP2A B subunits are absent from this PP2A/T-Ag complex which has led to the
common view that the regulatory subunits are displaced by the viral proteins [173].
Site-directed mutagenesis experiments of PR65 determined that binding sites for the
B subunits and T antigens are located on overlapping regions of the PR65 N-terminal
HEAT  repeats.  SV40  ST  binds  to  PR65  HEAT  repeats  3-6,  PyV  ST  and  MT  to
repeats 2-8 [173], and the regulatory B subunits bind to repeats 1-10 [174] (Figure
1.7.). Further mutational experiments showed that some amino acids are involved in
the binding of all types of B subunits, whereas others are specifically involved in
binding one or two isoforms. The T-antigen binding sites are uncorrelated to any of
these B subunit binding sites [28].
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Figure 1.7. Binding sites of the B subunits and T-antigens located on PR65.
PP2Ac binds to HEAT repeats 11-15. Binding  sites  for  the  B  subunits  (HEAT
repeats 1-10) and T antigens (SV40 ST HEAT repeats 3-6, PyMT and PyST HEAT
repeats 2-8) are located on overlapping regions of the PR65 N-terminal repeats and
are mutually exclusive.
SV40 ST targets PP2A to overcome its negative role in signaling pathways leading to
an increased cell proliferation. For example, SV40 ST-PP2A inhibits
dephosphorylation of ERK1 and MEK1, resulting in receptor independent activation
of these protein kinases [100]. Thus, cell growth is observed through deregulating
this mitogen activated protein kinase (MAPK) cascade [170]. Interestingly, the
interaction of SV40 ST with PR65 alters the activity of PP2AD towards its substrates.
For instance, 2-D peptide mapping has shown that PP2A dephosphorylates SV40 LT
Ser-120 and Ser-123 [175, 176] and p53 at multiple sites. Most of this
dephosphorylation is inhibited by the presence of SV40 ST [177]. In another role,
SV40 ST has been shown to increase some of PP2A’s binding activity. ST binds to
the N-terminal HEAT repeats in PR65, inducing conformational changes. This
49
allows PP2AD to bind to the ligand-activated androgen receptor (AR). SV40 ST then
dissociates from the complex and PP2A dephosphorylates AR at multiple sites [178,
179].
1.5.2 Polyomavirus
The early genomic region of polyomavirus encodes three antigens; ST, MT and LT.
PyV LT can also bind to the retinoblastoma proteins, however, it can not bind to p53
or transform cells, which makes it unique among the other DNA tumor viruses [180].
PyV ST has been shown to interact with the core dimer of PP2A and promote cell
cycle  progression  [181].  PyV  ST  shares  much  of  the  same  sequences  with  the  N-
Terminus of the MT antigen so it is not surprising that MT also binds PP2AD [182].
However, it is the actions of MT that are more prominent in the cell transformation
process. The identification of MT accounted for the diverse transforming properties
of SV40 and PyV; PyV transformed cells have an irregular growth pattern whereas
SV40 transformed cells appear to be deregulated with regard to cell division. In
addition, PyMT/ST-PP2A complexes still display serine/threonine phosphatase
activity [183] and exhibit 10 times higher tyrosine phosphatase activity compared
with PP2AD, in contrast to SV40 ST-PP2A interaction that just alters substrate
specificity of PP2AD [184].
MT induces cell transformation by stimulating many of the pathways used by
tyrosine kinase associated growth factor receptors and so can be thought of as a
permanently active analogue of a growth factor receptor. Two of the major signalling
pathways that are stimulated by MT are the MAPK and Phosphatidylinositol 3-
kinase  (PI3K)  cascades.  Membrane  bound  MT  binds  to  PP2A  and  one  of  the  src
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proteins[185]: pp60c-src, pp62c-yes [186] or pp59c-fyn [187], which results in the
phosphorylation of several tyrosine residues in the carboxyl-terminal end of MT.
This creates binding sites for Src and PI3K, activating the MAPK pathway and PI3K
pathway, respectively. In the MAPK pathway, MT Tyr250 binds the phospho-
tyrosine binding domain of SHCA (SRC-homology 2 (SH2) domain- containing
transforming protein A) [188, 189], which in turn becomes tyrosine phosphorylated,
creating binding sites for growth-factor-receptor-bound protein 2 (GRB2) [189]. This
brings mSos, the exchange factor of p21ras into the MT complex. It is this membrane
association of mSos that activates p21ras and the MAPK pathway, and leads to cell
proliferation. In the PI3K pathway, MT Tyr315 binds to the SH2 domains in the
85kDa component of PI3K, activating the kinase activity of its p110 subunit, which
phosphorylates Phosphatidylinositol phosphatase 2 (PIP2) to form PIP3 [190].
Membrane PIP3 phosphorylates and activates AKT, which can in turn phosphorylate
several proteins, culminating in the inhibition of apoptosis, cell cycle progression and
glucose metabolism, inhibition of p53 functions and increase in growth. The
activation of PI3K can also stimulate additional proteins involved in tumorigenesis
such  as  RAC1,  CDC42  and  PKC  [191].  Other  proteins  are  also  activated  by  the
association of protein phospholipase C-γ1 (PLC-γ1) [192], 70kDa heat shock protein
[193], and members of the 14-3-3 family of proteins [194] to MT, although the exact
role of the latter two proteins is not clear. The interaction of the src-family members
with MT is vital to the cell transformation process, but, the molecular mechanism of
this binding is not well understood. What is certain is that the presence of PP2A is
necessary for MT to interact with the src proteins [195, 196] and as a consequence,
the kinase activity of the src protein is stimulated. The identified primary interacting
proteins of MT are summarised in Figure 1.8. [195].
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Figure 1.8. The MT complex.
A diagrammatic scheme showing MT inserted within the cell membrane at its
carboxyl-terminal end. The cellular interacting proteins are marked above and below
the MT sequence and the amino acids involved in the phosphorylation are shown.
Phosphorylation of Shc leads to the activation of ERK MAPK pathway resulting in
cell proliferation. Phosphorylation of Phosphatidylinositol 3-kinase (PI3K) leads to
activation of the AKT pathway which results in cell cycle arrest, apoptosis and
growth. Other cellular proteins that interact with MT are: Heat shock protein 70
(Hsc70), PP2A dimer (PP2A.A+C), one of the c-SRC proteins (pp60c-src),
phospholipase Cγ-1 (PLCγ1), and some of the subtypes of the 14-3-3 family of
proteins.
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1.5.3 Adenovirus and human papillomavirus
Other DNA tumor viruses have also been shown to encode PP2A interacting proteins
which disturb its normal activity. For example, the E7 oncoprotein expressed by the
human papillomavirus binds to both PP2Ac and PR65, thus inhibiting the normal
interaction  of  PP2A  with  PKB  which  results  in  sustained  PKB/Akt  signaling,  an
important pathway in cell proliferation [197]. Adenovirus encodes a protein E4orf4
that interacts with PP2A to induce apoptosis in transformed cells [198]. As PP2A
regulates cell signalling cascades by opposing the activity of signaling kinases,
inactivation of normal PP2A complexes could alter multiple pathways, contributing
to cell transformation.
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1.6 PP2A and cancer
PP2A was first suggested as being a tumour suppressor through experiments
involving OA, a selective inhibitor of PP2A. Mice treated with OA develop tumors
on their skin [199], which has been attributed to the activation of several cancer
promoting pathways [200]. More recently, cytostatin, a powerful anti-metastic drug,
has been shown to inhibit cell adhesion by selectively inhibiting PP2A [201]. In
addition, proteins expressed by the DNA tumour viruses interact with the core dimer
of PP2A (already described in section 1.5), competing with B subunits and resulting
in an altered enzymic activity towards substrates. This disruption in the normal
activity of PP2A leads to a deregulation of similar pathways found disturbed by OA
[200]. Furthermore, SV40 ST and PyMT and PyST induce cellular transformation
resulting from PP2A inhibition [202].
Mutations in the genes expressing the subunits of PP2A have been identified in many
human cancers. For example, PR65α is mutated in lung and breast carcinomas [33]
and PR65β in 15% of primary lung and colon tumors [21]. Over expression of PR61γ
has been observed in malignant melanomas [203]. Furthermore, the role of PP2A in
regulating c-myc stability has been recently linked to human cell transformation
[204]. The proto-oncogene c-myc has  a  diverse  range  of  cellular  functions  and
aberrant c-myc signaling has been observed in many human cancers (reviewed in
[205]). In particular myc has been shown to have an extended half life in some cancer
cell lines. PR61α-PP2A complex dephosphorylates c-myc at  ser62  which  results  in
destabilization of the protein [204]. The degradation of c-myc occurs through an
ubiquitination process which requires the dephosphorylation of c-myc by PP2A
before the Ubiquitin E3 ligase, FBW7 can recognise c-myc. This then results in
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polyubiquitination of this oncogene, targeting it for degradation [206]. Inhibition of
PR61α-PP2A increases levels of Ser62 phosphorylation which leads to an increase in
c-myc activity due to its stability, resulting in upregulation of genes, some of which
are involved in cell proliferation.
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1.7 The role of PP2A in other human diseases
Disruption in the normal activity of PP2A has been implicated not only in cancer but
in  many other  diseases  such  as  Alzheimer’s  (AD)  and  Cystic  Fibrosis  (CF).  AD is
characterised by neuronal cell death and two kinds of deposits, neurofibillary tangles
(NFT) and amyloid-β containing senile plaques. The main component of NFT is
paired helical filaments which consist mainly of hyperphosphorylated tau protein
(reviewed in [207]). Tau, is a microtubule-associated protein expressed in axons
[208], with roles in stabilizing microtubules, signal transduction, organisation of the
actin cytoskeleton, intracellular vesicle transport and anchoring of phosphatase
kinases. In physiological conditions, tau is a phosphoprotein, but in AD brains tau is
hyperphosphorylated [209, 210]. This abnormal hyperphosphorylation of tau occurs
mainly  on  serine  and  threonine  sites  [211]  and  results  from an  imbalance  between
PKs and PPs. PP2A has been identified as the most important PP in this activity
because specific inhibition of PP2A by OA can induce tau hyperphosphorylation
[212]. The mechanism for PP2A inactivation in AD brains is still not fully
understood. However, what has been shown by microarray analysis is, that PP2Acα
is downregulated [213] and PR55α is decreased [214] which could account for a lack
of PP2A activity in AD. Further investigations have also revealed that decreased
methylation of PP2Ac Leu309 disrupts the formation of PR55α-PP2A holoenzymes,
which leads to the reduced activity of PP2A in AD brains [215, 216].
In CF PP2A has been demonstrated to be a relevant CFTR (CF transmembrane
conductance regulator) phosphatase. Inhibition of PP2A results in a CFTR-dependent
increase in the airway surface liquid [217, 218].
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As PP2A is vital in many processes, further identification and characterisation of
how signalling molecules and other proteins interact with PP2A is important to our
understanding of these complex signalling networks. This is also necessary in the
development of clinically relevant drug targets for pathological diseases and for the
advancement of therapeutic agents that can be used against PP2A deregulation in
virally transformed cells and in some cancers.
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1.8 Project Aim
Protein Phosphorylation is an important post translational modification that regulates
most cellular processes. It is controlled by the opposing actions of protein kinases
and protein phosphatases. The major serine/threonine phosphatase in eukaryotic cells
is Protein Phosphatase 2A (PP2A). The PP2A core enzyme is a dimer consisting of a
structural subunit of 65kDa (PR65/A) and a catalytic (PP2Ac) polypeptide, which is
usually found associated with one of the several regulatory B subunits. Assembly of
the PP2A core enzyme with the regulatory B subunits determine the catalytic activity,
substrate specificity and subcellular distribution of the complex. Major diseases such
as  cancer  are  linked  with  the  deregulation  of  PP2A  composition,  therefore,  it  is
important that we understand which components are associated with the PP2A core
enzyme. The overall objective of this study has been to elucidate novel interacting
proteins of PP2A and what effect they have on PP2A’s activity and regulation. In
addition, any changes in PP2A complex composition will be analysed when the viral
T-antigens are expressed.
The first approach concentrated on the generation and characterisation of monoclonal
antibodies directed towards PR65 and two of the regulatory B subunits, PR61α and
PR61γ1, of PP2A. These have then been used to isolate specific PP2A complexes,
and the proteins present have been identified by Mass Spectroscopy. A novel
associated protein of the PP2A core dimer has been confirmed and the effect this
interaction has on PP2A has been investigated in part by creating a knock-down cell
line.
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The second approach was to construct a novel tagged PR65 subunit which has been
transfected into a variety of cell lines, including one in which expression of small T
antigen of the Polyoma virus can be switched on and off by the addition of
Doxycycline. This has provided a valuable tool for identifying changes in PP2A
composition when the viral antigens are expressed.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Materials
All chemicals and solvents used were of analytical grade and obtained, as indicated,
from Abcam, Cambridge, UK; Amersham Biosciences/GE Healthcare, Amersham,
UK; Amresco, Ohio, USA; Applied Biosystems, Cheshire, UK; BDH/VWR
Chemicals, Lutterworth, UK; BD Biosciences/ BD Transduction Laboratories,
California, USA; Bioline, London, UK; Bio-Rad, Hemel Hempstead, UK;
Calbiochem/Novagen, Nottingham, UK; Cambrex, Iowa, USA; Chemicon, Harrow,
UK; DAKO Cytomation, Glostrup, Denmark; Dharmacon, Louisiana, UK;
Fermentas, Ontario, USA; Finnzymes, Espoo, Finland; Fisher Scientific,
Loughborough, UK; Genome Research Ltd, Cambridge, UK; IBA-BioTagnology,
Göttingen, Germany; Invitrogen/Gibco BRL/Zymed, Paisley, UK; Jackson, Suffolk,
UK; Millipore/Upstate, Watford, UK; NBS Biosciences, Oslo, Norway; New
England Biolabs, Hitchin, UK; Pierce, Illinois, USA; Premier Foods, St. Albans, UK;
Promega, Southampton, UK; Qiagen, Crawley, UK; Roche, Lewes, UK; Santa Cruz
Biotechnology, Heidelberg, Germany; Sigma-Aldrich Company Ltd, Poole, UK;
Stratagene, Texas, USA; Thermoscientific/Open Biosystems, Epsom, UK; Web
Scientific, Crewe, UK; Zymo Research, California, USA.
2.1.1 Chemicals, Reagents and Solvents
20% (w/v) Sodium Dodecyl Sulfate (SDS) Solution Amresco
30% (w/v) Acrylamide/Bis 37.:1 Amresco
37% (w/w) HCl BDH
Acetic Acid BDH
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Adenosine Triphosphate (ATP) Sigma-Aldrich
Agarose Invitrogen
Ammonium Persulphate (APS) Bio-Rad
Ammonium Sulfate Sigma-Aldrich
Ampicillin Sigma-Aldrich
b-Mercaptoethanol Sigma-Aldrich
Benzonase Novagen
Bio-Rad Protein Assay Reagent Bio-Rad
Boric Acid VWR
Bovine Gamma Globulin Pierce
Bovine Serum Albumin (BSA) Sigma-Aldrich
100x BSA (10mg/mL) New England Biolabs
Bradford Reagent Sigma
Bromophenol Blue Sigma-Aldrich
CaCl2 Sigma-Aldrich
Carbenicillin Invitrogen
Chloramphenicol Sigma-Aldrich
Citric Acid VWR
Complete Protease Inhibitors Roche
Cyclohexamide Sigma-Aldrich
Deoxynucleotide Triphosphate (dNTP) New England Biolabs
Dimethyl Sulfoxide (DMSO) Fisher Scientific
Dithiothreitol (DTT) Fisher Scientific
Ethanol Fisher Scientific
Ethylenediaminetetraacetic Acid (EDTA) Sigma
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Full-Range Rainbow Molecular Weight Markers GE Healthcare
Gelatine Sigma-Aldrich
Glutathione Sepharose 4B GE Healthcare
Glycerol BDH
Glycine Sigma-Aldrich
HEPES Sigma-Aldrich
Hybond ECL GE Healthcare
Imidazole VWR
Image-iT  FX Signal enhancer Invitrogen
Immobilon Western Chemilumescent HRP Substrate Millipore
Isopropanol Fisher Scientific
Isopropyl β-D-1-Thiogalactopyranoside (IPTG) Sigma-Aldrich
Kanamycin Sigma-Aldrich
KCl Sigma-Aldrech
Lysozyme Novagen
KH2PO4 Sigma-Aldrich
Methanol Fisher Scientific
MG132 Calbiochem
MgCl2 Sigma-Aldrich
MgSO4 Sigma-Aldrich
MOPS BDH
NaAc 3M pH5.5 Sigma-Aldrich
NaCl Sigma-Aldrich
Na2HPO4 Sigma-Aldrich
NaOH Sigma-Aldrich
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Nonylphenyl Polyethylene Glycol (NP40) Alternative Calbiochem
Oligonucleotides Invitrogen
PageBlue Protein staining solution Fermentas
PageRuler Prestained Protein Ladder Plus, SM1811 Fermentas
PageRuler Unstained Protein Ladder, SM0661 Fermentas
Phenol Red VWR
Prolong Gold Invitrogen
Protease Inhibitor Cocktail, complete EDTA free Roche
Protein A-Agarose Calbiochem
Protein A-Sepharose CL-4B Roche
Polyethylene Glycol 3350 Sigma-Aldrich
Sepharose Cl-4B GE Healthcare
Skimmed Milk Powder (Marvel) Premier Foods
StrepTactin Sepharose GE Healthcare
Supersignal West Femto Maximum Sensitivity Substrate Pierce
SYBR Safe Strain, Nucleic acid strain NBS Biologicals
TALON metal Affinity Resin BD Biosciences
TEMED Sigma-Aldrich
Thrombin Novagen
Tris Base Sigma-Aldrich
Tris Borate Sigma-Aldrich
Tris HCl Sigma-Aldrich
Triton X-100 Sigma-Aldrich
Tween-20 Sigma
West Pico Detection System Pierce
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2.1.2 Enzymes
Antartic phosphatase New England Biolabs
Quick T4 DNA Ligase New England Biolabs
Phusion DNA Polymerase Finnzymes
Restriction Endonucleases New England Biolabs
T4 DNA Ligase Invitrogen
T4 PNK New England Biolabs
2.1.3 Miscellaneous
Electroporation Cuvette (1mm gap) Web Scientific
Glass coverslips 13mm VWR
Super premium microscope slides 1.0-1.2 mm BDH
Glass Plates for Setting Polyacrylamide Gels Web Scientific
Hybond PVD-F Membrane GE Healthcare
Optical 96-well Plates for QRT-PCR Abgene
2.1.4 Kits
AminoLink Plus Immobilisation kit Pierce
HiSpeed Plasmid Maxi Kit Qiagen
HiSpeed Plasmid Midi Kit Qiagen
HiSpeed Plasmid Mini Kit Qiagen
AminoLink Plus Immobilization Kit Pierce
One-STrEP Protein Protein interaction follow up Kit IBS BioTAGnology
QIAEX II Gel Extraction Kit Qiagen
Quick Ligation Kit New England Biolabs
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SilverQuest Staining kit Invitrogen
TNT Quick Coupled Transcription/Translation System Promega
2.1.5 Plasmids
Working stocks of plasmid DNA were stored at 4°C at a concentration of 0.25-
1mg/mL. Plasmid DNA was stored long term at -20°C.
pcDNA3.1mychis- Invitrogen
pcDNA3.1-V5-6H Invitrogen
pEXPR-IBA 105 IBA BioTAGnology
PR65mouse in pSport1 (30062580) Open Biosystems
PR65rat in pExpress-1 (7126254) Open Biosystems
PP2A 65αGem3Z Gift from Prof. B. Hemmings
PR61α in pET 15b Gift from Prof. J. Goris
PR61γ1 in pGEX4T3 GST` Gift from Prof. J. Goris
USPmouse in pYX-Asc (30459522) Open Biosystems
2.1.6 shRNA
Mouse pLKO.1 lentiviral target gene shRNA set for the silencing of USP28 was
obtained from Open Biosystems. 5 clones (TRCN0000030864, TRCN0000030865,
TRCN0000030866, TRCN0000030867, TRCN0000030868) were supplied, that
target different regions of the USP28 sequence. The shRNA was stored at -80°C in a
glycerol stock until transformation and then purification of plasmids, before
transfection into fibroblast cells.
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2.1.7 Antibodies
Primary Antibodies
EF1α (05-235) Upstate
Hsp70 (610607) BD Transduction Laboratories
Hsp70 3A3 (sc-32239) Santa Cruz
Hsp70/Hsc70 5A5 (sc-59571) Santa Cruz
Hsp90 H33220 BD Transduction Laboratories
Hsp90 4874 Cell Signalling Technology
Myc, 9E10 Gift from Dr. Gerard Evan
PP2A-Aα 6F9 (sc-56953) Santa Cruz
PP2A-Aα 6G3 (sc-56954) Santa Cruz
PP2A B subunit 2G9 (05-592) Upstate
PP2A B56-α C-18 (sc-6116) Santa Cruz
PP2A B’ subunit (07-334) Upstate
PP2Ac F2.5G4 Gift from Martina Olofsson
PP2Ac F2.8F5 Gift from Martina Olofsson
PP2Ac F2.12G10 Gift from Martina Olofsson
PP2Ac F2.12H1 Gift from Martina Olofsson
PP2Ac M1.2A1 Gift from Martina Olofsson
MT Dilworth et al. 1994 Nature 367
MT pAb762-biotinylated In house
Ubiquitin (P4D1) Santa Cruz
USP28 (HPA006778) Sigma
V5 (46-0705) Invitrogen
53BP1 (ab21083) Abcam
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53BP1 H-300 (sc-22760) Santa Cruz
Secondary Antibodies
Cy3 conjugated sheep anti-mouse Jackson
Cy3 conjugated sheep anti-rabbit Jackson
Anti-Mouse HRP DAKO Cytomation
Anti-Rabbit HRP DAKO Cytomation
Anti-Rat HRP Jackson
Streptavidin-biotinylated HRP Jackson
Streptavidin- HRP Jackson
2.1.8 Bacterial Strains
DH5a are chemically competent or electrocompetent Escherchia coli (E. coli) used
when cloning DNA fragments into vectors and for amplification of plasmids. They
replicate DNA with high efficiency, making them suitable for preparing DNA in
small and large quantities.
ROSETTA DE-3 is a BL21 derivative designed to enhance the expression of
eukaryotic proteins that contain codons rarely used in E.coli and can be made
chemically or electrically competent for transformation by heat shock.
2.1.9 Cell Lines
C2 Rat2 fibroblasts with a stable expression of polyoma middle T
antigen
Hela Human epithelial cervical cancer cell line
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NIH/3T3 Mouse fibroblast cell line
Rat2  Thymadine kinase-deficient derivatives from the
immortalised cell line, Rat1
PyST inducible Rat2 fibroblast cell line in which the Tet-On system has been
utilised. Polyoma Small T antigen expression is switched on
by addition of doxycycline
Splenocytes Primary spleen cells from mice
SP2/0-Ag14 Hybrid between BALB/c spleen cells and the myeloma cell
line P3X63AG8; cells were described as not synthesising or
secreting immunoglobulin chains being resistant to azaguanine
at  20  aeg/mL.  and  not  growing  in  HAT medium;  cell  line  is
used as a fusion partner for the production of hybridomas
secreting specific monoclonal antibodies
2.1.10 Bacterial Media
Bactotryptone, yeast extract and Bactoagar were supplied by BD.
LB-Agar 1% (w/v) Bactotryptone
0.5% (w/v) Yeast Extract
0.5% (w/v) NaCl
0.1% (w/v) Glucose
1.5% (w/v) Bactoagar
LB-Broth 1% (w/v) Bactotryptone
0.5% (w/v) Yeast Extract
0.5% (w/v) NaCl
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0.1% (w/v) Glucose
RF-1 pH 5.8 100 mM RbCl
50 mM MnCl24H20
30 mM Potassium acetate
10 mM CaCl
15% w/v Glycerole
RF-2 pH 6.8 10 mM RbCl
10 mM MOPS
75 mM CaCl
15% w/v Glycerole
2.1.11 Cell Culture Materials
BM-Condimed Hybridoma Cloning Supplement (BMCH1) Roche
Doxycycline Calbiochem
Dulbecco’s Modified Eagle Medium (DMEM) Sigma-Aldrich
FBS Gibco
G418 Gibco
L-Glutamine Sigma-Aldrich
Hypoxanthine Azaserine Sigma
Oxaloacetate, Pyruvate and bovine Insulin (OPI) Sigma
Penicillin (100U/ml) Sigma-Aldrich
Puromycin Sigma
RPMI 1640 Gibco
Streptomycin (50mg/ml) Sigma-Aldrich
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Tissue Culture Grade Plasticware VWR
Trypsin Sigma-Aldrich
2.1.12 Buffers, Solutions and Gels
Cell Culture
Versene (Sterile) 140 mM NaCl
3 mM KCl
3 mM Na2HPO4
15 mM KH2PO4
0.5 mM EDTA
0.001% Phenol red
Fibroblast freezing media 70% DMEM
20% FCS
10% DMSO
Hybridoma freezing media 95% FCS
5% DMSO
2x HEPES transfection buffer (pH7.1) 42 mM HEPES
273 mM NaCl
100x Phosphate transfection buffer 70 mM Na2HPO4
70 mM NaH2PO4
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DNA Techniques
Annealing Buffer 500 mM NaCl
200 mM Tris pH8.5
20 mM MgCl2
10x DNA Loading buffer 0.2% (w/v) Bromophenol Blue
40% (v/v) Glycerol
100 mM EDTA pH8.0
10x TBE 900 mM Tris Borate
20 mM EDTA pH8.0
TE Buffer 10 mM Tris HCl pH8.0
1 mM EDTA pH8.0
Protein Analysis
Immunocytochemistry Buffers
I.F Fixing Buffer 170 mM NaCl
3 mM KCl
2 mM KH2PO4 pH7.2
100 mM Na2HPO4 pH7.2
3.6 % (v/v) Formaldehyde
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I.F Permeabilising Buffer 170 mM NaCl
3 mM KCl
2 mM KH2PO4 pH7.2
100 mM Na2HPO4 pH7.2
1% (v/v) NP40
Lysis Buffers
Lysis Buffer 100 mM NaCl
100 mM Tris HCl pH8.5
1% (v/v) NP40
Complete Protease Inhibitors
Lysis Buffer 2 100 mM NaCl
20 mM Tris HCl pH8.0
1 mM EDTA
1% (v/v) NP40
Complete Protease Inhibitors
SDS-PAGE
Laemmli Sample Buffer 2% (w/v) SDS
10% (v/v) Glycerol
80 mM Tris HCl pH6.8
0.004% (w/v)Bromophenol Blue
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5% (v/v) b-mercaptoethanol (1x),
or 15% b-mercaptoethanol (3x)
Polyacrylamide Gels (resolving) 375 mM Tris HCl pH8.8
10-12% (w/v) Acrylamide/Bis
0.1% (w/v) SDS
0.1% (w/v) APS
0.04% (v/v) TEMED
Polyacrylamide Gels (stacking) 125 mM Tris HCl pH6.8
5% (w/v) Acrylamide/Bis
1% (w/v) SDS
1% (w/v) APS
0.1% (v/v) TEMED
SDS-PAGE Fixing Buffer 30% (v/v) Methanol
10% (v/v) Acetic Acid
SDS Running buffer 25 mM Tris base
190 mM Glycine
0.1% (w/v) SDS
Silver Fixing Buffer 50% (v/v) Ethanol
10% (v/v) Acetic Acid
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Western Blotting Buffers
Milk Solution 5% (w/v) skimmed milk powder
130 mM NaCl
20 mM Tris pH7.6
0.1% (v/v) Tween-20
TBS-T 130 mM NaCl
20 mM Tris pH7.6
0.1% (v/v) Tween-20
Transfer Buffer 25 mM Tris Base
190 mM Glycine
20% (v/v) Methanol
Purification Buffers
His-tag wash buffer pH 7 50 mM Na2HPO4
300 mM NaCl
10 mM Imidazole
GST wash buffer 140 mM NaCl
2.5 mM KCl
1.5 mM KH2PO4 pH7.2
10 mM Na2HPO4 pH7.2
1 mM EDTA
1 mM DTT
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Borate Buffer saline pH 8.3 150 mM NaCl
50 mM Boric Acid
StrepTactin Wash Buffer pH8 100 mM Tris/HCl
150 mM NaCl
1 mM EDTA
Miscellaneous Buffers and Solutions
PBS 140 mM NaCl
2.5 mM KCl
1.5 mM KH2PO4 pH7.2
10 mM Na2HPO4 pH7.2
TBS-N 50 mM Tris HCl pH8
150 mM NaCl
0.05 % NP40
Phosphate Buffer pH 9 1 M Na2HPO4
1 M NaH2PO4
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Defined Qiagen Supplied Buffers and Solutions
Qiagen Buffer EB 10 mM Tris HCl pH8.0
Qiagen Buffer P1 50 mM Tris HCl pH8.0
10 mM EDTA
100 mg/ml RNase A
Qiagen Buffer P2 200 mM NaOH
1% (v/v) SDS
Qiagen Buffer P3 3 M KAc pH5.5
Qiagen Buffer QBT 750 mM NaCl
50 mM MOPS pH7.0
15% (v/v) Isopropanol
0.15% (v/v) Triton X-100
Qiagen Buffer QC 1 M NaCl
50 mM MOPS pH7.0
15% (v/v) Isopropanol
Qiagen Buffer QF 1.25 M NaCl
50 mM Tris HCl pH8.5
15% (v/v) Isopropanol
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Qiagen TE Buffer 10 mM Tris HCl pH8.0
1 mM EDTA
New England Biolabs Supplied Buffers
NEBuffer 1 10 mM Tris Propane HCl pH7.0
10 mM MgCl2
1 mM DTT
NEBuffer 2 10 mM Tris HCl pH7.9
10 mM MgCl2
50 mM NaCl
1 mM DTT
NEBuffer 3 50 mM Tris HCl pH7.9
10 mM MgCl2
100 mM NaCl
1 mM DTT
NEBuffer 4 20 mM Tris Acetate pH7.9
10 mM MgCl2
50 mM KAc
1 mM DTT
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2 X Quick Ligation Buffer (pH 7.6) 132 mM TrisHCL
20 mM MgCl2
2 mM ATP
2 mM DTT
15% Polyethylene Glycol-8000
Pierce supplied Buffers and Solutions
BupH PBS pH 7.2 0.1 M phosphate
0.15 M sodium chloride
BupH Citrate Carbonate Buffer pH10 0.1 M sodium citrate
0.05 M sodium carbonate
Quenching Buffer pH 7.4 1 M TrisHCl
0.05% NaN3
AminoLink Wash solution 1 M NaCl
0.05% NaN3
Sodium cyanoborohydride Solution 5 M
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2.1.13 In Silico Materials
Software Packages
DNASTAR Lasergene
Office Software Suite Microsoft
Cn3D version 4.1 NCBI
MetaMorph MDS Analytical Technologies
Websites and Databases
http://www.ncbi.nlm.nih.gov/blast/Blast.cgi
http://www.ncbi.nlm.nih.gov/sites/entrez
http://align.genome.jp.mafft
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2.2 Methods
2.2.1 Bacterial Techniques
All bacterial techniques were performed aseptically.
Storage of Bacteria
Amplification of DNA plasmids were performed in Escherichia coli strain DH5a.
All the plasmids described possessed resistance genes to ampicillin, kanamycin,
carbenicillin or chloramphenicol. Transformed bacteria were grown in LB-broth or
LB-agar containing either: 100 mg/ml ampicillin, 50 mg/ml kanamycin, 100 mg/ml
carbenicillin or 30 mg/ml chloramphenicol. Bacterial stocks were stored in LB-broth
containing 40% (v/v) glycerol at -80°C.
Preparation of Competent Bacteria for Transformation by Heatshock
DH5a were streaked onto an LB-agar plate without antibiotic and incubated at 37°C
overnight. A single colony was used to inoculate 10 ml LB-broth, incubated at 37°C
overnight. 4ml of overnight culture was used to inoculate 400 ml broth and incubated
at 37°C until the bacteria were in log-phase growth, as judged when the OD595
(optical density) measured 0.6. The culture was then transferred to two pre-chilled
centrifuge tubes and incubated on ice for 10 minutes. The cells were then recovered
by centrifugation at 4000 rpm and 4°C for 10 minutes, and the media discarded. The
pellets were resuspended in 120 ml pre-chilled RF1 buffer and left on ice for 1 hour.
The bacteria were centrifuged at 4000 rpm and 4°C for 10 minutes, and the
supernatants discarded. The pellets was then resuspended in 32 ml pre-chilled RF2
buffer and aliquoted for storage at -80°C.
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Transformation of Bacteria by Heatshock
Chemically competent DH5a cells were thawed on ice. 50 ml and 100 ml of bacteria
were transferred to a pre-chilled microfuge tubes and 250-500 ng plasmid DNA or 20
ml  cloning  ligation  reaction  was  added  to  the  competent  cells,  respectively,  and
mixed. The bacteria/DNA mixture was incubated on ice for 40 minutes before
heatshock  at  41°C  for  1  minute.  Cells  were  placed  back  on  ice  for  5  minutes  and
200 ml LB media added to each transformation. The transformation reactions were
then incubated at 37°C for 1 hour, plated on selective plates and incubated at 37°C
overnight.
2.2.2 Nucleic Acid Manipulation
Restriction Digest
Restriction digests were performed in accordance with New England Biolabs
guidelines. To generate vector backbone DNA, 1 mg of plasmid DNA was digested
with 100 units of the appropriate restriction endonucleases in a 50 ml reaction
containing the recommended buffer, 10 ng/ml BSA if required, and incubated at the
appropriate temperature, typically 37°C for 1.5 hours.
50 units of bacterial alkaline phosphatase was added to single digest reactions and
incubated at 37°C for 15 minutes followed by 65°C for 5 minutes.
The restriction products were then analysed by agarose gel electrophoresis, the
vector backbone DNA excised from the gel and purified using QIAEX II Gel
Extraction Kit.
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Insert DNA was derived from digesting 1 mg of the appropriate plasmid DNA or the
purified  product  from  a  PCR  reaction.  1 ml of the appropriate restriction enzymes
were  used  in  a  50 ml reaction and incubated for 1.5 hours at the appropriate
temperature. Restriction products were then analysed by agarose gel electrophoresis,
the insert DNA excised and purified using QIAEX II Gel Extraction Kit.
Oligonucleotide Phosphorylation and Annealing
Lists of Oligonucleotides used for cloning applications can be found in Table 2.1.
Oligonucleotides were phosphorylated by combining T4 PNK and buffer with 1.4 ml
of Mycfor and Mycrev (both 100mM),  10  mM  ATP  and  water  up  to  90 ml, and
incubated for 1 hour at 37°C followed by 15 minutes at 70°C. 10 ml of (10x)
annealing buffer was added and the Oligonucleotides were incubated at 90°C for 5
minutes and allowed to cool slowly to room temperature over 40 minutes before
being placed on ice.
Polymerase Chain Reaction
List of Oligonucleotides used for PCR can be found in Table 2.1. Polymerase chain
reactions (PCRs) were performed with Phusion polymerase. Reactions were typically
50 ml and were performed in accordance with polymerase manufacturer’s guidelines
and with the supplied buffers. The reactions contained 200-400 mM dNTPs, 10 pM
forward and reverse Oligonucleotide primers, 250 ng of DNA template, 10 ml PCR
buffer HF, 0.5ml phusion polymerase and water up to 50ml. Cycling conditions were
determined empirically for each reaction, and were within the polymerase
manufacturer’s guidelines. Typical cycling conditions are shown in Table 2.2. PCR
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products were analysed by agarose gel electrophoresis, excised from the gel and
purified using QIAEX II Gel Extraction Kit. Purified products could then be used for
restriction digest and ligation into a vector.
The Oligonucleotides used in the PCR reactions to create the specific PR65
fragments, tagged PR65 and tagged USP28 are detailed in Table 2.3.
Agarose Gel Electrophoresis
0.8-1% (w/v) agarose gels were cast by dissolving agarose into TBE buffer by
heating in a microwave, allowing the solution to cool, adding 3 ml of SYBR Safe
Dye per 50 ml gel, and pouring into an appropriate size mould. Gels were then
submerged in TBE buffer and DNA samples loaded into wells following the addition
of 10x DNA loading buffer to the samples. Electrophoresis was performed at 80V
until  the  DNA fragments  were  resolved.  SYBR Safe  stained  DNA fragments  were
then visualised in a transilluminator (UVP). The size of fragments was estimated by
comparing to HyperLadder DNA markers. DNA fragments required for cloning were
then excised from the gel using a scalpel and purified using QIAEX II Gel Extraction
Kit.
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Table 2.1. Oligonucleotides used in Nucleic Acid manipulation techniques.
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Table 2.2. Summary of PCR cycling conditions for Phusion polymerase.
Tm refers to the lowest melting temperature of the primers in the reaction.
Cycle Step Temp (ºC) Time
Initial Template Denaturation 94 3 minutes
Template Denaturation 94 45 secs
Primer Annealing Tm+3 60 secs 25 cycles
Product Extension 72 2 minutes
Final Product Extension 72 10 mins
Phusion
Table 2.3. Oligonucleotides used to create specific fragments.
FRAGMENT OLIGONUCLEOTIDES USED
F1 N1, C1
F2 N2, C2
F3 F3, C2
F4 F4, C2
F5 F5, C2
F6 F6, C2
F7 F7, C2
F8 F8, C2
F9 F9, C2
F10 F10, C2
F11 F11, C2
F12 F12, C2
F13 N1, F13
F14 N1, F14
F15 N1, F15
F16 N1, F16
F17 N1, F17
F18 N1, F18
F19 N1, F19
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DNA Purification by QIAEX II Gel Extraction Kit
The QIAEX II kit uses silica particles (QIAEX II), which absorb DNA fragments in
the presence of high salt (QX1 buffer). The impurities are washed with an ethanol
containing buffer (PE) and eluted in Tris buffer or H2O. DNA fragments were
purified in accordance with the manufacturer’s guidelines. The excised gel slices
containing the required DNA fragments were placed in a fresh microfuge tube and
weighed. 3 gel volumes of buffer QX1 was added to 1 volume (100 mg) of gel slice
with the addition of 20ml  QIAEX II, and incubated at 50ºC with occasional agitation
for 10 minutes or until the gel melted. The samples were centrifuged at 13000 rpm
for 30 seconds. The flow through was discarded and the DNA washed by applying
500 mL buffer QF1, vortexing and centrifuged as before. The flow through was then
discarded and the DNA washed twice with 750 mL buffer PE. The flow through was
discarded and the DNA pellet was air dried for 10-15 minutes or until the pellet
became white. 20 ml H2O was then applied to white pellet, vortexed and incubated at
50ºC for 5-10 minutes depending on the size of the DNA fragment, before
centrifugation at 13000 rpm for 30 seconds and the supernatant (DNA) pipetted into
a fresh microfuge tube.
DNA Precipitation
DNA was precipitated by addition of salt and ethanol and resuspended in an
appropriate volume to increase the concentration of the DNA and purify DNA from
samples.  0.1  sample  volumes  of  3  M  NaAc  was  added  to  the  DNA  and  mixed,
followed by 2.5 volumes of ethanol, and incubated on dry ice for 1 hour. Samples
were centrifuged at 15300rpm and 4°C for 30 minutes to pellet the DNA. The pellets
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were washed with 1 volume of 70% (v/v) ethanol and centrifuged as before for 15
minutes. The supernatant was discarded and the pellets allowed to air-dry. The DNA
was resuspended in an appropriate amount of TE buffer or H2O and quantified by
measuring absorbance at 260 nm.
DNA Ligation
Ligation  reactions  were  performed  in  accordance  with  the  enzyme  manufacturer’s
instructions. Backbone vectors and PCR product inserts were prepared by restriction
digest, purified, and quantified by agarose gel electrophoresis. Oligonucleotide
inserts with the appropriate 5’ and 3’ overhangs were prepared by annealing and
phosphorylating. Ligation reactions were 20 ml in total volume and consisted of 1x
Quick Ligase buffer, 1ml  Quick  T4  Ligase  and  50  ng  DNA.  The  DNA  used  in
ligation reactions consisted of vector and insert combined in a 1:3 ratio, or of vector
alone for control reactions. Ligation reactions were incubated for 5 minutes at room
temperature. All the ligation mix was used to transform chemically competent
bacteria.  The  presence  of  the  insert  in  the  vector  backbone  was  determined  by
preparing miniprep DNA and performing analytical restriction digest followed by
sequencing.
TOPO Cloning
TOPO reactions were performed in accordance with Invitrogen’s guidelines. Inserts
possessed the 5’-CACC strand invasion sequence required to provide directional
ligation into pcDNA3.1-V5-6H, and were either Oligonucleotides or generated by
PCR using Phusion polymerases. 0.5 ml Insert was added to 0.5 mL TOPO vector and
2 ml H2O in a fresh microfuge tube and incubated at room temperature for 5 minutes.
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The reaction was then transformed into 50 ml TOP10 bacteria and plated on
ampicillin selective plates. The presence of the insert in the vector backbone was
determined by preparing miniprep DNA and performing an analytical restriction
digest.
DNA Preparation
All  DNA  preparation  techniques  were  performed  in  accordance  with  Qiagen
guidelines.
Small Scale DNA Preparation by Qiagen QIAprep Spin Miniprep Kit
Qiagen QIAprep Spin Miniprep Kits were routinely used to prepare plasmid DNA on
a small scale, typically generating 15-25 mg of DNA. Briefly, individual transformed
colonies were selected from agar plates to inoculate 5 ml selective LB-broth and
incubated overnight at 37°C. The cultures were then centrifuged at 4000 rpm and
4°C  for  10  minutes  to  pellet  the  bacteria  and  the  media  removed.  Pellets  were
resuspended in 250 ml buffer P1 and the cells lysed by addition of 250 ml buffer P2.
The lysis reaction was neutralised and bacterial genomic DNA and proteins
precipitated by addition of 350 ml buffer N3. Samples were then centrifuged at 15000
rpm for 10 minutes and the supernatant applied to the provided spin column, which
binds DNA to a silica resin under high salt concentrations. Plasmid DNA was bound
to the resin by passing the supernatant through the column by centrifugation or by
using a vacuum manifold. The DNA was then washed with 750 ml  buffer  PE  and
dried by centrifugation. The purified plasmid DNA was eluted with 50 ml buffer EB
by incubating at room temperature for 1 minute and centrifugation at 15000 rpm for
2 minutes. The concentration of the eluted DNA was determined by measuring
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absorbance at 260 nm. Miniprep DNA was then used for analytical restriction digests,
DNA sequencing, in vitro protein expression or downstream cloning procedures.
Large Scale DNA Preparation by Qiagen HiSpeed Plasmid Maxi Kit
For larger scale DNA preparations, Qiagen HiSpeed Plasmid Maxi Kits were
routinely used to prepare 0.5-1 mg of plasmid DNA. The Maxi Kits work by the
same principle as the miniprep procedure. Briefly, an individual colony from a
selective plate was used to inoculate 5 ml selective LB-broth and incubated for 8
hours at 37ºC. 200 ml of this starter culture was then used to inoculate 200 ml of
fresh selective LB-broth and incubated overnight at 37°C. Cultures were centrifuged
at 4500xg and 4°C for 10 minutes to pellet the bacteria and the media removed.
Pellets were resuspended with 10 ml buffer P1, lysed with 10 ml buffer P2, and the
reaction neutralised by 10 ml buffer P3. Bacterial lysates were then filtered with the
provided QIAfilter Cartridge and applied to a HiSpeed Maxi Tip previously
equilibrated with 10ml buffer QBT. The lysate was passed through the tip by gravity
flow, allowing the plasmid DNA to bind to the silica resin.  The DNA was washed
with 60 ml buffer QC and eluted with 10 ml buffer. 10.5 ml isopropanol was added
to the eluate and incubated at room temperature for 5 minutes to precipitate the DNA.
Precipitated DNA was then applied to the provided QIAprecipitator, washed with
2  ml  70%  (v/v)  ethanol,  and  air-dried.  The  plasmid  DNA  was  eluted  in  1  ml  TE
buffer, and the concentration measured by absorbance at 260 nm. Maxiprep DNA
was then used for transfection, in vitro protein synthesis or downstream cloning
procedures.
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DNA Sequencing
Oligonucleotides used for sequencing can be found in Table 2.1. 0.5-1 μg miniprep
DNA and 3.2 pmol of the appropriate Oligonucleotide was prepared in H20 of a 10 μl
volume. DNA sequencing was performed by the sequencing services at the MRC
Genomics department, Hammersmith Hospital. DNA sequence files were analysed
using DNASTAR software package.
2.2.3 Cell Culture Methods
Maintenance of Cell Stocks and Storage of Cells
Hela, NIH/3T3 Rat2 and C2 cells were maintained in standard medium consisting of
DMEM supplemented with 10% (v/v) FBS, 2 mM penicillin/streptomycin and 4 mM
L-glutamine  at  37ºC  and  10%  CO2. Cells were grown as a monolayer on tissue
culture grade plastics.
Hybridoma cell lines were maintained in media consisting of RPMI supplemented
with 10% (v/v) FBS, 2 mM penicillin/streptomycin and 4 mM L-glutamine at 37ºC
and 5 % CO2. Cells were grown as a monolayer on tissue culture grade plastics.
Monoclonal Antibody preparation
Immunisation
Immunisations were carried out on Balb/c x B6F1 F1 mice by subcutaneous injection
with 50 μg fusion protein suspended in Titremax Gold (CytRx Corporation) in a 1 to
1 dilution. Immunisations once a month over a three month time period were
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performed and then the mice were rested for 3 months. The mice were then boosted
by intraperitoneal injection of protein, six and three days prior to fusion.
Fusion
Antibody secreting cells were established by fusing splenocytes from the immunised
mouse with the myeloma line Sp2/0-Ag14 by polyethylene glycol (PEG) treatment
using conventional procedures. The hybrid cells were plated onto 96 well plates in
RPMI media supplemented with 20% FBS, 2 mM penicillin/streptomycin, 4 mM L-
glutamine,  10%  BMCHI,  2%  OPI  and  selected  for  with  addition  of  1%  HAZ.
Individual wells were screened for antibody production by a modified dot blot
procedure using bacterially expressed fusion protein. Positive clones were single cell
cloned on 96 well plates, grown and screened for antibody secretion by the dot blot
method. Single cell cloning was repeated until all tested clones were positive. After
the first week of production HAZ is omitted from the media. BMCHI is added only
when the cells are being cloned.
Transfection Techniques
DNA transfection into fibroblasts were carried out using calcium phosphatase
mediated transfection. A mixture of 10 μg of DNA was diluted with 125 mM CaCl2
in a total volume of 490 μl and added drop by dop whilst bubbling air through a pre-
plugged Pasteur pipette, into a tube containing 10 μL 100x PO4 buffer and 500 μl 2x
HEPES buffer. The 1 ml cloudy DNA precipitation was applied to a 60-70%
confluent 90 mm TC dish containing 9 mL of DMEM media supplemented with 5%
FBS, 2 mM penicillin/streptomycin and 4 mM L-glutamine and left in incubator for
4 hours or over night before fluid changing to DMEM supplemented with 10% FBS,
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2 mM penicillin/streptomycin and 4 mM L-glutamine. After 4 hours the transfected
cells were split 1:5 into media containing the appropriate selection. Media was
changed  every  few  days  until  separate  colonies  have  formed.  These  were
individually picked and screened for expression of the tagged proteins, or, in the case
of transfection with shRNA, screened for a lower expression of USP28.
2.2.4 Protein Analysis
Cell Lysis
Media was removed from the confluent Tissue culture dish and the cells washed with
PBS. The plates were put on ice to chill and 1 ml of chilled Lysis buffer was added to
each 90 mm dish and left on ice for 15 minutes, agitating gently. The cell extract was
then pipetted off the plates and centrifuged for 10 minutes at 15300 rpm and 4°C.
The supernatant was removed into fresh chilled microfuge tubes and immediately
frozen to -80°C.
Protein Expression in Bacteria
A plasmid encoding PR65 sequence fused to a 6x Histidine tag, PET28HisPR65, and
a plasmid encoding PR61α sequence fused to a 6x  Histidine tag, were transformed
into the ROSETTA strain of E.coli by the Heatshock protocol. The transformed
bacteria were grown overnight on Luria- Bertani (LB) agar plates containing 50
μg/ml Kanamycin, and 100 μg/mL Ampicillin and 34 μg/ml of Chloramphenicol,
respectively. A single colony was used to inoculate 10ml LB-broth containing the
appropriate antibiotics. After incubation overnight at 37oC, the culture was
transferred to 500 mL of the same medium in a shaking flask pre-warmed to 37oC.
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At an OD595 of 0.6, protein expression was induced by addition of 1 mM IPTG and
shaking continued for 3-4 hours. Cells were then harvested by centrifugation (4000
rpm, 20 minutes, 4oC) before resuspending in 40 ml of His-tag wash buffer with the
addition of complete EDTA-free Protease Inhibitor cocktail tablets (Roche), 7.5
KU/ml Lysozyme and 2 U/ml Benzonase Nuclease, mixing for 20 minutes at room
temperature.  The  lysate  was  then  subjected  to  4  cycles  of  sonication  before  being
centrifuged (16,000xg, 20 minutes, 4oC) and the pellet discarded. Immobilised Metal
Affinity Chromatography (IMAC) was carried out using TALON metal affinity resin,
consisting of sepharose beads bearing the tetradentate chelator of the Co2+ metal ion.
The  resin  was  pre-equilibrated  in  His-tag  wash  buffer  and  then  incubated  with  the
solubilised tagged protein for 3 hours. The resin was isolated by centrifugation and
washed three times with 20 ml of His-wash buffer, then transferred to a plastic
column and washed a further 3 times. Elution of the protein was achieved by addition
of  10x  1  ml  fractions  of  Elution  buffer  (9  ml  His-tag  wash  buffer  +  1  ml  3M
Imidazole,). 1 μl of each of the eluted samples were subjected to 10% SDS-PAGE
(Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis) and the protein
samples visualised by staining with PageBlue Protein Staining Solution. The samples
containing the highest concentrations of PR65 were dialysed twice for 8 hours
against 2 L PBS at 4oC.
The coding sequence of human PR61γ1 fused to a glutathione-S-transferase (GST)-
tag in the vector pGEX-4T-3 was transformed into Rosetta DE3. A single colony was
inoculated into 10 ml LB containing 100 μg/ml Ampicillin, then incubated overnight
in a 37oC shaker. The culture was diluted into a large volume and grown to an OD595
of 0.6 and protein expression induced by addition of 1 mM IPTG, as above. The
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bacteria was pelleted and resuspended in GST wash buffer with the addition of
Protease Inhibitor,  3 μl  Benzonase Nuclease and 30 KU/ml rLysozyme. The lysate
was sonicated and centrifuged as above and the supernatant incubated with
Glutathione Sepharose 4B resin overnight at 4oC. The resin was washed in PBS and
the tagged protein eluted by addition of 10 mM reduced Glutathione in 50 mM Tris,
pH 8, and the protein cleaved from the GST tag by thrombin. This was then re-
incubated with the resin to remove the GST tag. The solution was dialysed and the
precipitated protein washed several times in PBS to remove the thrombin
contamination.
Antibody Purification
25 ml of 1 M Tris pH 8 was added to 500 mL TCF from each of the antibody clones,
to neutralise the acidic growth conditions. 2 ml of Protein A Agarose, pre-
equilibrated in borate buffer saline, BBS, was added to the TCF, and incubated for 4
hours at room temperature. The agarose-antibody slurry was then centrifuged at 1000
rpm for 5 minutes and washed three times with 20 ml BBS before being transferred
to a column, then washed with a further three times with 10ml BBS. Elution of the
antibody was achieved by addition of 3x 1 ml fractions of 20 mM Citric Acid pH 2.8
and collected into 1.5ml microfuge tubes containing 100 μl 1 M Phosphate Buffer
pH 9.0. The three eluates were pooled and dialysed twice for 8 hours against 2L PBS
at 4oC. The purity of all the antibodies were confirmed by SDS-PAGE and staining,
and the concentration was determined using the Bradford Reagent protein assay and
Bovine Gamma Globulin as the standard.
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Amino-Linking of the Antibodies
Purified Antibodies were linked through amino groups to agarose beads using an
AminoLink Plus Immobilization Kit and the manufacturer’s pH 10.0 coupling buffer
protocol. Each 1 mg of purified antibody requires 1 ml of AminoLink Column
agarose, pre-equilibrated in BupH Citrate Carbonate Buffer pH10. These are
incubated together with 4 times the antibody volume of BupH Citrate Carbonate
Buffer pH10, and end over end rocked at room temperature for 4 hours. The
supernatant was removed by centrifuging at 3000 rpm for a few seconds and the
column was washed with 2 ml of BupH PBS pH 7.2. The supernatant was removed
as above. In fume hood, 2 ml of BupH PBS pH 7.2 with the addition of 40 μl of
Sodium Cyanoborohydride Solution was added to the column and mixed over night
at 4°C. The column was washed with 2 ml of Quenching buffer and centrifuged at
3000 rpm for a few seconds and the supernatant discarded. In fume hood, 2 ml of
Quenching buffer with the addition of 40 μl of Sodium Cyanoborohydride Solution
was  added  to  the  column  and  mixed  end  over  end  rocked  for  30  minutes  at  room
temperature. The column was washed 4 times with 2 ml of AminoLink Wash
solution and the supernatant discarded. PBS pH 7.2 with the addition of 0.05%
sodium azide was added in a 1:1 dilution and the column was stored upright at 4°C.
Antibody Isotyping
The Mouse Monoclonal Antibody IsoStrip Kit, was used to determine the isotype
(IgG1, IgG2a, IgG2b, IgG3, IgM, IgA) for each of the antibody clones. This kit uses
latex beads bearing anti-mouse kappa and anti-mouse lambda antibodies which will
react with any mouse monoclonal antibody and travel up the isostrip strip via
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capillary action until it is bound by the immobilised goat anti-mouse antibody
specific for the monoclonal’s isotype and by the immobilized antibody specific for
the monoclonal’s light chain. The procedure was carried out according to the
manufacturer’s instructions. 150 μl of diluted tissue culture fluid (1:50 in PBS) is
added to the latex in the developing tube, vortexed and incubated at room
temperature for 30 seconds. The isostrip is inserted into the developing tube and for
5-10 minutes  to reveal the mouse monoclonal antibody isotype.
In Vitro Protein Synthesis
In vitro protein synthesis was performed using the TNT Quick Coupled
Transcription/Translation System. This system couple RNA transcription from a
DNA template possessing a T3, T7 or SP6 promoter with translation of the
transcribed RNA in a single reaction that utilises rabbit reticulocyte lysate. Reactions
were assembled on ice according to the manufacturer’s guidelines and performed in a
total reaction volume of 50 ml with 1 mg  of  plasmid  DNA  and  1 ml methionine.
Reactions were incubated at 37°C for 90 minutes and the product used in western
blot and immunoprecipitation experiments.
Measurement of Protein Concentration
Protein concentration was determined by using BCA Protein Assay kit or Bradford
Reagent. Reactions were performed in accordance with the manufacturer’s
guidelines.
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BCA Protein Assay
The BCA Protein Assay procedure is based on the ability of peptide bonds to reduce
Cu2+ from cupric sulphate to Cu1+, which then chelates with two molecules of
bicinchoninic acid forming a purple solution that absorbs light at 592 nm. Protein
extracts were diluted as necessary in HEPES lysis buffer, typically 1:10 or 1:100, and
25 ml added to one well a 96-well plate. Protein standards ranging from 25 mg/ml to 2
mg/ml were prepared from BSA, and 25 ml of each standard added to the 96-well
plate. BCA working reagent was prepared by mixing 50 parts BCA Reagent A with 1
part BCA Reagent B and 200 ml was added to each standard and sample. The
reaction was incubated for 30 minutes at 37°C and absorbance was measured at 592
nm.
Bradford Reagent
The Bradford Reagent procedure is based on the formation of a complex between
dye, Brilliant Blue G-250, and proteins in solution. The complex causes a shift in the
absorption maximum of the dye from 465 to 595 nm. The amount of absorption is
proportional to the amount of proteins present in the solution. Protein standards were
prepared from BSA or BGG, ranging from 20 mg/ml to 625 mg/ml, and samples
were prepared by diluting appropriately, typically 1:10. 10ml of standard or sample
was added to 500 ml of diluted reagent, vortex mixed, incubated at room temperature
for 5 minutes and absorbance at 595 nm was measured.
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Immunoprecipitation from Protein Extracts
Fibroblast  lysates were prepared as described above with Lysis Buffer.  The lysates
were pre-cleared by addition of 45 μl of Sepharose Cl-4B per 1 ml of lysate, on ice
for 15 minutes, vortexing every 5 minutes. 100 μl of this pre-cleared lysate was
incubated on ice for 1 hour with 50 μl of tissue culture fluid containing the antibody,
or 0.5 μg of purified antibody. 25 μl of a 50% Protein A Sepharose Cl-4B bead slurry
was added to each sample and incubated on ice for 30 minutes, mixing every 5
minutes. 1 ml of ice cold TBS-N was added and then centrifuged at 3000 rpm for a
few seconds and the supernatant removed with a syringe needle. This was repeated 5
times. 30 μl of 1x Laemmli sample Buffer was added to each sample, and incubated
at room temperature for 3 minutes and the samples centrifuged at 15000 rpm for a
few seconds to separate the beads from the eluted proteins. The eluates were then
subjected to western blotting.
This protocol was also carried out under denaturing conditions by subjecting the
lysate  to  1%  SDS,  boiling  for  5  minutes  and  then  diluting  ten  fold  in  lysis  buffer
supplemented with 1% DOC and 1% NP40, before the IP procedure. To further
denature complexes the IP experiment was carried out with native lysate as above,
however the elution of the proteins were achieved by addition of 1% SDS and 1%
DTT, and boiling for 5 minutes. This eluate was then re-immunoprecipitated with the
same antibody.
IP using Amino-Linked antibodies
Each of the Purified Antibodies were linked through amino groups to agarose beads
using an AminoLink Plus Immobilization Kit, as already described. 25 μl of the
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amino linked antibody-agarose was then incubated on a rotator with 1 ml of pre-
cleared lysates for 4 hours at 4oC. The slurry was washed with 5x 1 ml TBS-N and
eluted by addition of 1x Laemmli sample buffer as described above. The complexes
were then visualised by separating on a 10% SDS-PAGE and either silver stained
using a SilverQuest Silver Staining Kit according to the manufacturer’s protocol or
PageBlue. Volumes of amino-linked antibody and lysate were increased to 50 μl and
15 ml respectively, for further analysis.
Purification of Strep- tagged proteins
Proteins linked to a Strep III tag were purified from cell extracts using StrepTactin, a
streptavidin derivative. All procedures to be kept at 4°C unless stated otherwise.
StrepTactin Sepharose
10 ml of cell lysate containing strep-tagged proteins were thawed on ice and added to
200 μl of pre-equilibrated (with StrepTactin wash buffer) StrepTactin sepharose and
incubated on a rotator 4 hours at 4oC. The slurry was washed with 5 times with 1 mL
StrepTactin wash buffer and eluted by addition of 40 μl of 1x Laemmli sample buffer.
The complexes were then analysed for composition by SDS/PAGE followed by
either western blot analysis or Coomassie and silver stain procedures.
StrepTactin Column
Cell lysate containing strep-tagged proteins were thawed on ice. The volume of
lysate required is dependent on the column volume (see Table 2.4). The StrepTactin
column is pre-equilibrated with 2 column volumes of StrepTactin wash buffer prior
to addition of the lysate. After the cell extract has completely entered the column, it
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is then washed 5 times with 1 column volume of StrepTactin wash buffer. Elution of
the strep-tagged proteins is then achieved by addition of 6 times 0.5 column volumes
of Biotin Elution buffer (StrepTactin wash buffer + 2mM biotin). The fractions
containing the protein are then identified by western blot analysis using a
Streptavidin HRP. The positive fractions are pooled and can then be used in either a
tandem purification, in which this pooled elution is incubated with 50 μl of the amino
linked anti-myc, 9E10 antibody and an IP experiment performed as described above,
or, analysed for composition by SDS/PAGE followed by either western blot analysis
or Coomassie and silver stain procedures.
Table 2.4. Recommended buffer and protein extract volumes for
chromatography on StrepTactin columns.
Column Bed
Volume (CV)
Protein Extract
Volume
Washing Buffer
Volume
Elution Buffer
Volume
0.2 mL 1-4 mL 5 x 0.2 mL 6 x 0.1 mL
1 mL 4-12 mL 5 x 1 mL 6 x 0.5 mL
SDS-PAGE
10% and 12% resolving gels were poured by combining the components listed in the
section 2.1.12, pipetting the gel solution between glass plates, and overlaying with
H2O to ensure the gel is level. 5% stacking gels were then poured over set resolving
gels and a comb inserted. Protein samples with addition of 3x Laemmli sample
buffer, were heated at 90°C for 5 minutes prior to loading onto gels alongside Pre-
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Stained and Un-Stained Protein Standards, and subjected to electrophoresis at 150 V
until the marker had sufficiently separated.
Coomassie and Silver Staining
Coomassie and silver staining procedures were performed on polyacrylamide gels in
accordance with the stain manufacturer’s guidelines.
Coomassie Staining
Following SDS-PAGE, gels were rinsed for 5 minutes with an excess of distilled
H2O, and incubated with PageBlue Gel Staining Reagent for 1 hour or overnight, and
washed  with  distilled  H2O  until  background  staining  was  reduced.  Gels  were  then
dried on to filter paper using a Savant SGD2000 Slab Gel Dryer or stained protein
bands  were  cut  out  using  a  scalpel  in  sterile  conditions,  and  subjected  to  mass
spectrometry. Mass spectrometry was carried out by Dinah Rahman, Proteomics
Facility, MRC Clinical Sciences Centre, Hammersmith Hospital and Paul Hitchen,
Glycomics technologist, Division of Molecular Biosciences, South Kensington
Campus.
Silver Staining
SDS-PAGE gels were fixed in silver fixing buffer for 1 hour or overnight, followed
by  washing  in  30%  (v/v)  ethanol  for  10  minutes.  Gels  were  then  washed  with
distilled H2O for 10 minutes, and incubated with Sensitiser solution for 10 minutes,
followed by a further wash with distilled H2O for 10 minutes and incubation with
Silver solution for 10 minutes. Gels were then washed for 90 seconds with distilled
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H2O and developed in Developer solution until the appropriate staining intensity was
achieved. Gels were dried on to filter paper using a Savant SGD2000 Slab Gel Dryer.
Western Blotting
Standard Protocol
Following SDS-PAGE, proteins were transferred to Nitrocellulose membrane by
electroblotting using the Hoeffer Blot system. The membrane was placed directly
onto the gel, ensuring no air bubbles were present, and the gel and membrane placed
between two pieces of 3 mm filter paper and two sponge pads. This was assembled
in transfer buffer and held together in a transfer cassette. Electroblotting was
performed at 100V at 4°C for 1.2 hours. Membranes were rinsed in TBS-T, and
additional protein binding sites on the membrane were blocked with 5% milk
solution for 1 hour at room temperature or overnight at 4°C. Purified primary
antibodies were diluted in milk solution, typically 1:1000, or undiluted TCF was
incubated  with  the  membrane  at  either  room  temperature  for  1  hour  or  at  4°C
overnight.  Membranes  were  washed  three  times  for  5  minutes  with  TBS-T,  before
incubation with the appropriate HRP-conjugated secondary antibody diluted 1:5000
in milk solution for 1 hour at room temperature. Membranes were again washed four
times for 10 minutes in TBS-T, and the bound secondary antibody was then detected
by incubation with Immobilon Western Chemilumescent HRP Substrate or
Supersignal West Femto Maximal Sensitivity Substrate. Biotinylated antibodies
require all incubations to be with BSA and not milk. For detection of streptavidin and
biotinylated proteins in the extract, the membrane is incubated with 5% milk powder
for 1 hour followed by incubation with streptavidin HRP in 3% BSA for 1 hour. The
membrane is then washed four times for 10 minutes in TBS-T and detection carried
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out using Immobilon Western Chemilumescent HRP Substrate or Supersignal West
Femto Maximal Sensitivity Substrate.
Dot Blot Procedure
Nitrocellulose membrane was incubated overnight with the bacterially expressed
fusion protein and blocked with 5% milk in PBS for one hour. The membrane was
then spotted with a drop of tissue culture fluid from each of the wells. The membrane
was washed 4x 10 minutes in PBS-T before incubation with horseradish peroxidase
linked - Anti-mouse Ig, for 1 hour. The membranes were then washed a further 4
times in PBS-T and Immobilon Western a chemiluminescent HRP substrate kit was
used to detect the positive colonies.
Immunofluorescence
Fibroblasts were grown overnight in regular medium on glass coverslips. Cells were
washed at 37oC with DMEM prior to fixing. 10 mL IF Fixing buffer was added to the
TC  plate  and  incubated  for  10  minutes.  The  coverslips  were  washed  3  times  with
PBS and permeabilised for 10 minutes with IF permeablising buffer. The coverslips
were then treated with Image-iT  FX Signal enhancer to diminish any background
staining. Cells on each coverslip were incubated for 1 hour with antibody, washed in
PBS, and stained by incubation with the appropriate Cy3 conjugated antibody in 1%
BSA, 1% gelatine, PBS, for 1 hour. The coverslips were washed 3 more times before
being mounted onto slides using ProLong Gold antifade reagent and examined under
the Nikon epifluorescent microscope.
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2.2.5 In Silico Techniques
The alignment of USP28 and PR65 sequence was performed using the Mafft online
sequence alignment website. All other sequence alignments were performed using
the MegAlign program, which forms part of the DNASTAR software suite. This
software package also includes the Primer Select program which was used when
designing the Oligonucleotides used in the PCR reactions. 3D molecule images of
the PP2A subunits were manipulated using the 3n3D Viewer. Immunofluorescent
and live cell images were captured using the MetaMorph software.
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CHAPTER 3: PRODUCTION AND CHARACTERISATION OF
MONOCLONAL ANTIBODIES
3.1 Introduction
To understand more about how PP2A is regulated it is important to study the
complex composition of this phosphatase. To achieve this, tools are required that can
isolate PP2A containing complexes from cellular lysate. The first approach, has been
to generate antibodies towards different subunits of PP2A. It was decided that
monoclonal antibodies (mAb) would be produced as they are more desirable than
polyclonal antibodies because they are more specific, the results are more standard
and they can resolve a single protein from a complex mixture or a single epitope
responsible for a specific function of a macromolecule complex. Establishing our
own mAb producing cell lines is advantageous for an unlimited supply of antibodies
that can precipitate different PP2A complexes to the ones already identified by the
existing commercial antibodies. This chapter describes the production of monoclonal
antibodies towards the structural PR65 subunit and two of the regulatory B subunits
of PP2A. These antibodies have been characterised and used to examine PP2A
subunit and complex composition in normal cell lines and cell lines expressing some
of the viral antigens.
3.2 Results
3.2.1 Protein Purification: PR65
To produce monoclonal antibodies directed towards PR65α, fusion protein was
generated for immunizing mice. A plasmid containing the coding sequence of human
PR65  fused  to  a  polyhistidine  (His)6- tag was transformed into DH5α competent
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bacteria. When the bacterial culture reached an optical density (OD595) of 0.6, protein
expression was induced by addition of IPTG (Figure 3.1.a). Immobolised Metal
Affinity Chromatography (IMAC) was carried out to purify the protein using
TALON metal affinity resin (Co2+).  This system consisted of sepharose beads
bearing  the  tetradentate  chelator  of  the  Co2+ metal ion which binds to the
polyhistidine tag on the proteins. These beads have an advantage over standard
Nickel IMAC resins due to its specificity, minimal wash steps and less stringent
conditions. Elution from the cobalt column was achieved by an imidazole containing
buffer. The progress of the purification was monitored by running samples of each
stage on 10% SDS-PAGE and visualised by staining with coomassie blue (Figure
3.1.b). A large amount (~4 mg/mL from 500 mL bacteria culture) of PR65 was
purified (Figure 3.1.b, Lane 9) and this was dialysed against PBS. The pure fractions
were then used to immunize mice in order to create an immune response. Hybridoma
cell lines were generated by fusing the spleen cells of the immunized mouse with the
SP2 myeloma cell line using PEG, a fusogen. The myeloma cells provided the
correctly expressed genes for continued cell division and the spleen cells provided
continual expression of the functional immunoglobulin. The hybrid cells were then
plated onto 96 well plates and selected for by the addition of hypoxanthine azaserine.
An overview of the procedures used to generate mAbs are shown in Figure 3.2. The
antibody secreting Hybridoma cells were detected using a dot blot screen. Examples
of this are shown in Figure 3.3. Following the fusions, supernatant from each of the
wells were spotted onto nitrocellulose membrane that had been soaked in PR65
fusion protein (Figure 3.3.a). The positive hybrids were single cell cloned at least 2
times (Figure 3.3.b) and grown up to large volumes.
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Figure 3.1. Coomassie stained gels of the PR65 Purification steps.
PR65 fused to a polyhistidine (His)6 tag was transformed into DH5α competent
bacteria, induced and purified using TALON metal affinity resin (Co2+).
M= protein standard marker
a) Total bacterial lysate before (lane 1) and after (lane 2) induction of PR65
expression
b)    10 μL samples of each stage of the purification process:
 1=resuspended bacteria in lysis buffer 6-8= wash steps
 2=bacterial solution after sonication 9 =elution of PR65
 3=solubilised lysate after centrifugation
 4=lysate and resin
 5= flow through from beads – unbound protein
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Figure 3.2. Overview of the processes involved in making monoclonal antibodies.
Mice are immunized by inoculations of the antigen to stimulate the production of
antibodies. The antibody producing cells are isolated from the mouse's spleen and
fused  to  myeloma cells  using  PEG.  These  Hybridoma cells  are  then  plated  into  96
well TC plates and the hybrids selected by the addition of hypoxanthine azaserine in
to the media. Supernatant from each well is removed and used in a dot blot screen to
test for the presence of antibodies against the fusion protein. The positive wells are
cloned a number of times before being grown up and the monoclonal antibodies
harvested in the tissue culture fluid.
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a)
b)
Figure 3.3. Examples of dot blots used to test the hybridomas lines for antibody
production.
The PR65 antigen is bound to the nitrocellulose membrane. Supernatant from each of
the wells on the 96 well plate is removed and spotted onto the membrane in the same
dimensions as they appear on the plate. The unbound antibodies are removed by
washing, and the bound antibodies are detected by an anti-mouse secondary reagent.
This method identified the presence of the antibody, giving a positive result.
a) An example of the first screen of the hybridomas after the fusion. Cells from
the positive wells were then chosen to be cloned
b) An example of a screening result after the second round of single cell cloning.
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3.2.2 Antibody Isotypes: PR65
The isotype  of  the  antibodies  determine  the  affinity  for  important  reagents  such  as
protein A. There are 5 classes of antibodies; IgG, IgM, IgA, IgE and IgD, which is
dependent on the structure. IgG molecules normally have a higher affinity for the
antigen  than  IgMs  due  to  the  affinity  maturation  of  heavy  chains.  The  Isotypes  of
each of the secreted antibodies were determined using a Mouse Monoclonal
Antibody Isotyping kit. The isotypes for all the anti-PR65 monoclonal antibodies are
summarised in Table 3.1. The antibodies were then successfully purified using
protein A agarose.
Table 3.1. Isotypes of anti-PR65 antibodies.
The isotypes of the anti-PR65 antibodies found using a Mouse Monoclonal Antibody
Isotyping Kit.
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3.2.3 Antibody Specificity: PR65
The specificity of the antibodies towards the PR65 antigen were investigated by
Western blot analysis using total cell lysates from different cell lines. Figure 3.5.a
showed that all clones recognised the endogenous protein in Rat2 lysate but with
varying abilities. For example, clones G3.8F11, R5.1A7 and C5.9E10 were the
strongest, whilst C5.12B12 and C5.7F2 are weaker. As antibodies recognise
relatively small regions of sequence (about 4-5 amino acids), it is possible they can
bind  to  similar  epitopes  on  other  molecules.  Therefore,  other  bands  were
occasionally seen on western blots such as the band at approximately 130 kDa
present with the clones C5.3F8, C5.7A1 and R5.8F8 (Figure 3.4.b). Western blots
using all the anti-PR65 subunit antibodies showed the same result in the middle T
transformed Rat2 lysate (C2) (data not shown). Two widely used anti-PR65
antibodies were purchased from Santa Cruz, PP2A-Aα 6F9 and 6G3 and also tested
for antigen specificity towards the endogenous protein in Rat2 lysate. Clone 6F9 did
not recognise the protein well and has a quite unspecific binding result, whereas
clone 6G3 did recognise PR65 specifically, but is weaker than many of the produced
mAbs presented here (Figure 3.4.b).
The specificity of the antibodies towards PR65 from different species were also
examined by performing western blot analysis of total cell lysates from Human,
Mouse,  Hamster,  Chicken,  Rabbit  and  Yeast  (Figure  3.5.).  The  results  from  the
human (Figure 3.5.a) and mouse (Figure 3.5.b) westerns were almost identical to the
rat  western  (Figure  3.4.).  This  is  unsurprising  as  alignment  for  these  three  protein
sequences using MegAlign DNASTAR in Figure 3.6.a showed only one amino acid
difference at position 324. A western blot carried out on hamster lysate also showed
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a similar result (Figure 3.5.c). However, the westerns carried out with chicken
(Figure 3.5.d) and Rabbit (Figure 3.5.e) lysates were slightly different. Clone
C5.9E10 did not recognise its antigen in chicken and rabbit lysate, revealing the
precise epitope for this clone is not present in chicken and rabbit PR65.
Unfortunately  these  PR65  sequences  are  not  present  in  the  NCBI  database  (at  the
time  of  submission  of  this  thesis),  so  they  could  not  be  aligned  to  reveal  the
differences in sequences. In Figure 3.6.b the alignment of all mammalian PR65
available  in  the  NCBI  database  are  presented  and  this  shows  how  much  PR65
sequences are conserved. However, there are a few differences between the amino
acids, in particular within the 9th HEAT motif, which could be where the epitope for
the  mAb  C5.9E10  is  located.  The  western  blot  carried  out  on  yeast  lysate  (Figure
3.5.f) showed a dramatically different result. Only clones C5.9E10 and R2.7E9
recognised any protein in the yeast lysate. R2.7E9 recognised a peptide at around 70
kDa the size of yeast PP2A PR65 subunit, but, C5.9E10 recognised a peptide of
molecular weight around 55 kDa, this is probably due to a cross reaction. The other
mAb clones did not recognise any proteins suggesting the epitope for the majority of
the  antibodies  is  not  present  on  this  sequence.  This  is  unsurprising  as  yeast  and
human  PR65  sequences  are  very  different  (Figure  3.6.c).  All  these  western  blot
results indicated that some of the antibodies recognised different parts of the PR65
sequence and will therefore have different properties.
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Figure 3.4. Western Blots of anti-PR65 antibodies using Rat2 lysate.
Rat2 cell lysate was seperarted by SDS-PAGE and western blotted with each of the anti-PR65 monoclonal antibodies. The antibodies
showing a varying ability to recognise its antigen
a) Short exposure
b) Long exposure
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Figure 3.5. Specificity of anti-PR65 antibodies towards different PR65 species.
Western Blots showing the specificity of each antibody towards the endogenous PR65
subunit in different lysates.
a) Human (Hela)
b) Mouse (NIH 3T3)
c) Hamster (CHO)
d) Chicken (CEF)
e) Rabbit (Rabbit reticulocyte from the TNT T7 Quick Coupled
Transcription/Translation System )
f) Yeast (YC82α3)
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Figure 3.6. Alignment of PR65α sequences.
Sequences have been aligned using MegAlign DNASTAR software.
a) human, Rat, Mouse
b) human, muose, rat, pongo abelii (orangutun), bos Taurus (cow), sus scrofa (wild boar)
c) human, yeast
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3.2.4 Antibody Binding sites: PR65
To identify the region within PR65 that the antibodies recognised, different sized
fragments of the protein were cloned into pcDNA3.1/myc-His(-) and in vitro translated
using the TNT T7 Quick Coupled Transcription/Translation System. The retic lysates
were then separated by SDS-PAGE and analysed by western blotting. The fragments
were immunoblotted with each of the antibodies. Figure 3.7.a shows the produced PR65
fragments summarised against a schematic representation of PR65 HEAT motifs. The
PR65 sequence was initially split into two fragments; 1-290 amino acids (F1) and 291-
590 amino acids (F2). The N-terminal half was then split up into smaller fragments; 23-
590, 143-590, 179-590, 207-590, 244-590 amino acids (F3 to F7 respectively) and 253-
590, 261-590, 274-590, 284-590 amino acids (F8 to F12 respectively). To confirm that
all of the fragments had been translated, an anti-myc antibody was used in western blots
with all of the fragments (Figure 3.7.b).
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Figure 3.7. Binding site Fragments of the N-terminal half of PR65.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick coupled transcription/translation system.
a) Schematic diagram of the cloned fragments against the 15 PR65 HEAT motifs.
b) The retic lysates were separated by SDS-PAGE and all the translated fragments were
detected by western blotting with the anti-myc antibody, 9E10.
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
R=R2 lysate
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The antibody C5.3D10 was incubated with a blot containing F1, F2 and a negative
control of translation mix without any DNA (-ve). C5.3D10 recognised F1 and so was
incubated with F3-F7 and F8-F12. C5.3D10 bound to F3-F7 and F8-F10 but not F11 and
F12 (Figure 3.8.a). The fragments C5.3D10 recognised are highlighted in bold in Figure
3.9b on a schematic diagram of PR65 HEAT motifs and the fragments the antibody
failed to bind are shown in grey. This suggested the epitope for C5.3D10 is between
amino acids 265-275 of PR65. The same experiment was carried out on the other
antibody clones. C5.1G7 (Figure 3.9.), C5.7F2 (Figure 3.10.), C5.12B12 (Figure 3.11.),
G3.5F9 (Figure 3.12.), G3.8F11 (Figure 3.13.), R5.1A7 (Figure 3.14.), R5.8A4 (Figure
3.15.) and R8.8A8 (Figure 3.16.) also recognised F1 and F3-F10 but not F2, F11 and
F12. Therefore, these antibodies also have an epitope within the same area, 265-275
amino acids. C5.3F8 (Figure 3.17.a) and C5.7A1 (Figure 3.18.a) recognised only F1 and
F3 suggesting the epitope for these clones to be between 23-143 amino acids of the
PR65 as shown in Figure 3.17.b (C5.3F8) and Figure 3.19.b (C5.7A1).
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Figure 3.8. Binding site of the anti-PR65 antibody C5.3D10.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
C5.3D10.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
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Figure 3.9. Binding site of the anti-PR65 antibody C5.1G7.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
C5.1G7.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
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Figure 3.10. Binding site of the anti-PR65 antibody C5.7F2.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
C5.7F2.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
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Figure 3.11. Binding site of the anti-PR65 antibody C5.12B12.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
C5.12B12.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
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Figure 3.12. Binding site of the anti-PR65 antibody G3.5F9.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
G3.5F9
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
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Figure 3.13. Binding site of the anti-PR65 antibody G3.8F11.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
G3.8F11.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
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Figure 3.14. Binding site of the anti-PR65 antibody R5.1A7.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
R5.1A7.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
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Figure 3.15. Binding site of the anti-PR65 antibody R5.8A4.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
R5.8A4.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
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Figure 3.16. Binding site of the anti-PR65 antibody R5.8F8.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
R5.8F8.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
F8 =253-590, F9 = 261-590, F10 = 265-590, F11 = 274-590, F12 = 284-590
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Figure R17. Binding site of the anti-PR65 antibody C5.3F8.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
C5.3F8.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
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Figure R18. Binding site of the anti-PR65 antibody C5.7A1.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
C5.7A1.
R=R2 lysate  -ve=translated retic lysate with no fragment
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
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The remaining two antibodies recognised F2 and not F1 (Figure 3.19.), therefore, further
fragments were produced to split up the C terminal half of PR65. As shown previously
in Figure 3.5.a-e, clone C5.9E10 did not recognise endogenous PR65 in rabbit and
chicken lysate but did in human, mouse and hamster lysate, which indictaed that the
epitope is located within an area of sequence which diverges between species.
Alignment of the mammalian PR65 sequences (Figure 3.6.b) revealed many of the
differences in amino acid sequence to be located within HEAT motif 9 and the C-
terminal end, therefore, fragments of PR65 were constructed that did not include these
areas; 1-315, 1-554 and 1-515 amino acids (F13-F15). Further fragments were also made
to exclude the other HEAT motifs in the C-terminal half; 1-356, 1-395, 1-434 and 1-473
amino acids (F15-F19). Figure 3.20.a shows the constructed PR65 fragments
summarised against a schematic representation of PR65 HEAT motifs. To confirm that
all the fragments had been translated, an anti-myc antibody was used in western blots
with all the fragments (Figure 3.20.b). Clone C5.9E10 was incubated with a blot of F13-
F15 (Figure 3.21.a) and recognised F14 and F15 but not F13, and consequently was
incubated with F16-F19 and shown to recognise all of these fragments (Figure 3.21.a).
The fragments C5.9E10 recognised are highlighted on a schematic diagram of PR65 in
bold in Figure 3.21.b and the fragments the antibody failed to recognise are shown in
grey. This suggested the epitope for this antibody is located within HEAT motif 10 (357-
396 amino acids) of PR65. Clone R2.7E9 recognised F14, F15, F18 and F19 but not F13,
F16 and F17 (Figure 3.22.a). The positive fragments R2.7E9 recognised are highlighted
against a schematic diagram of PR65 in bold in Figure 3.22.b and the fragments the
antibody failed to recognise are shown in grey. This suggested the epitope for R2.7E9 is
located within HEAT motif 11 (396-435 amino acids).
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Figure 3.19. Binding of the anti-PR65 antibodies C5.9E10 and R2.7E9 to F2.
F1 and F2 were created by cloning fragments of 1-290 amino acids and 291-590 amino
acids of PR65 respectively, into pcDNA3.1/myc-His(-). These fragments were in vitro
translated using TNT Quick coupled transcription/translation system and the retic lysates
were separated by SDS-PAGE and used in western blot analysis with C5.9E10 (a) and
R2.7E9 (b).
R=R2 lysate  -ve= translated retic lysate with no fragment
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Figure 3.20. Binding site Fragments of the C-terminal half of PR65.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick coupled transcription/translation system.
a) Schematic diagram of the cloned fragments against the 15 PR65 HEAT motifs.
b) The retic lysates were separated by SDS-PAGE and all the translated fragments were
detected by western blotting with the anti-myc antibody, 9E10.
R=R2 lysate  -ve= translated retic lysate with no fragment
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F13 = 1-315, F14 = 1-554  F15= 1-515
F16 = 1-356, F17 = 1-395, F18= 1-434,   F19 = 1-473
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Figure 3.21. Binding site of the anti-PR65 antibody C5.9E10.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
C5.9E10.
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
R=R2 lysate  -ve= translated retic lysate with no fragment
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F13 = 1-315, F14 = 1-554  F15= 1-515
F16 = 1-356, F17 = 1-395, F18= 1-434,   F19 = 1-473
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Figure 3.22. Binding site of the anti-PR65 antibody R2.7E9.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System.
a) The retic lysates were separated by SDS-PAGE and used in western blot analysis with
R2.7E9.
b) Fragments antibody reacts with in bold displayed against a schematic representation
on PR65 HEAT motifs. Fragments antibody does not react with shown in grey
R=R2 lysate  -ve= translated retic lysate with no fragment
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F13 = 1-315, F14 = 1-554  F15= 1-515
F16 = 1-356, F17 = 1-395, F18= 1-434,   F19 = 1-473
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The binding site of the commercial antibody PP2A-Aα, 6G3 was also mapped by the
same method. 6G3 recognised F1 but not F3-F7 (Figure 3.23.), suggesting the epitope
for this antibody must be within the first 23 amino acids. This result is validated by the
data sheet provided with the antibody explaining it was raised against the N-terminal end
of the sequence. Commercial antibody PP2A-Aα 6F9 performed weakly in western blot
experiments and could not detect any of the translated PR65 fragments. The epitope for
this antibody could not be mapped.
Figure 3.23. Binding site of the commercial anti-PR65 antibody 6G3.
The PR65 fragments (F) were created by cloning different lengths of PR65 into
pcDNA3.1/myc-His(-). These fragments were in vitro translated using the TNT T7
Quick Coupled Transcription/Translation System. The retic lysates were separated by
SDS-PAGE and used in western blot analysis with 6G3
R=R2 lysate  -ve=translated retic lysate with no fragment
Amino acid sequence:
F1 = 1-290, F2 = 291-590
F3 = 23-590, F4 = 143-590, F5 = 179-590, F6 = 207-590, F7 = 244-590
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The location of the binding sites of all of the produced antibodies were marked against
PR65 on a schematic diagram of the PP2A trimer (Figure 3.24.). It is surprising that the
majority of the antibodies have an epitope within the same area of sequence (265-275
amino acids), even though they were produced from different fusions. This short
sequence has been highlighted on the crystal structure of PR65 using the Cn3D software
from NCBI. Figure 3.25. shows 265-275 amino acids highlighted in yellow on PR65
from two different positions. These 11 amino acids appear to be located on a loop
around the outer rim of the structure making it easy to be recognised by the mouse
immune system and therefore, an accessible area of sequence for the antibodies to be
raised towards.
Figure 3.24. Schematic diagram of PP2A showing which HEAT motifs in the PR65
sequence the antibodies recognised.
PP2Ac (blue) binds to HEAT motif 11-15 and the B subunits and T-antigens (both in
green) bind to overlapping regions along the first 10 HEAT motifs of PR65 (red).
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Figure 3.25. Position of the antibodies epitope (265-275 amino acids) on the crystal
structure of PR65.
Crystal structure obtained from Cn3D (NCBI). The epitope 265-275 amino acids is
highlighted in yellow, and appears to be located on a loop (blue) linking the α-helices
(green) of PR65.
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3.2.5 B’ Subunit Protein Purification
B subunits are important in the functions of PP2A as they are thought to determine the
catalytic activity [59, 60, 71], substrate specificity [19, 53] and subcellular distribution
[47, 56] of the complex, and some of the B’ subunits in particular have been implicated
in cancer formation [55]. Consequently, a project was initiated to generate antibodies
against two of the B’ subunits, PR61α and PR61γ1, to investigate their roles further.
To produce these antibodies a polyhistidine (His)6 tagged PR61α protein and a GST
tagged PR61γ1 protein were generated for mouse immunization. A plasmid containing
the coding sequence of PR61γ1 fused to a glutathione-S- transferase (GST)- tag was
transformed into DH5α competent bacteria and grown to an optical density (OD595) of
0.6, before addition of IPTG to induce protein expression. The protein was purified from
the bacterial culture using Glutathione Sepharose 4B beads, and eluted, and the GST tag
cleaved by digestion with thrombin. The tag was then removed by re-incubation with the
Glutathione slurry. The protein precipitated during dialysis against PBS, hence the
thrombin was removed by washing the precipitate several times with PBS. The protein
was then solubilised with 6M guanidine hydrochloride, as instructed in the
manufacturer’s protocol. The progress of the purification was monitored by running
samples of each stage on 10% SDS-PAGE (Figure 3.26.).
A plasmid containing the polyhistidine (His)6 PR61α was  transformed  into  DH5α
competent bacteria and expressed as above. Immobolised Metal Affinity
Chromatography (IMAC) using TALON metal affinity resin was carried out to purify
the protein from the bacterial culture, as described for PR65 production. Elution from
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the column was achieved by a buffer containing Imidazole. The Imidazole contaminant
was then removed from the protein samples by dialysis. The progress of this purification
was also monitored by running samples of each stage on 10% SDS-PAGE (Figure 3.27.).
The Hybridoma cell lines were created the same way as the anti-PR65 secreting
hybridomas and this process is summarised in Figure 3.2.
Figure 3.26. Coomassie blue stained gel of the purification steps of PR61γ1.
PR61γ1 fused to a GST tag was transformed into DH5α competent bacteria, induced and
purified using Glutathionine Sepharose 4B beads. 10 μL samples of each stage of the
purification was separated by SDS-PAGE and visualised with Coomassie blue.
M- molecular weight marker
1-bacterial culture 7-PR61γ1 + Glutathione beads
2-culture after induction of protein 8-combined wash steps
3-resuspended bacteria in lysis buffer                        9-12 elutions of PR61γ1
4-bacterial solution after sonication 13- beads after elutions
5-solubilised lysate after centrifugation
6- flow through from beads – unbound proteins
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Figure 3.27. Coomassie blue stained gel of the purification steps of PR61α.
PR61α fused to a polyhistidine (His)6 tag was transformed into DH5α competent
bacteria, induced and purified using TALON metal affinity resin. 10 μL samples of each
stage of the purification was separated by SDS-PAGE and visualised with Coomassie
blue.
M= protein standard marker
1-bacterial culture 5-7- wash steps
2-culture after induction of protein             8-10-Elution of protein
3-bacterial solution after sonication
4- flow through from beads – unbound proteins
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3.2.6 Antibody Isotype: B’
From the six fusions undertaken, one clone raised towards the PR61γ1 isoform, denoted
by the initial N, and four clones raised towards the PR61α isoform, denoted by the initial
O, have been isolated. Isotypes of each of these were determined using a mouse
monoclonal antibody isotyping kit. The results were summarised in Table 3.2. Three of
the five antibodies had unfavourable IgA and IgM isotypes.
Table 3.2. Isotypes of anti-PR61α and PR61γ1 antibodies.
The isotypes of the anti-PR61α and PR61γ1 antibodies found using a Mouse
Monoclonal Antibody Isotyping Kit. The clones denoted by O are raised towards PR61α
and the clones denoted by N are raised towards PR61γ1.
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3.2.7 Antibody Specificity: B’ subunits
The anti-B’ antibodies were tested on western blots containing the PR61α and PR61γ1
fusion proteins (Figure 3.28.), to assess how strong the reaction was towards the protein
they were raised, and also whether they recognised the other B’ isoform. Clones O2.5A8,
O2.2A8, O2.10B7 gave strong positive results against PR61α, and, N2.9C8 gave strong
positive results against PR61γ1. Clone O1.11A6, cross reacted with both fusion proteins.
This is not surprising as the B’ subunits are a highly conserved group with only the N
and C terminal ends varying (Figure 1.5.). Several anti-B’ antibodies were purchased
from various companies and those which were shown to recognise the B’ subunits in
western blots were included in Figure 3.28. B56α (Santa Cruz sc-6116) recognised
PR61α  and B’ Rabbit (Upstate 07-334) recognised PR61α and PR61γ1 as it was raised
towards an area of sequence which is homologous to all B’ isoforms.
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Figure 3.28. Immunoblots carried out using anti-B’ antibodies.
The specificity of each antibody towards the fusion proteins, PR61α and PR61γ1 are
assessed in western blot experiments. The clones denoted by O are raised against and the
clones denoted by N are raised against PR61γ1. Commercial antibodies PR61α (Santa
Cruz) and B’ Rabbit (Upstate) are also included. Not unsurprisingly some of the clones
recognise both isoforms.
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The specificity of the antibodies towards the endogenous subunits were investigated
initially by western blot analysis on total Rat2 cell lysate. Only N2.9C8 and O1.11A6
bound to polypeptides in the correct region, and these were weak reactions (Figure
3.29.). The rest of the antibodies were unable to bind to any endogenous proteins. This
could be due to a very low expression of the proteins in these particular cells or poor
antibody affinity.  The commercial B’ Rabbit antibody did not recognise any
endogenous protein in Rat2 cell lysate probably because it was raised towards an area of
sequence that is not so conserved between rat and rabbit B’ proteins. The commercial
B56α antibody recognised a protein about the right size of PR61α. The result of a
commercial B55 antibody (Upstate 05-592) and G3.5F9 (anti-PR65) has been included
to show the size and relative strength of the detection as a comparison. A western blot
was then carried out with lysate from mouse muscle cells (C2C12) (Figure 3.30.), as
previous northern blot analysis experiments showed that the PR61α subunit is widely
expressed in this tissue [219]. From the produced mAbs, only O1.11A6 detected any
protein in this lysate and it was a very weak reaction compared to the commercial
antibodies. After assessing these results, it was decided that further work on the
produced anti-B’ antibodies would not be continued due to poor antibody affinity, which
in most cases was probably due to the unfavourable isotypes. As the commercially
available antibodies have already proved to be better in the preliminary characterisation
studies they will be used for all further work regarding the B subunits.
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Figure 3.29. Western Blots of anti-B’ antibodies on Rat2 lysate.
Rat2 lysate was separated by SDS-PAGE and western blotted with each of the produced
anti-B’ antibodies and the commercial B’ antibodies; B’ Rabbit (Upstate) and B56α
(Santa Cruz). A commercial B55 (PR55) antibody (Upstate 05-592) and G3.8F11 (anti-
PR65) has been included to show the size and relative strength of the detections.
Figure 3.30. Western Blots of anti-B’ antibodies on muscle lysate.
Muscle cell (C2C12) lysate was separated by SDS-PAGE and western blotted with each
of the produced anti-B’ antibodies and the commercial B’ (Rabbit) antibodies; B’
(Upstate) and B56α (Santa Cruz). A commercial B55 (PR55) antibody 5G9 (Upstate 05-
592) and G3.8F11 (anti-PR65) has been included to show the size and relative strength
of the detections.
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3.3 Discussion
To understand how viruses affect PP2A functions and its regulation, it is important to
study the trimeric state and complex composition of this phosphatase. One of the
approaches to achieve this goal has been to produce monoclonal antibodies towards
some of the subunits of PP2A.
The α isoform of PR65 is more abundant than the β isoform [220], therefore, it was
decided that antibodies were to be raised towards this isoform, to acquire different mAbs
that could recognise different PR65 containing complexes. From the numerous fusions
undertaken, hundreds of monoclonal antibodies have been generated. However, many of
these have been shown to have undesirable isotypes, and although they reacted towards
the fusion protein, they had unspecific results in western blots of total cell lysates.
Thirteen of the anti-PR65 mAbs have IgG isotypes and the characterisation of these are
presented in this chapter. The thirteen mAbs have been shown to recognise the
endogenous protein in Rat2 cells (Figure 3.4.), with at least half of them displaying a
stronger specificity towards PR65 than the widely used commercial antibodies PP2A-Aα,
6G3 and 6F9 (both from Santa Cruz). All clones also recognise endogenous PR65 in
human (Figure 3.5.a) and mouse (Figure 3.5.b) which is unsurprising as homology
between these 3 species is 99.8% (Figure 3.6.a). A western blot carried out with hamster
lysate showed a similar result (Figure 3.5.c). All antibody clones except C5.9E10 also
recognised endogenous PR65 in rabbit and chicken lysate (Figure 3.5.d,e). These
monoclonal antibodies can thus be used as tools to identify the presence of PR65 in all
these species. The mAbs were also tested for specificity in western blots of yeast lysate,
but only R2.7E9 recognised the endogenous yeast protein and this is not a strong
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detection (Figure 3.5.f). Yeast PR65 displays only a 42.7% homology with human PR65
(Figure 3.6.c), suggesting the other antibody clones must recognise areas of the sequence
which is not conserved between these two species. Therefore, my produced antibodies
can not be used to investigate PR65 in yeast, antibodies raised specifically for yeast
PR65 would be needed.
The  first  difference  in  the  properties  of  the  mAbs  were  displayed  when  each  of  the
clones were tested on western blots of rabbit and chicken cell lysate. Clone C5.9E10 did
not recognise the endogenous protein in these lysates, whereas the other clones did,
suggesting that the epitope for C5.9E10 must be located on area of sequence that differs
between PR65 sequences. This was confirmed when the epitope for C5.9E10 was
mapped to HEAT motif 10 (Figure 3.21.) and alignment of human, rat, mouse,
orangutan, cow and wild boar PR65 sequences within this area revealed two differences
between 357-360 amino acids (Figure 3.7.b). It is likely that the epitope for C5.9E10 is
within this region. The binding site for clones C5.1G7, C5.3D10, C5.3F8, C5.12B12,
G3.5F9, G3.8F11, R5.1A7, R5.8A4 and R5.8F8 has been mapped to 265-275 amino
acids (Figure 3.24.) and this short sequence has been displayed on the crystal structure
of PR65 (Figure 3.25.).
It has already been reported that the incorporation of a B subunit into the holoenzyme
can direct PP2A to a particular subcellular localisation, change the substrate specificity
and/or alter activity of the catalytic site. To investigate this further, mAbs raised against
two of the different B’ subunits were generated, in an attempt to use these mAbs as vital
tools in studying the B subunits when the viral T-antigens are expressed. Unfortunately,
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the antibodies generated towards PR61α and PR61γ1 have not been easy to characterise.
This can be attributed to a very low expression of these proteins in cells; in addition to
the fact that some of the antibodies have an unfavourable IgM and IgA isotype (Table
3.2.). IgM and IgA isotypes do not have a high affinity for their antigen, unlike IgG
molecules, which have a faster, more potent and persistent response. IgG antibodies are
generally produced in a secondary immune response, suggesting that the presence of
IgM isotypes could be due to the immunizations not being as effective as those carried
out in the generation of anti-PR65 antibodies. Finally, Western Blots carried out on total
Rat2 (Figure 3.29.) and mouse muscle (Figure 3.30.) cell lysates revealed that the
commercial antibodies perform better than the produced ones. Hence, any future
experiments requiring B antibodies have been carried out using the commercial
antibodies; B56α (Santa Cruz), B’ Rabbit (Upstate) and anti-B clone 5G9 (Upstate).
In summary, the anti-PR65 monoclonal antibodies produced have provided important
tools for investigating PR65 presence in various cell lines. The next chapter focuses on
how well these antibodies recognise PR65 in its native form in contrast to the
experiments carried out with denatured PR65 presented in this chapter.
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CHAPTER 4. PP2A NATIVE COMPLEXES
4.1 Introduction
The previous chapter demonstrated the antibodies ability to recognise the denatured
proteins they were raised towards. To examine native PR65 and its interacting proteins,
the antibodies need to recognise native PR65 in vitro. This chapter focuses on the use of
the mAbs in immunochemical techniques, particularly in immuno-affinity purification,
as it is one of the most powerful methods used in the isolation of proteins in a single step.
These isolated PP2A complexes have been elucidated and any interacting proteins
identified. With this established, differences in PP2A complexes can be assessed when
the viral T-antigens are expressed.
4.2 Results
4.2.1 Immunoprecipitation of PR65 in complex with other PP2A subunits
and viral antigens
Immunoprecipitation experiments (IP) using Rat2 and C2 (MT expressing) cell lysates
were performed using tissue culture fluid (TCF) containing the expressed antibodies
from each of the clones. The eluates were separated by SDS-PAGE and immunoblotted
with an anti-PR65 (Figure 4.1. upper panel) and anti-PP2Ac (Figure 4.1. lower panel)
antibodies. For western blotting, the clone G3.8F11 was used as it had the strongest
binding ability in western experiments (Figure 3.4.) and the anti-PP2Ac F2.5G4 clone
(unpublished) was chosen from antibodies existing in the lab for similar reasons. All the
antibodies analysed in the screen precipitated PR65, but with varying abilities. The
clones C5.1G7, C5.3D10, C5.7F2, C5.9E10, C5.12B12, G3.8F11, R5.8A4 and R5.8F8
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precipitated high levels of the endogenous PR65 subunit and significant amounts of
PP2Ac (Figure 4.1. highlighted with asterisks). Co-precipitation of PP2Ac can not be
clearly seen with the IP experiments performed using clones C5.3F8 and C5.7A1 and the
amount of PR65 precipitation with these two antibodies is low (Figure 4.1.). This
suggests these two antibodies have a poor ability to recognise the native form of PR65.
Interestingly, clone R2.7E9 can only precipitate PR65 and not PP2Ac, suggesting it may
recognise free PR65 in the cell. The presence of free PR65 existing in the cell has not
been previously documented. The ability of the commercial antibodies to precipitate
PR65 were also tested, to compare the produced antibodies with the commercially
available anti-PR65 monoclonal antibodies. PP2A-Aα 6F9 and 6G3 (both from Santa
Cruz) precipitated very small amounts of native PR65 and no PP2Ac can be detected,
demonstrating that the mAbs presented here perform better than the available
commercial ones.
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Figure 4.1. Immunoprecipitation of PR65 and PP2Ac with anti-PR65 monoclonal antibodies.
Rat2 and C2 lysates were subjected to immunoprecipitation, using Protein A sepharose as detailed in the materials and
methods chapter, with different anti-PR65 antibodies. The eluates were separated by SDS-PAGE and western blot analysis
was performed using anti-PR65, G3.8F11 (top panel) and anti-PP2Ac, F2.5G4 (bottom panel) antibodies.
Antibodies performing the IP are written above the blot. Commercial antibodies are included (PP2A-Aα 6F9 and 6G3).
L= lysate input,   R=IP performed in Rat2 lysate,    C= IP performed in C2 lysate
HC = antibody heavy chain
LC = antibody light chain
The antibodies that precipitate PR65 and PP2Ac well have been highlighted with an asterisk (*) above the clone name
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To further elucidate the binding properties of the mAbs, IP experiments were performed
under native and denatured conditions with all the produced anti-PR65 clones. This
indicated whether the epitope of the antibodies is being masked by other proteins
interacting with PR65 when they are in their native forms. If the antibody binding site is
being masked, denaturing the proteins in the lysate would reveal the epitope, enabling
the antibodies to precipitate the endogenous subunit in larger amounts. The lysate was
denatured by adding 1% SDS and boiling for 5 minutes. The proteins were then refolded
by diluting the SDS with buffer containing 1% NP40 and 1% DOC, prior to performing
the IP. The eluates from the IPs were immunoblotted with anti-PR65 G3.8F11 (Figure
4.2. upper panel) and anti-PP2Ac F2.5G4 (Figure 4.2. lower panel) antibodies. As
expected PP2Ac disappears in most of the IPs performed with the denatured lysate, as
the proteins dissociate from each other in these conditions. When the western blot is
subjected to a longer developing exposure, clone C5.3D10 can still co-precipitate some
PP2Ac, suggesting this antibody can still precipitate some PP2Ac associated with PR65.
This is probably because not all the proteins have been denatured, and some complexes
are re-annealing. The antibody clones should precipitate the same amount of PR65 in
both lysate conditions, if the antibodies epitope is accessible when the proteins are in a
complex. However, some of the clones (G3.5F9, R5.1A7, R5.8A4 and R5.8F8)
precipitated less PR65 in the denatured IPs. This is probably due to the IP not being as
efficient in the diluted lysate when SDS is present. Clone R2.7E9 can precipitate more
PR65 in denatured conditions compared with native conditions, revealing the antibody’s
epitope is masked by another protein when PR65 is in a complex. The epitope for this
antibody has already been identified to be located within HEAT motif 11 (Figure 3.23.),
the area with which PP2Ac is associated [173, 174]. This suggests that when PR65 is in
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its dimeric or trimeric form, R2.7E9s epitope is not accessible and hence this antibody
can only precipitate free PR65. However, by denaturing the complexes in the lysate,
PR65 and PP2Ac dissociate, which enables R2.7E9 to precipitate more PR65.
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Figure 4.2. Denatured Immunoprecipitation with anti-PR65 antibodies.
Cell lysates were subjected to immunoprecipitation, using Protein A sepharose as detailed in the materials and methods
chapter, with different anti-PR65 antibodies. The eluates were separated by SDS-PAGE and western blot analysis was
performed using anti-PR65, G3.8F11 (top panel) and anti-PP2Ac, F2.5G4 (bottom panel) antibodies.
Antibodies performing the IP are written above the blot.
IPs carried out on native Rat2 lysate (n) and compared with denatured lysate (d).
L= lysate input      HC = antibody heavy chain
Denaturing conditions: lysates treated with 1% SDS, boiled, then diluted 10 x with 1% NP40, 1% DOC.
Longer exposure for PP2Ac precipitates included.
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To determine whether the antibodies can precipitate any of the B subunits in complex
with PR65, IP experiments were carried out using the antibody TCF and the eluted
complexes were immunoblotted with the anti-B antibody, 2G9 (Figure 4.3.).
Unfortunately, none of the antibodies appear to precipitate the B subunit in complex
with PR65. The result of this experiment is hard to confirm, due to the heavy chain of
the antibodies masking any other protein bands on the western blots around the same
size. Different approaches to this experiment have been attempted. For example; β-
mercaptoethanol was omitted from the laemmli sample buffer when eluting the proteins.
This prevents the disulphide bonds in the antibody from being disrupted, resulting in the
antibody chain migrating to 150kDa. Also a different secondary antibody has been used
that does not recognise IG chains. However, the presence of the B subunits precipitating
with PR65 can still not be conclusively determined.
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Figure 4.3. Immunoprecipitation of the B subunits with the anti-PR65 antibodies.
Rat2 cell lysate was subjected to immunoprecipitation, using Protein A sepharose as detailed in the materials and methods
chapter, with different anti-PR65 antibodies. The eluates were separated by SDS-PAGE and western blot analysis was
performed using anti-PR55 antibody, 2G9.
L=input lysate
Antibodies performing IP:
1=C5.1G7 5=C5.7F2   9=G3.8F11 13=R5.8F8
2=C5.3D10 6=C5.9E10 10=R2.7E9 14=9E10
3=C5.3F8 7=C5.12B12 11=R5.1A7 15=PP2A- Aα 6G3
4=C5.7A1 8=G3.5F9 12=R5.8A4 16=PP2A- Aα 6F9
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The ability of the antibodies to precipitate MT, a viral protein known to interact with
PP2AD was also analysed. Immunoprecipitation experiments were performed in the MT
expressing C2 lysates using TCF of all the antibodies (Figure 4.4.). The eluted
complexes were separated by SDS-PAGE and the presence of MT detected by western
blotting. The biotinylated anti-MT pAb762 antibody and a HRP- streptavidin were used
to avoid the antibody chains from the IP being detected. As a control, an IP using the
anti-MT antibody was also included (lane 17), to show MT has been precipitated from
the Lysate. Figure 4.4. shows that none of the anti-PR65 antibodies can precipitate MT
in complex with PR65 in a detectable amount. This can be correlated with the results
from the epitope mapping experiments, showing that the binding sites for the majority of
these antibodies are within the N-terminal half of the peptide, the area which also
interacts with MT. Therefore, it is probable that MT bound to PP2AD masks the antigen
site recognised by these mAbs, and hence prevents precipitation.
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Figure 4.4. Immunoprecipitation of the T-antigens with the anti-PR65 antibodies.
The middle-T transformed cell lysate was subjected to immunoprecipitation, using Protein A sepharose as detailed in the
materials and methods chapter, with different anti-PR65 antibodies. The eluates were separated by SDS-PAGE and western
blot analysis was performed using biotinylated anti-MT antibody, pAb762.
L=input lysate
Antibodies performing IP:
1=C5.1G7 5=C5.7F2   9=G3.8F11 13=R5.8F8 17=pAb762 (MT)
2=C5.3D10 6=C5.9E10 10=R2.7E9 14=9E10
3=C5.3F8 7=C5.12B12 11=R5.1A7 15=PP2A- Aα 6G3
4=C5.7A1 8=G3.5F9 12=R5.8A4 16=PP2A- Aα 6F9
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The epitope for the majority of the produced monoclonal antibodies has been localised
to 265-275 amino acids of the PR65 sequence (Figure 3.25.). This has been highlighted
on a diagram of the crystal structure of PR65 in a complex with the other PP2A subunits
(Figure 4.5.). The position of this short sequence does not appear to be located close to
the association of PP2Ac, revealing why most of the mAbs are able to precipitate this
subunit in complex with PR65. The interaction of the B subunits with PR65 occurs near
to the antibodies epitope, suggesting that when the holoenzyme is assembled these
regulatory subunits are masking the binding site of the antibodies, preventing it from
precipitating PR65 in the trimer. As the T-antigens have also been shown to interact
within the N-terminal half of the PR65 sequence [173] it is also probable that the same
explanation applies, hence why these produced monoclonal antibodies can only
precipitate PP2AD.
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Figure 4.5. Position of the epitope 265- 274 amino acids on the crystal structure of
PP2A.
Crystal structure obtained from Cn3D (NCBI). The epitope of the antibodies (265-275
amino acids) is highlighted in yellow on the HEAT motifs of PR65
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4.2.2 Identification of PR65 associated proteins
To identify proteins associating with PP2A, the purified monoclonal antibodies were
coupled to a solid gel, as described in the materials and methods section. This would
enable batch purification of PR65 complexes recognised by the mAbs, from cell lysates.
The precipitated complexes were detected by SDS-PAGE and stained with Coomassie
Blue (Figure 4.6.). The clones C5.1G7, C5.3D10, C5.12B12, R5.1A7, R5.8A4 and
R5.8F8 precipitate large amounts of PR65 and also smaller amounts of PP2Ac. However
IPs carried out with C5.3F8, C5.7A1 and R2.7E9 were too weak to see any protein
bands, hence the results for these antibodies have not been included. The IP experiments
were performed in Rat2 and C2 lysates using the amino-linked antibodies, in an attempt
to detect any downstream effects of MT being expressed. However, no differences were
seen. A band at approximate size 130kDa was observed in the IPs performed with clones
C5.1G7, C5.3D10 and C5.12B12. Bands were also observed at approximate sizes: 250
kDa with R5.8A4 and R5.8F8; 70 kDa and 90 kDa with C5.1G7, C5.3D10, C5.1A7,
R5.8A4 and R5.8F8; 40 kDa with C5.3D10; and 50 kDa with C5.3D10, C5.12B12,
R5.8A4 and R5.8F8. These results suggested that the antibodies precipitated separate
peptides, indicating they can recognised different PP2A complexes.
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b)
170
c)
Figure 4.6. Identification of proteins associated with PR65, by IP experiments.
Purified anti-PR65 antibodies were linked to an agarose support using an AminoLink kit
as described in the materials and methods chapter. These amino-linked antibodies were
used in immunoprecipitation experiments. The eluted complexes were separated by
SDS-PAGE and visualised with Coomassie Blue.
A= purified antibody, R=IP carried out in Rat2 cells,  C=IP carried out in C2 cells
Antibodies performing IP are shown above the gel.
LC = antibody light chain    HC = antibody heavy chain
1-6 = protein bands excised from gel and sent to be MS identified
a) IPs performed with mAbs: C5.1G7, C5.3D10, C5.9E10
b) IPs performed with mAbs: C5.7F2, C5.12B12, G3.5F9, G3.8F11
c) IPs performed with mAbs: R5.1A7, R5.8A4, R5.8F8
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4.2.3 Mass Spectroscopy identification of PP2A associated proteins
The peptide bands 1-6 from Figure 4.6. were excised from the gel along with bands at 65
kDa and 35 kDa, expected to be PR65 and PP2Ac respectively. Trypsin digestion of the
protein bands followed by Quadruple Time of Flight (Q-ToF) Mass Spectroscopy (MS)
was performed by Dinah Rahman, Proteomics Facility, MRC Clinical Sciences Centre,
Hammersmith Hospital and Paul Hitchen, Glycomics technologist, Division of
Molecular Biosciences, South Kensington Campus. The Q-ToF data obtained from the
protein band at 65 kDa shown in Figure 4.7.a, revealed several peptide fragments with
significant hits. These peptides correspond to areas of PR65 sequence as identified by a
protein BLAST (Figure 4.7.b). The positive identification of PR65 and PP2Ac is a
confirmation that the IP experiments, followed by MS, is a validated method for
identifying PP2A complexes. Band 1 from Figure 4.6. at approximately 130kDa was
subject to Q-ToF MS. Several peptide fragments were regarded as having significant hits
(Figure 4.8.) and were used in protein BLAST searches to identify Ubiquitin Specific
Protease 28 (USP28). Bands 2, 3, 4, 5 and 6 were subjected to the same method as above
and identified as Heat-Shock related 70 kDa protein 2 (Hsp72), translation elongation
factor 1-alpha (tEF1α), Heat shock protein 90 (Hsp90), Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and Filamin, respectively (data not shown). All the MS data is
summarised in Table 4.1.
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ALASVIMGLSPILGKDNTIEHLLPLFLAQLKDECPEVRLNIISNLDCVN
EVIGIRQLSQSLLPAIVELAEDAKWRVRLAIIEYMPLLAGQLGVEFFDE
KLNSLCMAWLVDHVYAIREAATSNLKKLVEKFGKEWAHATIIPKVLAMS
  MAGDPVANVR
GDPNYLHRMTTLFCINVLSEVCGQDITTKHMLPTVLRMAGDPVANVRFN
LTQDQDVDVK
VAKSLQKIGPILDNSTLQSEVKPILEKLTQDQDVDVKYFAQEALTVLSL
A
Figure 4.7. MS data obtained for the identification of PR65.
a) Graph showing the probability score of the identification by Q-ToF analysis
b) The alignment of identified peptides with PR65
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Peptide
NLSYDER
ESVIALYR
FPLPDMLK
FPLPDMLK
FPLPDMLK + Oxidation (M)
FPLPDMLK + Oxidation (M)
TLLEQFADR
TLLEQFADR
LPPVLTFELSR
FVDPSAALDLLK
LLDPSAEIIVLK
LLDPSAEIIVLK
TVTDEEMNFVK
SEIEQDIQDLK
TVTDEEMNFVK + Oxidation (M)
FEFNQSLGQPEK
FEFNQSLGQPEK
EQTAQAIANTAHAYEK
Figure 4.8. MS data obtained for the identification of band 1 by Q-ToF analysis
a) Graph showing the probability score of the identification by Q-ToF analysis
b) Peptide fragments that correspond to areas of the USP28 sequence
Protein identified as Ubiquitin Specific Protease 28 (USP28)
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Table 4.1. Results obtained from MS analysis.
Band No./
Name
Protein Name Accession
number
MW Probability
based score
PR65 PR65 BC083859 65934 358
PP2Ac PP2Ac NM_017039 35552 645
1 USP28 NM_001108144 123333 1165
2 Hsp72 XM_001053871 69978 94
3 tEF-1 alpha NM_175838 50360 245
4 Hsp90 P11499 83273 138
5 GAPDH P04797 35805 108
6 Filamin Q8BTM8 281018 4607
The bands from Figure 4.6. Were excised and subjected to trypsin digestion followed by
Q-ToF mass spectroscopy. The data obtained was compared against the NCBI database
to identify the proteins.
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4.2.4 USP28
To determine whether USP28 is precipitated by the antibodies and is not a false
identification from the MS results, immunoprecipitation experiments were performed in
Rat2 and C2 cell lines using TCF from all the monoclonal antibodies. The eluates were
immunoblotted with an anti-USP28 antibody purchased from Sigma (Figure 4.9. upper
panel) and anti-PR65 G3.8F11 antibody (Figure 4.9. bottom panel). Clones C5.1G7,
C5.3D10 and C5.12B12 precipitated USP28 along with PR65, which correlates with the
results from Figure 4.6. Further investigation into this interaction will be described in
Chapter 5.
4.2.5 Hsp72, tEF1 alpha, Hsp90, GAPDH and Filamin
To confirm the MS identification of Hsp72, tEF1α, Hsp90, GAPDH and Filamin,
immunoprecipitation experiments were also performed in Rat2 and C2 cell lines using
TCF from all the antibodies. However, IP westerns could not confirm these proteins to
co-precipitate with PR65, as the results were not reproducible. Further research into
these proteins revealed them to be often present in purification and isolation procedures,
suggesting they interact with a large number of other proteins. In addition, they are
present in the cell in high abundance, suggesting they may be non-specific interactions.
No further investigations into the possible associations of these proteins have been
carried out.
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Figure 4.9. Immunoprecipitation of USP28 with the anti-PR65 antibodies.
Rat2 and C2 lysates were subjected to immunoprecipitation, using Protein A sepharose as detailed in the materials and
methods chapter, with different anti-PR65 antibodies. The eluates were separated by SDS-PAGE and western blot analysis
was performed using an anti-USP 28 antibody (top panel) and anti-PR65, G3.8F11 (bottom panel).
Antibodies performing the IP are written above the blot.
L= lysate input,   R=IP performed in Rat2 lysate,    C= IP performed in C2 lysate
HC = antibody heavy chain
LC = antibody light chain
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4.2.6 Subcellular localisation of PR65
To investigate where in the cell the PR65 containing complexes recognized by each
monoclonal antibody are localised, immunocytochemistry experiments were performed
on formaldehyde fixed Rat 2 fibroblasts (Figure 4.10.). These showed that the cell
staining is similar for all the mAbs despite having different epitopes and performing
differently in IP experiments. All the antibodies showed strong nuclear staining (Figure
4.10.a), suggesting the PR65 containing complexes these antibodies recognised are
located within the nucleus. Visualisation at a higher magnification using two of the
clones displayed a slight difference in the nuclear staining pattern (Figure 4.10.b).
C5.7A1 staining was speckled whereas R5.1A7 had a more uniform staining. The
intensity of the staining is different between the antibodies, and interestingly the
antibodies that precipitated USP28 with PR65 display a weaker staining. G3.8F11 also
stains the cells poorly (Figure 4.10.a), and staining with C5.7F2 was so weak it was not
able to be detected (data not shown). A possible explanation why monoclonal antibodies
do not demonstrate satisfactory staining is if their epitopes are masked within a cell
structure. This is probably not the case for G3.8F11 and C5.7F2 as they were not able to
recognise more antigen in IPs performed in denatured lysate compared with those
carried out in native lysate (Figure 4.2.). Therefore, the weaker staining is probably due
to the epitope for these antibodies being destroyed during fixation.
It was expected that when the T-antigens are expressed some complexes may be altered,
and this could be detected by the difference in subcellular localisation patterns displayed
by the antibodies when IF on Rat2 and the MT expressing cells C2 are compared.
However, no differences in localisation between these cell lines was observed, this is
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unsurprising as MT is not precipitated with PR65 by my mAbs (Figure 4.4.) and no
difference in PP2A complexes could be detected when MT was expressed (Figure 4.6.).
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Figure 4.10. Subcellular Localisation of PP2A complexes in Rat2 cells.
Immunofluorescence experiments carried out on formaldehyde fixed fibroblast cells.
The cells were incubated with each of the antibodies, washed, and then incubated with a
Cy3 conjugated Anti-Mouse IgG. The fluorescence was examined under an inverted
microscope.
Antibody used for the immuno-fluorescence is written underneath each slide.
a) 10x magnification
b) 100x magnification
10μm
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4.3 Discussion
The aims of this PhD project have been to examine PP2A subunit composition and
interacting proteins. To achieve this, antibodies were generated towards the structural
subunit, PR65 and these were required to immunoprecipitate PP2A containing
complexes. Monoclonal antibody clones C5.1G7, C5.3D10, C5.7F2, C5.9E10,
C5.12B12, G3.8F11, R5.8A4 and R5.8F8 precipitated PP2AD well in IP experiments
(Figure 4.1.). Clone R2.7E9 can precipitate only PR65, but no PP2Ac, suggesting this
clone recognises free PR65 subunit in the cell. This result was confirmed when the
abilities of the antibodies to precipitate PR65 and PP2Ac in denatured Rat2 lysate
compared with native Rat2 lysate were analysed (Figure 4.2.). R2.7E9 recognised more
endogenous subunit in the denatured lysate suggesting that its epitope is not accessible,
probably due to interacting proteins masking this site, when the proteins are in their
native form. The binding site for this clone has been located to HEAT motif 11 (Figure
3.22.) the area which PP2Ac is known to associate, so it is suspected that PP2Ac
interacting with PR65 prevents R2.7E9 from recognising its epitope. Therefore, R2.7E9
can only precipitate free PR65 and not PP2AD.
Unfortunately none of the anti-PR65 antibodies appear to precipitate any of the B
subunits with PR65 (Figure 4.3.), nor were they able to precipitate MT associated with
PP2AD (Figure 4.4.). These results can be explained by the epitope mapping experiments
from the previous chapter, revealing the epitope for the majority of the antibodies to be
situated within the N-terminal half of PR65, the region in which the B subunits and T
antigens interact. Therefore, when these proteins bind to PP2AD the antibodies do not
have access to their binding site. The original view was that the dimer was an artefact
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resulting from dissociation and proteolytic breakdown of the B subunits during isolation.
However, this has been proved not to be true. To ensure minimal disruption of
complexes during isolation processes, these procedures were carried out in conditions to
avoid proteolysis, by performing the experiments quickly at 4°C, and using effective
protease inhibitors, that have a broad specificity. The produced monoclonal antibodies
can be used to confirm that the PP2A dimer is available in the cell in high levels, maybe
acting as a reservoir ready to associate with the regulatory B subunits depending on the
requirements of the cell. In addition free PR65 subunit has also been shown to exist.
To identify proteins associating with PP2AD, the anti-PR65 antibodies have been
successfully coupled to a matrix and used in IP experiments. Although the sensitivity of
detection is a lot lower than IP western experiments, clones C5.1G7, C5.3D10,
C5.12B12, R5.8A4 and R5.8F8 precipitated PR65 and PP2Ac in reasonable amounts
(Figure 4.6.). Some of the clones such as C5.7F2, C5.9E10 and G3.8F11 performed a lot
worse than in the IP western experiments. This could be a result of the amino-linking
process causing a small change in the antibody structure, which could affect the strength
of the antibody-antigen reaction. Although the antibodies do not precipitate MT in
complex with PP2AD, it is possible that MT expression could have a downstream effect
and still disrupt the PP2A complexes. This could be by the dephosphorylation of PP2A
substrates, rendering them unable to interact with the phosphatase, or, by sequestering
interacting proteins. To examine this, the IP experiments were performed in Rat2 and C2
lysates and the precipitated polypeptides compared. Unfortunately, no changes between
the IPs carried out with Rat2 and C2 lysates were detected. However, different
antibodies precipitated different PP2A complexes, and proteins at sizes 130 kDa, 70 kDa,
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50 kDa, 80 kDa, 40 kDa and 250 kDa have been identified by MS approaches as USP28,
Hsp72, tEF1α, Hsp90, GAPDH and Filamin, respectively (Table 4.1.).
As already mentioned, the immunoprecipitation experiments were carried out under
conditions to minimize protein dissociation. However, because immunoprecipitation
experiments have many points at which specific and non-specific contaminants can be
detected, care must be used before any band is classified as an associated protein. Other
approaches such as co-purification and co-precipitation are required to confirm the
results, hence, IP western experiments were initially performed.  Figure 4.9. confirmed
that C5.1G7, C5.3D10 and C5.12B12 precipitated USP28 with PR65. Further results
regarding this interaction are described in Chapter 5. The other proteins identified by
MS approaches, Hsp72, tEF1α, Hsp90, GAPDH and Filamin were concluded to be non-
specific interactions, as results regarding these proteins were not reproducible.
Immunofluorescence experiments were undertaken to reveal the subcellular localisation
of the PR65 complexes. All the anti-PR65 antibodies showed nuclear staining (Figure
4.10.), suggesting that PR65 containing complexes the antibodies recognised are
localised within the nucleus.
In summary, the antibodies presented here can be used as tools to isolate free PR65 and
PP2AD complexes from cells. A PP2A dimer associating with deubiquitinating enzyme,
USP28 has been identified, potentially in the nucleus of cells. However, there are
limitations with using this approach for isolating PP2A complexes as false interacting
proteins have been identified. Also, clearly not all PP2A complexes can be precipitataed,
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in particular any holoenzymatic complexes. Other tools are needed to isolate a wider
range of associated proteins.
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CHAPTER 5. PP2A-USP28
5.1 USP28
5.1.1 Introduction
The result from the MS analysis identified a PR65-interacting partner, Ubiquitin specific
protease, USP28. USP28 belongs to a family of enzymes called Deubiquitinating
enzymes (DUBs) which play a vital regulatory role in protein ubiquitination. Ubiquitin
modification is well established to play fundamental roles in a wide range of cellular
processes such as cell cycle progression, DNA repair, signal transduction and
degradation in the proteasome and lysosome (reviewed in [221, 222]). This is a dynamic
process involving enzymes that add ubiquitin (ubiquitinating enzymes) and enzymes that
remove ubiquitin (DUB enzymes). In the past, studies into this highly regulated pathway
have been focussed on the ubiquitination enzymes, now it is becoming apparent that
DUBs also play an essential role in maintaining this protein modification system [223,
224]. Failure in the exact regulation of this process has been implicated in many human
diseases such as neurodegenerative disorders and cancer.
USP28 was first identified in 2001 by Valero et al. [225], and found to map to 11q23, a
region frequently deleted in tumours. USP28 has since been shown to be implicated in
Chk2-p53-PUMA signalling, a pathway involved in DNA damage induced apoptosis.
This DUB associates with 53BP1, Mdc1 and Claspin, three of the checkpoint mediators
in this DNA damage response [226]. Also USP28 has been shown to bind to c-myc
through an interaction with FBW7, to stabilize c-myc in the proliferation of several
tumours, and high expression levels of USP28 are found in colon and breast cancer
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[227]. In addition, mutations in USP28 are present in lobular tumours [228]. As protein
phosphorylation, in particular of serine and threonine residues, is noticeably described in
the literature relating to DNA damage and c-myc stabilisation and PP2A has already
been shown to become associated with proteins involved in these processes such as
Claspin and c-myc, it seems probable that USP28 could become part of a PP2A complex.
5.1.2 Results
5.1.2 1 Confirmation of the USP28 –PR65 interaction by Antibody
approaches
To confirm that USP28 is present in the IP eluate as a result of an interaction with the
PP2AD complex and not an artefact of the precipitation, IP experiments were performed
on all anti-PR65 antibodies and immunoblotted with an anti-USP28 antibody (Figure 4.9.
upper panel) and an anti-PR65 antibody (Figure 4.9. lower panel). The result was
reproducible, only three clones C5.1G7, C5.3D10 and C5.12B12 precipitated this
enzyme, suggesting the presence of USP28 in the elution is not due to non specific
interactions through being a ‘sticky’ protein. The next question to address was whether
USP28 was present due to association with a PP2A complex, or through a direct
interaction with the antibody? If the latter was true, the antibodies would be able to
recognise USP28 in western blots of total cell lysates, in particular with clone C5.3D10,
as considerable USP28 can be precipitated with this antibody. Figure 5.1. showed that
C5.1G7, C5.3D10 and C5.12B12 do not recognise any other protein apart from PR65 in
total cell lysate. In Figure 5.2. the eluates from anti-PR65 IPs were immunoblotted with
C5.3D10. Only bands corresponding to PR65 and the antibody heavy chain can be seen
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on the immuno-blot, further confirming that the antibodies do not recognise USP28
directly in western blots.
Figure 5.1. Western Blots of anti-PR65 antibodies and anti-USP28 antibody.
Rat2 lysate was separated by SDS-PAGE and western blotted with the anti-PR65
antibodies that co-precipitate USP28. C5.1G7, C5.3D10 and C5.12B12 are very specific
for PR65 and do not recognise any other proteins in the lysate. An anti-USP28 antibody
is used as a molecular weight control.
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Figure 5.2. Immunoblotting of anti-PR65 IP eluates with C5.3D10.
Cell lysates were immunoprecipitated using three anti-PR65 antibodies that precipitate
USP28 (C5.1G7, C5.3D10 and C5.12B12) and one that does not (R5.8A4). Western blot
analysis was performed using anti-PR65 antibody C5.3D10 that precipitates USP28.
Antibodies performing the IP are written above the blot
If the antibodies were directly interacting with USP28, the antibody’s epitope would be
present in the USP28 sequence. Alignment of the PR65 and USP28 sequences (Figure
5.3.) revealed there is no obvious homology. The sequence of USP28 has also been
aligned with 265-275 amino acids of PR65 sequence, the area which the antibodies
C5.1G7, C5.3D10 and C5.12B12 epitope have been localised to (Figure 5.4.). The
closest similarity occurs between amino acids 97-106 of USP28 sequence. Only three
amino-acids out of four are identical, and only two of these are consecutive. Although
antibody epitopes are generally a short sequence (about 4-5 amino-acids), two
consecutive identical amino-acids probably would not be sufficient for the antibody to
interact, and if it did, the detection would be weak. This further confirmed that C5.1G7,
C5.3D10 and C5.12B12 did not directly interact with USP28.
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CLUSTAL format alignment by MAFFT (v6.707b)
USP28           MTAELQQDDAAGAADGHGSSCQMLLNQLREITGIQDPSFLHEALKASNGDITQAVSLLTD
PR65            M-----------------------------------------------------------
                *
USP28           ERVKEPSQDTVATEPSEVEGSAANKEVLAKVIDLTHDNKDDLQAAIALSLLESPKIQADG
PR65            ------------------------------------------------------------
USP28           RDLNRMHEATSAETKRSKRKRCEVWGENPNPNDWRRVDGWPVGLKNVGNTCWFSAVIQSL
PR65            ------------------------------------------------------------
USP28           FQLPEFRRLVLSYSLPQNVLENCRSHTEKRNIMFMQELQYLFALMMGSNRKFVDPSAALD
PR65            ------------------------------------------------------------
USP28           LLKGAFRSSEEQQQDVSEFTHKLLDWLEDAFQLAVNVNSPRNKSENPMVQLFYGTFLTEG
PR65            ------------------------------------------------------------
USP28           VREGKPFCNNETFGQYPLQVNGYRNLDECLEGAMVEGDVELLPSDHSVKYGQERWFTKLP
PR65            --------------------------------AAADGDDSLYP----------------I
                                                * .:** .* *
USP28           PVLTFELSRFEFNQSLGQPEKIHNKLEFPQIIYMDRYMYRSK-ELIRNKRECIRKLKEEI
PR65            AVLIDELRNEDVQLRLNSIKKL-------STIALALGVERTRSELLPFLTDTIYDEDEVL
                .**  ** . :.:  *.. :*:       . * :   : *:: **:    : * . .* :
USP28           KILQQKLERYVKYGSGPARFPLPDMLKYVIEFASTKPASESCPPESDTHMTLPLSSVHCS
PR65            LALAEQLGTFTTLVGGP---------EYV---HCLLPPLES------------LATVEET
                  * ::*  :..  .**         :**    .  *. **            *::*. :
USP28           VSDQTSKES---TSTESSSQDVESTFSSPEDSLPKSKPLTSSRSSMEMPSQPAPRTVTDE
PR65            VVRDKAVESLRAISHEHSPSDLEAHFVPLVKRLAGGDWFTSRTSACGLFSVCYPRVSS--
                *  :.: **    * * *..*:*: * .  . *. .. :**  *:  : *   **. :
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USP28           EINFVKTCLQRWRSEIEQDIQDLKTCIASTTQTIEQMYCDPLLRQVPYRLHAVLVHEGQA
PR65            ----------AVKAELRQYFRNL--CSDDT----------PMVRRA-----------AAS
                            ::*:.* :::*  *  .*          *::*:.           . :
USP28           NAGHYWAYIYNQPRQSWLKYNDISVTESSWEEVERDSYGGLRNVSAYCLMYINDKLPYFN
PR65            KLGEFAKVLELDNVKS-----EIIPMFSNLASDEQDS---VRLLAVEACVNIAQLLPQED
                : *.:   :  :  :*     :*    *.  . *:**   :* ::. . : * : **  :
USP28           AEAAPTESDQMSEVEALSVELKHYIQEDNWRFEQEV-EEWEEEQSCKIPQM-ESSTNSSS
PR65            LEALVMPT------------LRQAAEDKSWRVRYMVADKFTELQKAVGPEITKTDLVPAF
                 **    :            *::  ::..**..  * ::: * *..  *:: ::.  .:
USP28           QDYSTSQEPSV--ASSHGVRCLSSEHAVIVKEQTAQAIANTARAYEKSGVEAALSEVMLS
PR65            QNLMKDCEAEVRAAASHKVKEFCENLSADCRE-----------------------NVIMS
                *:  .. *..*  *:** *: :..: :.  :*                       :*::*
USP28           PAMQGVILAIAKARQTFDRDGSEAGLIKAFHEEYSRLYQLAKETPTSHSDPRLQHVLVYF
PR65            QILPCIKELVSDANQ---------------HVKSALASVIMGLSPILGKDNTIEHLLPLF
                  :  :   ::.*.*               * : :    :   :*   .*  ::*:*  *
USP28           ---FQNEAPKRVVERTLLEQFADKNLSYDERSISIMKVAQAKLKEIGPDDMNMEEYKKWH
PR65            LAQLKDECPE--VRLNII-----SNLDCVNEVIGIRQLSQSLL----PAIVELAEDAKWR
                   :::*.*:  *. .::     .**.  :. *.* :::*: *    *  ::: *  **:
USP28           EDYSLFRKVSVYL-LTGLELYQKGKYQEALSYL---VYAYQSNA-ALLMKGPRRGVKESV
PR65            VRLAIIEYMPLLAGQLGVEFFDEKLNSLCMAWLVDHVYAIREAATSNLKKLVEKFGKEWA
                   :::. :.:     *:*::::   . .:::*   *** :. * : * *  .:  ** .
USP28           IALYRRKCLLELNAKAASLFETNDDHSVTE--GINVMNELIIPCIHLIINNDISKDDLDA
PR65            HATIIPKVL-------AMSGDPNYLHRMTTLFCINVLSEVCGQDI-------TTKHMLPT
                 *    * *       *   :.*  * :*    ***:.*:    *        :*. * :
USP28           IEVMRNHWCSYLGQDIAENLQLCLGEFLPRLLDPSAEIIVLKEPPTIRPNSPYDLCSRFA
PR65            VLRMAGDPVANVRFNVAKSLQKIGPILDNSTLQSEVKPILEKLTQDQDVDVKY-------
                :  * ..  : :  ::*:.**     :    *:...: *: * .     :  *
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USP28           AVMESIQGVSTVTVK
PR65            ---FAQEALTVLSLA
                    : :.::.:::
Figure 5.3. Protein sequence alignment of PR65 with USP28 using Mafft software.
Identical residues are marked with an asterix (*)
: Indicates if the residues have a strong similarity
. Indicates if the residues have a weak similarity
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CLUSTAL format alignment by MAFFT (v6.707b)
USP28           MTAELQQDDAAGAADGHGSSCQMLLNQLREITGIQDPSFLHEALKASNGDITQAVSLLTD
265-274         ------------------------------------------------------------
USP28           ERVKEPSQDTVATEPSEVEGSAANKEVLAKVIDLTHDNKDDLQAAIALSLLESPKIQADG
265-274         ------------------------------------DKFTELQKAV--------------
                                                    *:  :** *:
Figure 5.4. Protein sequence alignment of mAb epitope (265-274 amino acids of PR65) with USP28 using Mafft
Software.
The homology is shown between 97-106 amino acids of USP28 sequence
Identical residues are marked with an asterix (*)
: Indicates if the residues have a strong similarity
. Indicates if the residues have a weak similarity
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To further elucidate the interaction of PR65 and USP28, IP experiments were carried out
under native and denatured conditions using tissue culture fluid (TCF) from all anti-
PR65 antibody clones. The eluates were immunoblotted with an anti-USP28 antibody
(Figure 5.5. upper panel) and an anti-PR65 antibody (Figure 5.5. lower panel). The
lysate was denatured prior to performing the IP, by adding 1% SDS and boiling for 5
minutes. The proteins were then refolded by diluting the SDS with buffer containing 1%
NP40 and 1% DOC, two detergents that form mixed micelles with the SDS. These
conditions denature the complexes in the lysate, so if the antibody was binding to USP28
directly it would still be present in the IP elution. The IPs carried out with C5.1G7 and
C5.12B12 with the denatured lysates did not precipitate USP28, and although C5.3D10
still precipitated some USP28, the levels decreased dramatically. One reason that USP28
could still be precipitated with C5.3D10, is that there could be a very strong binding
affinity between the antibody and antigen, therefore the antibody is still precipitating any
of the PP2A complexes that have not been completely denatured. Another explanation
could be that some of the complexes re-anneal when the lysate cools down after boiling.
PP2Ac can also be precipitated with C5.3D10 in the denatured IPs (Figure 4.2),
suggesting not all complexes are denatured when the IPs are performed. To ensure all
complexes were fully denatured, an IP was carried out with C5.3D10 and proteins were
eluted by addition of 1% SDS and 1% DTT, the elution was boiled for 5 minutes and re-
immunoprecipitated with the same antibody (Figure 5.6.). No USP28 (Figure 5.6. upper
panel) and PP2Ac (Figure 5.6. lower panel) can now be precipitated, suggesting the
proteins have now been completely denatured and are no longer in any complexes.
However, there is less PR65 (Figure 5.6. middle panel) precipitated in the denatured IP
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compared to the native IP. This is inevitable due to some of the proteins being lost in the
extra IP step.
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Figure 5.5. Denatured Immunoprecipitation with anti-PR65 antibodies.
Cell lysates were immunoprecipitated using different anti-PR65 antibodies, and western blot analysis was performed using
anti-USP antibody (top panel) and anti-PR65 antibody (lower panel). Antibodies performing the IP are written above the blot.
Immunoprecipitations carried out on Rat2 lysate (n) and compared with denatured lysate (d).
Denaturing conditions: lysates treated with 1% SDS, boiled for 5 minutes, then diluted 10x with 1% NP40, 1% DOC.
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Figure 5.6. Denatured Immunoprecipitation with C5.3D10.
Cell lysates were immunoprecipitated using C5.3D10. Elution of proteins in
denatured IP was achieved by addition of 1% SDS and 1% DTT; the elution was then
boiled for 5 minutes and then re-immunoprecipitated with C5.3D10. Western blot
analysis was performed using anti-USP28 antibody (top panel), anti-PR65 antibody
(middle panel), and anti-PP2Ac antibody (lower panel).
Immunoprecipitations carried out on Rat2 lysate (n) and compared with denatured
lysate (d).
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The next step in studying the USP28-PP2A association was to carry out the
reciprocal  IP  experiment,  to  see  if  PP2A  can  be  seen  associating  with  USP28.
Immunoprecipitation with purified anti-USP28 was performed on Rat2 and Hela
lysate and immunoblotted with anti-USP28 (Figure 5.7. upper panel), anti-PR65
(Figure 5.7. middle panel) and anti-PP2Ac (Figure 5.7. lower panel) antibodies. Anti-
USP28 antibody precipitated its endogenous antigen in both Rat2 and Hela lysate but
PR65 and PP2Ac were not present in the immunoprecipitations.
Figure 5.7. Immunoprecipitation experiments using anti-USP28 antibody.
Rat2 and Hela cell lysates were immunoprecipitated using anti-USP28 antibody, and
western blot analysis was performed using anti-USP28 antibody (top panel), anti-
PR65 antibody (middle panel) and anti-PP2Ac antibody (bottom panel).
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The clones C5.1G7, C5.3D10 and C5.12B12 also precipitated PP2Ac as well as
USP28,  therefore,  IP  experiments  were  carried  out  using  six  different  anti-PP2Ac
antibodies, existing in our lab, that recognise different regions of the PP2Ac
sequence (Figure 5.8.). F2.5G4, M1.12A1 and F2.12H1 recognise the first 165 amino
acids, F2.8F5 and F2.6A10 recognises the C-terminal end and F2.12G10 recognise
amino acids 182-217, of PP2Ac. The eluates were immunoblotted with anti-USP28
(Figure 5.8. upper panel), anti-PR65 (Figure 5.8. middle panel) and anti-PP2Ac
(Figure 5.8. lower panel) antibodies. USP28 was not present in the elutions of the IPs
carried out with any of the anti-PP2Ac antibodies, suggesting none of the antibodies
precipitated USP28 in complex with PP2A. However, only F2.6A10 and F2.8F5,
precipitated both PP2Ac and PR65, and the latter was present in very small amounts,
therefore it is not surprising that USP28 was not detected in these
immunoprecipitations.
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Figure 5.8. Immunoprecipitation experiments using different anti-PP2Ac
antibodies.
Rat2 cell lysates were immunoprecipitated using different anti-PP2Ac antibodies.
Western blot analysis was performed using anti-USP28 antibody (top panel), anti-
PR65 antibody (middle panel) and anti-PP2Ac antibody (bottom panel). Antibodies
performing the IP are written above the blot.
HC= Antibody heavy chain
Location of the antibodies epitope on PP2Ac sequence:
F2.8F5 = C-terminal end F2.5G4 = 1-165 amino acids
F2.6A10 = C-terminal end M1.12A1 = 1-165 amino acids
F2.12G10 = 182-217 amino acids F2.12H1 = 1-165 amino acids
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5.1.2.2. In Vitro binding studies of PR65 and USP28 interaction
To show USP28 and PR65 interacting in another system, USP28 mouse sequence
(USP28m) was cloned into pcDNATM3.1/myc-His(-) and PR65 mouse sequence
(PR65m) was cloned into pcDNATM3.1/V5-His  TOPO.  These  were  both  translated
using the TNT T7 coupled translation/transcription kit and immunoprecipitation
experiments performed. A western blot of rabbit reticulocyte (retic lysate) was
initially carried out to determine whether USP28 and PR65 are present endogenously
in the retic lysate used in the translation kit (Figure 5.9.). USP28 was not present
endogenously in retic lysate (lane 4, upper panel) but was in Hela (lane 1, upper
panel), NIH 3T3 (lane 2, upper panel) and Rat2 (lane 3, upper panel) lysates.
Endogenous PR65 was present in all the lysates (Lanes 1-4, lower panel).
Immunoprecipitation experiments were performed in normal retic lysate and retic
lysate containing translated USP28m and both translated USP28m + PR65m, using
C5.3D10 and R5.8A4, an antibody that did not precipitate USP28. Eluates were
separated by SDS-PAGE and immunoblotted with anti-USP28 (Figure 5.10. top
panel) and anti-PR65 (Figure 5.10. lower panel) antibodies. Lane 1 acts as a marker
showing the endogenous proteins in Rat2 lysate and lane 2 shows the translated and
endogenous proteins in the retic lysate before the IPs have been performed. As
expected  only  precipitation  of  PR65  was  seen  in  lanes  3  (C5.3D10  IP)  and  lane  6
(R5.8A4  IP),  as  these  IPs  are  performed  in  retic  lysate  where  there  is  no  USP28
present. When IPs were performed in USP28m, and USP28m + PR65m translated
lysates using R5.8A4 (lanes 7 and 8 respectively) only PR65 was precipitated. This is
expected as R5.8A4 has previously been shown not to precipitate USP28 (Figure
4.9.). When the IPs were performed in the USP28m translated lysate using C5.3D10
(lane 3), PR65 was precipitated along with some USP28. However, there was no
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difference in the amount of USP28 precipitated when an IP is performed in lysate
that PR65m has also been translated (lane 4). This suggested that translated PR65m
did not interact with translated USP28m. In Figure 5.11. IP experiments have been
performed in USP28m and PR65m translated lysate using C5.3D10 and an anti-V5
antibody. USP28 is only precipitated with C5.3D10 and not with anti-V5 antibody,
further illustrating that translated USP28m and PR65m did not associate.
Figure 5.9. Western Blots of USP28 expression in different cell lines.
Total cell lysate of Hela (lane 1), NIH 3T3 (lane 2), and Rat2 (lane 3) fibroblasts and
rabbit reticulocyte (lane 4) were separated by SDS-PAGE and immunoblotted with
anti-USP28 (upper panel) and anti-PR65 (lower panel) antibodies.
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Figure 5.10. In vitro translation binding studies of PR65 and USP28 interaction
using anti-PR65 antibodies.
Mouse PR65 (PR65m) was cloned into pcDNATM3.1/V5-His TOPO and mouse
USP28 (USP28m) was cloned into pcDNATM3.1/myc-His(-). These proteins were in
vitro translated using the TNT T7 Quick coupled transcription/translation system.
Immunoprecipitation experiments were carried out on these translated lysates using
anti-PR65 antibodies C5.3D10 and R5.8A4. The elutions were separated by SDS-
PAGE and immunoblotted with anti-USP28 antibody (upper panel) and anti-PR65
(lower panel) antibody.
Lane1 = Rat2 lysate
Lane 2= USP28m and PR65m translated lysate
Lane 3 = C5.3D10 IP preformed in rabbit reticulocyte
Lane 4= C5.3D10 IP preformed in USP28m translated lysate
Lane 5= C5.3D10 IP preformed in USP28m and PR65m translated lysate
Lane 6 = R5.8A4 IP preformed in rabbit reticulocyte
Lane 7= R5.8A4 IP preformed in USP28m translated lysate
Lane 8= R5.8A4 IP preformed in USP28m and PR65m translated lysate
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Figure 5.11. In vitro translation binding studies of PR65 and USP28 interaction
using anti-V5 antibody.
Mouse PR65 (PR65m) was cloned into pcDNATM3.1/V5-His TOPO and mouse
USP28 (USP28m) was cloned into pcDNATM3.1/myc-His(-). These proteins were in
vitro translated using the TNT T7 Quick coupled transcription/translation system.
Immunoprecipitation experiments were carried out on these translated lysates using
C5.3D10 (anti-PR65 antibodies) and anti-V5 antibody. The elutions were separated
by SDS-PAGE and immunoblotted with anti-USP28 antibody (upper panel) and anti-
PR65 (lower panel) antibody. Antibody performing IP are written above the blot.
I = translated lysate input
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5.1.2.3. Localisation of USP28 complexes
To investigate where in the cell the USP28 complexes recognised by the anti-USP28
antibody are localised, immunocytochemistry experiments were performed on Rat2
fixed fibroblasts (Figure 5.12.). USP28 antibody stained the cells only in the nucleus
(right slide), revealing the USP28 complexes are located in this cellular compartment.
This is a similar result to the IF results using the anti-PR65 antibodies (left slide),
providing further evidence that USP28 and PR65 could interact.
Figure 5.12. Subcellular Localisation of USP28 complexes in Rat2 cells.
Immunofluorescence experiments carried out on fixed fibroblast cells. The cells were
incubated with anti-USP28 and anti-PR65 antibodies, washed, and then incubated
with a Cy3 conjugated Anti-Mouse IgG. The fluorescence was examined under an
inverted microscope.
20μm
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5.2 Tagged PR65
As shown in the previous chapter there is a limitation in identifying PP2A complexes
using solely the monoclonal antibodies. Clearly not all the complexes are being
recognised; the holoenzyme can not be precipitated with the produced monoclonal
antibodies, and not all the interactions were found to be true PP2A associated
proteins. Therefore, a complementary approach was required to identify a broad
range of PP2A complexes, and in addition could be used to further confirm the
PP2A-USP28 interaction. Purification of protein in combination with MS allows
identification of interacting partners. However, often the limiting step in the process
appears to be protein purification. In response to the rapidly growing proteomics
field, use of recombinant proteins has also increased. Protein affinity tags have
become highly popular tools for purifying native protein complexes because they
allow at least 100 or 1000 fold purification from cellular extracts and the purification
can be carried out under mild conditions. Tandem affinity purification (TAP) has
greatly enhanced this work to allow for higher purity of protein complexes. The
conventional ‘TAP’ tag consists of two tags fused to the target protein of interest and
proteins interacting with the target are isolated by using two successive affinity
purification steps. The components of protein complexes are later separated by SDS-
PAGE and isolated for MS identification. The original TAP tag is composed of two
IgG binding domains of Staphylococcus aureus protein A (ProtA) and a calmodulin
binding peptide (CBP), separated by a TEV protease cleavage site [229]. This tagged
protein requires two purification steps. Initially ProtA binds tightly to an IgG matrix
which can be cleaved by the addition of TEV protease. The elution is then incubated
with calmodulin coated beads in the presence of calcium and the bound material is
released with EGTA [229, 230]. The TAP tag was originally developed in yeast and
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although it has been successfully applied to mammalian cells, the overall yield is low
and a  large  quantity  of  starting  material  is  needed.  Also,  the  tag  is  very  bulky  and
could disrupt native complexes. Hence, small peptide tags have been utilised that
should not interfere with the native complex of the fused protein. As multi-tagging
gives consecutive purification steps, resulting in higher purity, a novel ‘TAP’ tag
consisting of a Strep- tag III sequence linked to a c-myc epitope and fused to the N
terminus of PR65 human sequence has been constructed (Figure 5.13.). Comparison
of different affinity tags revealed the Strep tag to have excellent purification ability
with good yields at a low cost [231], therefore the Strep system was chosen for the
first tag. Strep- tag III consists of two Strep-tag  II  sequences  separated  by  a  short
linker region, and has been shown to have a higher binding affinity than Strep-tag II
resulting in more of the tagged protein being recovered from the cellular lysates
[232]. The Strep-tag III variation was chosen as an affinity tool for the purification of
the corresponding fusion protein, PR65, on an engineered streptavidin derivative
column known as StrepTactin [233]. Elution of the bound tagged fusion protein from
the StrepTactin column can be achieved in the native state by addition of low
concentrations of biotin, which binds to biotin pockets on StrepTactin in competition
with the Strep-tag III, due to it having a higher affinity than the tag. Proteins with the
c-myc epitope (EQKLISEEDL) tag can then be affinity purified using a monoclonal
antibody (9E10), raised towards this sequence on c-myc, coupled to agarose and an
IP experiment performed. As we have the murine anti-c-myc antibody hybridoma
cell line existing in our lab, this was chosen for the second tag. Conventional TAP
procedures utilize a cleavage site for the tag to be removed from the protein. This
would be useful if functional studies of the tagged protein were required. However,
the purpose of the constructed tag was for purification and identification of
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complexes only, therefore the extra step was not deemed necessary and a cleavage
site was not included. Several advantages of using this novel tag compared with the
conventional tag were considered; the Strep III-myc tag is a lot smaller and
purification can be carried out at a much lower temperature for a shorter time,
minimizing disruption of native complexes.
link                                                  One-STrEP- tag link
M A S W S H P Q F E K G G G S G G G S G G G S W S H P Q F E K G A E T E Q
  c-myc epitope
K L I S E E D L P N S –
Figure 5.13. Schematic representation of Strep III- myc PR65.
Amino- acid sequence of the constructed tag which is comprised of Strep- tag III
sequence linked to a c-myc epitope and fused to the N terminus of PR65 sequence.
PR65 Sequence
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5.2.1 Characterisation of cell lines
The constructed Strep III- myc PR65  human  tag  (SMPR65)  was  transfected  by  a
calcium chloride method into different cell lines, to create stable lines expressing the
tag. The cell lines used were: Rat2 fibroblasts (R2), the middle T expressing Rat2
fibroblast (C2 cells), Hela cells and an inducible Rat2 fibroblast cell line, in which
the expression of polyoma ST can be switched on and off by the addition of
Doxycycline. A tag was also constructed in which the rat sequence of PR65 fused to
the Strep III- myc tag (SMPR65r) was transfected into Rat2 fibroblasts. The
established cell lines were initially characterised, to assess if the phenotype of the
cell had been altered by addition of the tagged sequence. Figure 5.14. showed the
micrographs of the transfected cell lines compared to the parental cells. All the
transfected cell lines grew less dense than their parental cell line. Western blots were
then carried out on the transfected cell lysates to determine how much tagged PR65
was produced compared to endogenous PR65 (Figure 5.15.). Interestingly, more
tagged PR65 was expressed in the cell lines in which the viral T-antigens were
expressed. The difference in expression in the Rat fibroblasts (R2 compared with C2
and PyST) is probably due to the expression of the T antigens being able to up
regulate the CMV promoter of the transfected DNA in vector pEXPR-IBA105, hence
more tag is being expressed. Hela cells proliferate abnormally rapidly, so more
tagged protein is probably expressed in this cell line per lysate volume along with the
other cellular proteins compared to Rat2 cells.
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Figure 5.14. Phenotype of tagged PR65 cell lines compared parental cells.
The constructed Strep III- myc- PR65 human sequence (SMPR65) was transfected
into different cell lines. Appearance of the live cells visualised using an inverted
Microscope. Transfections carried out in:
a) Rat2 cells
b) C2 cells
c) Hela cells
d) PyST inducible cell line without (-) and with (+) the expression of ST
e) Strep III-myc- PR65 rat sequence in Rat2 cells (SMPR65r)
200μm
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Figure 5.15. Western blot analysis of total lysate from the transfected cell lines.
Total  cell  lysate  from  the  transfected  cell  lines  was  separated  by  SDS-PAGE  and
immunoblotted with anti-PR65 antibody.
a) SMPR65 in Rat2 cells
b) SMPR65 in C2 cells
c) SMPR65 in Hela cells
d) SMPR65 in PyST inducible cell line without (-) and with (+) the expression
of ST
e) SMPR65r in Rat2 cells
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5.2.2 Cellular Localisation of tagged PR65
To  investigate  where  in  the  cell  the  tagged  PR65  complexes  are  located,
immunocytochemistry experiments were performed on all the cell lines expressing
the tagged protein. The results of these were identical for all the tagged cell lines. An
example of these immunofluorescence (IF) experiments is shown in Figure 5.16.
PyST inducible cells displayed the strongest fluorescence, probably due to having the
highest expression of tagged PR65 compared to the other transfected cell lines. Clone
R5.1A7 was chosen to detect all PR65 in the cell because it performed well in
previous IF experiments (Figure 4.10.), and in western blot of the tagged cell lysates
(Figure 5.15.). No difference was observed when the tag was expressed (Figure 5.16.
lower right) compared to the parental cell line (Figure 5.16. upper right), with this
antibody. Anti-c-myc antibody, 9E10, was used to recognise the tagged PR65 in the
cells. No immuno-fluorescence is observed in the parental cells with this antibody
(Figure 5.16. upper left). The tagged PR65 is primarily located in the nucleus, as
observed for the endogenous protein (Figure 5.16. lower slides).
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Figure 5.16. Subcellular Localisation of tagged PR65 complexes in PyST cells.
Immunofluorescence experiments carried out on fixed fibroblast cells. The cells were
incubated with the antibodies, washed, and then incubated with a Cy3 conjugated
Anti-Mouse IgG. The fluorescence was examined using an inverted microscope.
Clone 9E10 was used as the anti-c-myc antibody and R5.1A7 as the anti-PR65
antibody. Fluorescence in the wild type cell line is shown in the upper slides.
10μm
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5.2.3 Strep Column Purification
The tandem purification of Strep III  – myc –PR65 initially involves binding of the
tag to an immobilised streptavidin derivative, StrepTactin. Elution of the proteins is
achieved by addition of a biotin analogue which competes with the Strep-tag for
binding to the column. The progress of the purification is monitored in the western
blot in Figure 5.17. 1/1000 of the volume of each step was loaded on to the gel for a
quantitative measure of the overall recovery of the purified tag. Purification is very
efficient, almost equal volumes of the tagged protein was present in the elution and
in the input. The eluates with the tag present, in the case of this example, lanes 10
and 11, were combined and an IP performed using amino-linked anti-c-myc antibody,
9E10.
Figure 5.17. Purification of Strep III- myc-PR65 using StrepTactin column.
Strep III- myc-PR65 was purified from cell lysates on StrepTactin column following
the protocol in One-STrEP kit manual. 1/1000 of the volume of each stage of the
purification run separated by SDS-PAGE and immunoblotted with 9E10, anti-c-myc
antibody.
1= lysate  8= Elution 1
2= flow through/unbound material  9= Elution 2
3= Wash 1 10= Elution 3
4= Wash 2 11= Elution 4
5= Wash 3 12= Elution 5
6= Wash 4 13= Elution 6
7= Wash 5
214
5.2.4 Association of tagged PR65 with other PP2A subunits and viral
antigens
To enable identification of a broader range of PP2A interactions, tagged PR65 needs
to become incorporated into a PP2A holoenzyme in the cells. This was confirmed by
separating the purified tag by SDS-PAGE and western blotting with anti-PP2Ac,
anti-PR61 and anti-B56 antibodies to show the presence of the other PP2A subunits.
As a control, the eluates were also western blotted with anti-PR65 antibody, to show
the tag was present with each purification. Figure 5.18. and Figure 5.20. show that
the  tags  in  the  Rat2  cells,  and  Figure  5.20.  show  that  the  tag  in  Hela  cells,  were
associated with PP2Ac (b), B (c) and B’ (d) subunits. The same is also true for the
tag in C2 cells (Figure 5.21.), and in the PyST cell line (Figure 5.22.).
To determine whether tagged PR65 is incorporated into complexes with the T-
antigens, western blot analysis was performed on the purified tag using pAB762, an
antibody raised against an area of sequence that is conserved between MT and ST,
hence can recognise both viral antigens. Figure 5.21.e shows MT was associated with
SMPR65 in C2 cells and Figure 5.22.e shows ST was associated with SMPR65 when
ST is expressed by addition of Doxycycline in the PyST inducible cells. Each of the
western blots in Figures 5.18.-5.22. contain a control purification in which
untransfected cell lines have been subjected to the same purification process as the
transfected cell lines and western blotted with the same antibodies. The purifications
from the untransfected cell lines did not contain any PP2A subunits and T-antigens.
This verifies that these proteins do not bind to the StrepTactin column directly and
they are only present due to the association with the tag. These results suggest that
the  complexes  formed  with  tagged  PR65  are  a  normal  representation  of  PP2A
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holoenzymes  within  the  cell,  and  this  implies  the  tag  can  be  used  to  identify  new
PP2A complexes.
Figure  5.18.  Western  blot  analysis  showing  SMPR65  in  complex  with  other
PP2A subunits in Rat2 transfected cells.
Strep III- myc-PR65 (SMPR65) was purified from cell lysates using the StrepTactin
column, following the protocol in One-STrEP kit manual. The elution containing the
highest amount of tag was separated by SDS-PAGE and western blotted with
antibodies: anti-PR65 (a), anti-PP2Ac (b), anti B56 (c) and anti-PR61 (d).
A lysate marker has been used to show the size of the endogenous proteins.
Elution from wild type Rat2 lysate purified using the StrepTactin column, following
the same protocol has been included as a negative control.
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Figure 5.19. Western blot analysis showing SMPR65rat in complex with other
PP2A subunits in Rat2 transfected cells.
Strep III- myc-PR65 rat sequence (SMPR65r) was purified from cell lysates using the
StrepTactin column, following the protocol in One-STrEP kit manual. The elution
containing the highest amount of tag was separated by SDS-PAGE and western
blotted with antibodies: anti-PR65 (a), anti-PP2Ac (b), anti B56 (c) and anti-PR61
(d).
A lysate marker has been used to show the size of the endogenous proteins.
Elution from wild type Rat2 lysate purified using the StrepTactin column, following
the same protocol has been included as a negative control.
217
Figure  5.20.  Western  blot  analysis  showing  SMPR65  in  complex  with  other
PP2A subunits in Hela transfected cells.
Strep III- myc-PR65 (SMPR65) was purified from cell lysates using the StrepTactin
column, following the protocol in One-STrEP kit manual. The elution containing the
highest amount of tag was separated by SDS-PAGE and western blotted with
antibodies: anti-PR65 (a), anti-PP2Ac (b), anti B56 (c) and anti-PR61 (d).
A lysate marker has been used to show the size of the endogenous proteins.
Elution from wild type Hela lysate purified using the StrepTactin column, following
the same protocol, has been included as a negative control
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Figure  5.21.  Western  blot  analysis  showing  SMPR65  in  complex  with  other
PP2A subunits and MT in C2 transfected cells.
Strep III- myc-PR65 (SMPR65) was purified from cell lysates using the StrepTactin
column following the protocol in One-STrEP kit manual. The elution containing the
highest amount of tag was separated by SDS-PAGE and western blotted with
antibodies: anti-PR65 (a), anti-PP2Ac (b), anti B56 (c), anti-PR61 (d) and anti-MT
(e).
A lysate marker has been used to show the size of the endogenous proteins.
Elution from wild type C2 lysate purified on StrepTactin column, following the same
protocol, has been included as a negative control.
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Figure  5.22.  Western  blot  analysis  showing  SMPR65  in  complex  with  other
PP2A subunits and ST in PyST inducible transfected cells.
Strep III- myc-PR65 (SMPR65) was purified from cell lysates using the StrepTactin
column following the protocol in One-STrEP kit manual. The elution containing the
highest amount of tag was separated by SDS-PAGE and western blotted with
antibodies: anti-PR65 (a), anti-PP2Ac (b), anti B56 (c), anti-PR61 (d) and anti-ST (e).
A lysate marker has been used to show the size of the endogenous proteins.
Elution from wild type PyST inducible lysate purified using the StrepTactin column,
following the same protocol, has been included as a negative control.
PyST– without addition of Doxycyline, no ST expressed
PyST+ without addition of Doxycyline, ST expressed
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5.2.5 Association of Tagged PR65 with USP28
To confirm whether USP28 interacts with tagged PR65, the purified tag from all the
lysates were immunoblotted with anti-USP28 antibody. Examples are shown in
Figure 5.23. (SMPR65 in C2 cells), Figure 5.24. (SMPR65 in Hela cell line) and
Figure 5.25. (SMPR65r in Rat2 cell line). No USP28 was seen in the elutions from
the purifications of the different tags, suggesting the PP2A complexes formed with
tagged PR65 did not contain USP28. This could be because tagged PR65 did not
undergo post-translational modifications that are required to enable USP28 to
interact, or the tag has caused a slight conformational change to the area of PR65
which USP28 associates.
Figure 5.23. Western Blot of purified Strep III-myc-PR65 in C2.
Strep III- myc-PR65 (SMPR65) was purified from cell lysates using the StrepTactin
column following the protocol in One-STrEP kit manual. The elution containing the
highest amount of tag was separated by SDS-PAGE and western blotted with anti-
USP28 antibody (upper panel) and anti-PR65 antibody (lower panel).
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Figure 5.24. Western Blot of purified Strep III-myc-PR65 in Hela.
Strep III- myc-PR65 (SMPR65) was purified from cell lysates using the StrepTactin
column following the protocol in One-STrEP kit manual. The elution containing the
highest amount of tag was separated by SDS-PAGE and western blotted with anti-
USP28 antibody (upper panel) and anti-PR65 antibody (lower panel).
Figure 5.25. Western Blot of purified Strep III-myc-PR65rat in Rat2.
Strep III- myc-PR65 (SMPR65) was purified from cell lysates using the StrepTactin
column following the protocol in One-STrEP kit manual. The elution containing the
highest amount of tag was separated by SDS-PAGE and western blotted with anti-
USP28 antibody (upper panel) and anti-PR65 antibody (lower panel).
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5.3 Associated proteins of tagged PR65
To identify proteins in complex with tagged PR65, tandem purification was
performed on the cell lysate and the eluted complexes separated by SDS-PAGE and
stained with Coomassie blue or silver. Figure 5.26 shows SMPR65 in C2 cells
purified using the StrepTactin column and the tandem approach. The bands expected
to be the PR65 tag, PP2Ac, B subunits and MT are highlighted. Other proteins can be
excised from the gels and sent for MS identification. Unfortunately, there was not
enough time to complete this part of the project.
Figure 5.26. Silver stained gels showing purification of Strep III- myc- PR65 in
C2 cells.
Strep III- myc- PR65 was constructed and transfected into C2 cells using a calcium
chloride method. Cells were lysed and the purifications carried out as described
below. Elutions were separated by SDS-PAGE and silver stained.
1-Purification  of  20  ml  wild  type  C2  lysate  on  1  ml StrepTactin column. Proteins
eluted in 30 µl laemmli sample buffer. All elution loaded on a gel.
2-Purification of 20 ml transfected C2 lysate on 1 ml StrepTactin column. Proteins
eluted in 30 µl laemmli sample buffer. All elution loaded on a gel.
3-Amino-linked anti-c-myc, 9E10, antibody.
4-Purification  of  20  ml  wild  type  C2  lysate  on  1  ml StrepTactin column. Proteins
eluted in biotin and IP performed with amino-linked 9E10. Proteins eluted in 30 µL
laemmli sample buffer. All elution loaded on a gel.
5-Purification of 20 ml transfected C2 lysate on 1 ml StrepTactin column. Proteins
eluted in biotin and IP performed with amino-linked 9E10. Proteins eluted in 30 µL
laemmli sample buffer. All elution loaded on a gel.
M= Marker,  LC= Light chain
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5.4 Tagged USP28
To further investigate USP28 interactions, a Strep- tag III USP28 mouse sequence
was constructed and transfected as described in the materials and methods section,
into Rat2 and also NIH 3T3 cells, as this would ensure normal associations to occur
with the tag that might require species specific interactions. The Strep- tag III system
was chosen as the affinity tag for similar reasons to those described before. These
established cell lines were initially characterised to assess if the phenotype of the cell
had been altered by addition of the tagged sequence. Figure 5.27. shows that the
transfected cells grow less dense compared with the parental cells. Figure 5.28 shows
how much tag protein is produced compared with the endogenous protein. Both Rat2
(Figure 5.28a) and NIH 3T3 (Figure 5.28b) express quite low levels of tagged USP28.
These were selected for when establishing the stable tagged cell lines, because the
cells with more Strep III-USP28 expressed grew extremely poorly.
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Figure  5.27.  Phenotype  of  cell  lines  transfected  with Strep- tag III- USP28
compared to parental cells.
The constructed Strep- tag III- USP28 mouse was transfected into different cell lines
and the appearance of the cells visualised using an inverted Microscope.
Transfections carried out in:
a) Rat2 cells
b) NIH 3T3
Figure 5.28. Western blot analysis of lysate from Strep- tag III- USP28 cell lines
Total cell lysate from the transfected cell lines were separated by SDS-PAGE and
immunoblotted with anti-USP28 antibody
a) Strep III-USP28 in Rat2 cells
b) Strep III-USP28 in NIH 3T3
200μm
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To identify proteins associated with Strep-tag III USP28, the purified tag complex
was separated by SDS-PAGE and western blotted with different antibodies. An-anti-
53BP1 antibody was purchased, because USP28 is known to bind to this check point
mediator [226]. Unfortunately, this antibody failed to recognise its endogenous
protein in cell lysate, hence can not be seen associated with tagged USP28 (data not
shown). The purified tag was also immunoblotted with anti-PR65 (middle panels)
and anti-PP2Ac (lower panels) antibodies in Figure 5.29. (Rat2 cells) and Figure 5.30.
(NIH 3T3 cells). As a control, the blot was also incubated with anti-USP28 antibody
to show the presence of purified tag (Figure 5.29. and 5.30. upper panels). PP2A was
not present in the eluates, suggesting PP2A did not form a complex with Strep-tag III
USP28 at a detectable amount; hence this tag can not be used to study the PP2A-
USP28 complex.
Strep-tag III USP28 can be used to further confirm that the anti-PR65 antibodies do
not directly bind to native USP28. IP experiments were performed with purified
StrepIII-USP28 complex, using C5.3D10 and an anti-USP28 antibody (Figure 5.31.).
The eluates were separated by SDS-PAGE and immunoblotted with an anti-USP28
antibody (upper panel) and an anti-PR65 antibody (lower panel). Rat2 total cell
lysate is included as a marker (lane1) and Strep-tag III USP28 elution is shown in
lane 2 as the input of the IP. USP28 is only precipitated with anti-USP28 antibody
(lane4) and not C5.3D10 (lane 3), illustrating C5.3D10 does not precipitate Strep-tag
III USP28 directly.
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Figure 5.29. Western Blot of purified Strep-tag III USP28 in Rat2 cells.
Strep-tag III USP28 was purified from cell lysates using the StrepTactin column
following the protocol in One-STrEP kit manual. The elution was separated by SDS-
PAGE and western blotted with anti-USP28 antibody (upper panel), anti-PR65
antibody (middle panel) and anti-PP2Ac antibody (lower panel).
Figure 5.30. Western Blot of purified Strep-tag III USP28 in NIH 3T3 cells.
Strep III- USP28 was purified from cell lysates using the StrepTactin column
following the protocol in One-STrEP kit manual. The elution was separated by SDS-
PAGE and western blotted with anti-USP28 antibody (upper panel), anti-PR65
antibody (middle panel) and anti-PP2Ac antibody (lower panel).
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6.5
Figure 5.31. Immunoprecipitation experiments using purified Strep-tag III
USP28.
Strep III- USP28 was purified from cell lysates using the StrepTactin column
following the protocol in One-STrEP kit manual. IP experiments were performed on
the elutions (lane 2) using C5.3D10 (lane 3) and anti-USP28 antibody (lane 4). Rat2
lysate is included as a size marker (lane1).
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5.5 Knockdown of USP28
To examine the effect the interaction of USP28 has on the proteome and in particular
PP2A, a cell line that has the USP28 gene knocked down was generated. This has
was achieved by RNA interference (RNAi). RNAi is a conserved response present in
many eukaryotes, it involves short interfering RNAs (siRNAs), about 22 nucleotides
in length, being incorporated into a silencing complex called RISC (RNA-induced
silencing complex). The RISC complex identifies mRNA substrates due to their
homology  with  siRNA,  and  targets  them  for  destruction.  ShRNA  is  a  sequence  of
RNA that  makes  a  tight  hairpin  turn,  which  is  recognised  by  the  RNAi  machinery
and cleaved into siRNA [234]. ShRNA expression vectors, of a lentiviral origin,
utilise the U6 RNA polymerase III promoter in mammalian cells to ensure shRNA is
always expressed. Transfection of shRNA into cells is advantageous to siRNA
because the vector can be inherited to daughter cells, creating a stable cell line.
USP28 levels were knocked down in Rat2 fibroblasts by lentivirus-mediated delivery
of shRNA. Cells were transfected with 5 different clones that target different regions
of USP28. Puromycin was added to select for cells with the incorporated DNA and
USP28 levels were determined by western blot. Clone 4 with a hairpin sequence of
CCGGGCTCTGTTGTTGGGATCAAATCTCGAGATTTGATCCCAACAACAGA
GCTTTTG, was the most effective in silencing USP28 expression. This is shown in
the western blot in Figure 5.32. of total cell lysate from the shRNA cell line
compared to the parental cell lysate, using anti-USP28 antibody (upper panel,) and
anti-β tubulin antibody (lower panel), to verify comparable protein loading. The cells
that had the lowest levels of USP28 were cloned twice to ensure stability of the line.
A stable cell line with the complete knock down of USP28 expression has been
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successfully generated, which is a useful tool for examining the effect of USP28 in
vitro.
Figure 5.32. Western blot analysis of USP28 knockdown cell line compared with
parental cells.
Stable cell line generated by transfection of shRNA clone with ID number
TRCN0000030867 (from Open Biosystems). Cells were grown in the presence of
puromycin to select for the transfected cells. Total cell lysate was separated by SDS-
PAGE and immunoblotted with anti-USP28 antibody (upper panel) and anti- β
tubulin antibody (lower panel).
Lane 1 = wild type cell lysate
Lane 2 = shRNA USP28 cell lysate
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5.6 Ubiquitin Studies of PP2A
The functional impact of USP28 knockdown was first assessed by measurement of
total cellular levels of ubiquitinated proteins and expression of PP2A subunits. Cell
lysates of shRNA USP28 or wild type cell lines were immunoblotted, using either
anti-ubiquitin, anti-PR65 or anti-PP2Ac antibodies. Both cell lines were also treated
with MG132, a potent membrane-permeable proteasome inhibitor, for 3 hours, prior
to lysis. Blocking proteasome activity, leads to accumulation of polyubiquitinated
proteins (reviewed in [235]). This is confirmed in the western blot in Figure 5.33.
when probed with an anti-ubiquitin antibody. There was a considerable increase in
the total level of ubiquitinated proteins detected when cells were treated with MG132
(Figure 5.33.a lanes 2, 4), compared with untreated cells (Figure 5.33.a lanes 1, 3).
Interestingly, there appears to be slightly higher levels of ubiquitinated proteins in
the shRNA USP28 cell line (Figure 5.33.a lane 3, 4) compared to the parental cell
line (Figure 5.33.a lane 1, 2), suggesting that this may represent the fraction of
proteins that would have their ubiquitin status modulated by USP28 activity. USP28
knockdown, however, had no affect on total cellular levels of PR65 (Figure 5.33.b)
or PP2Ac (Figure 5.33.c) antibodies. In addition, there was no increase in total
cellular  levels  of  PR65  (Figure  5.33.b)  or  PP2Ac  (5.33.c)  when  cells  were  treated
with MG132, suggesting that these proteins may not be rapidly targeted for
proteasome-mediated degradation.
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a)                                                b)                                          c)
Figure 5.33. Western Blot analysis of Rat2 cells and USP28 silenced Rat2 cells
with and without treatment of the proteasomal inhibitor, MG132.
Total cell lysate was separated by SDS-PAGE and immunoblotted with anti-
Ubiquitin antibody (a), anti-PR65 antibody (b) and anti-PP2Ac antibody (c).
Cell lysate used:
1= Rat2
2= Rat2 cells pre-treated with MG132 for 3 hours
3= shRNA USP28 in Rat2
4= shRNA USP28 pre-treated with MG132 for 3 hours
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To determine whether the ubiquitin status of PP2AD-associated protein complexes
are altered as a result of silencing USP28 expression, immunoprecipitation
experiments were carried out on shRNA USP28 and the parental Rat2 cell lysates,
using anti-PR65 mAb C5.3D10. Both cell lines were also pre-treated with MG132
for 3 hours prior to lysis. The precipitated complexes were initially immuno-blotted
with anti-ubiquitin antibody (Figure 5.34.a), and this revealed two distinct changes in
PR65-associated ubiquitin protein/s. Firstly, a band that is detected at an approximate
molecular weight of 44 kDa (highlighted with an asterisk in Figure 5.35a) in the IPs
performed on Rat2 lysate that is not present in the IPs performed on the USP28
knockdown cell lysate, regardless of MG132 treatment. In addition, there are several
ubiquitin-immuno-reactive  species  with  a  higher  molecular  weight  in  the  IPs
performed on the knockdown cell lysate that are not present in the Rat2 IPs (Figure
5.23.a). This data suggest that removing USP28 from this cell line, changes the
ubiquitin status of the precipitated PP2AD complex/es. However, little or no change
is observed between precipitations in lysates when the cells have been pre-treated
with MG132, despite prior experiments (Figure 5.33.a) that suggest 3 hour treatment
is sufficient to block the proteasome due to the dramatic increase in levels of total
ubiquitination of cellular proteins. The precipitated proteins were then immuno-
blotted with anti-PP2Ac antibody (Figure 5.34b). Interestingly, this blots shows the
band observed in the anti-ubiquitin blot in the Rat2 IPs has a slightly larger
molecular weight than PP2Ac, that may represent a ubiquitin modified PP2Ac. In
addition,  the  total  amount  of  PP2Ac  precipitated  appears  to  decrease  in  the  IPs
performed on the USP28 knockdown cell lysate. This suggests that USP28
knockdown inhibits some of the interaction of this form of PP2Ac with PR65, or
more PP2Ac is getting degraded.
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Figure 5.34. Immunoprecipitation of Rat2 and USP28 silenced Rat2 cells with
and without treatment of MG132.
Immunoprecipitation experiments were performed on lysates from Rat2 and shRNA
USP28 stably expressed in Rat2, with and without the treatment of MG132 for 3
hours. The anti-PR65 antibody C5.3D10 was used for the IP. The elutions were
separated by SDS-PAGE and immunoblotted with anti-ubiquitin (a) and anti-PP2Ac
(b) antibodies.
HC= heavy chain    LC= light chain
* = band only present in wild type Rat2 cells
(Ubq)n = polyubiquitination only present in USP28 knockdown cell lines
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5.7 Effect of the Viral T-antigens on ubiquitination of PP2A
To determine whether expression of the viral T-antigens has an effect on the
Ubiquitin status of cellular proteins, and in particular PP2AD, Western blot analysis
was  performed  on  Rat2  and  C2  (Rat2  cells  stably  expressing  Polyoma  middle  T
antigen) total cell lysates using an anti-Ubiquitin antibody (Figure 5.35.). No
difference in the Ubiquitin status of total cellular proteins was observed between
these two lysates. Immunoprecipitation experiments were then performed on Rat2
and C2 cell lysates, using an anti-PR65 antibody C5.3D10, which co-precipitates
USP28 with PP2AD (Figure 4.9.), and an anti-PR65 antibody R5.8A4, which does
not co-precipitate USP28 (Figure 4.9.). The precipitated complexes were immuno-
blotted with anti-USP28 (Figure 5.36.a), anti-PR65 (Figure 5.36.b), anti-PP2Ac
(Figure 5.36.c) and anti-ubiquitin (Figure 5.36.d) antibodies. C5.3D10 precipitated
equal levels of USP28, PR65 and PP2Ac, and R5.8A4 precipitated equal levels of
PR65 and PP2Ac, irrespective of whether MT was present or not (Figure 5.36.a-c).
This suggested that MT did not have any effect on the composition of the PP2A
complexes precipitated by these two antibodies. However, the anti-ubiquitin
immuno-blot of C5.3D10 immunoprecipitates exhibits an upregulation of a band at
an approximate molecular weight of 50kDa (highlighted with an asterisk) when MT
is expressed (Figure 5.36.d). No immuno-reactive bands were present in the anti-
ubiquitin immuno-blot following immunoprecipitation with R5.8A4. Similar
observations were found in PP2AD complexes when polyoma small T-antigen (PyST)
expression was induced by the addition of doxycycline (Figure 5.37.). There is no
difference in the amount of USP28, PR65 and PP2Ac precipitated (Figure 5.37.a-c),
but an up-regulation of a band at approximate molecular weight of 50kDa
(highlighted with an asterisk) was observed when PyST is induced in the C5.3D10
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anti-ubiquitin immuno-blot (Figure 5.37.d). These experiments suggested that the
viral  antigens  alter  the  levels  or  identity  of  a  protein,  or  proteins,  in  a  PP2AD
complex that co-precipitates with USP28.
Figure  5.35.  Levels  of  total  ubiquitinated  proteins  in  Rat2  and  C2  (middle  T
expressing) total cell lysate.
Total cell lysate was separated by SDS-PAGE and immunoblotted with an anti-
Ubiquitin antibody
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Figure 5.36. Immunoprecipitation of PP2A complexes from Rat2 and C2
(middle T expressing) cell lysates.
Immunoprecipitation experiments were performed on Rat2 (R) and C2 (C) cells
using the anti-PR65 antibodies C5.3D10 and R5.8A4. The elutions were separated by
SDS-PAGE and immuno-blotted with anti-USP28 (a), anti-PR65 (b), anti-PP2Ac (c)
and anti-Ubiquitin (d) antibodies.
LC= light chain, HC= heavy chain, * = band only present in C2
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Figure 5.37. Immunoprecipitation of PP2A from Polyoma ST inducible cell line
lysates.
Immunoprecipitation experiments were performed on Rat fibroblast with (+) and
without (-) the addition of Doxycycline to express (+) Polyoma ST antigen, using the
anti-PR65 antibodies C5.3D10 and R5.8A4. The elutions were separated by SDS-
PAGE and immuno-blotted with anti-USP28 (a), anti-PR65 (b), anti-PP2Ac (c) and
anti-Ubiquitin (d) antibodies.
LC= light chain,  * = band only present in C2
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5.8 Discussion
USP28 co-precipitated with PP2AD using three of my monoclonal antibodies;
C5.1G7, C5.3D10 and C5.12B12. Research into this fairly unknown protein revealed
it to be a deubiquitinating enzyme, having an important regulatory role in the
dynamic ubiquitination process. USP28 and PP2A have not previously been
identified in a complex. However, they both have common interacting proteins such
as Claspin and c-myc. Also, some USPs already have roles in signal cascades, for
example USP45 binds to phosphorylated TGF-β receptor [236]. Consequently, it was
feasible that there was a physiological relevance to this association, and validation of
the co-precipitation was required.
To confirm the association of these two proteins, IP experiments were performed
with anti-PR65 antibodies. This showed that only 3 of the antibodies precipitated
USP28 (Figure 4.9.) and western blotting with these antibodies demonstrated that
they did not recognise any proteins around the size of USP28 (Figures 5.1. and 5.2.).
When IP experiments were performed in different denatured conditions, USP28 was
no longer precipitated, probably because the PP2A-USP28 complex has become
disrupted (Figure 5.5. and 5.7.). These results lead to the conclusion that the
antibodies did not directly recognise denatured USP28. Although there was a small
homologous region between the sequences of PR65 and USP28 (Figure 5.3. and 5.4.),
this would not be enough to display the strong detection occurring in the IP
experiments.
To confirm the interaction by another approach, immunoprecipitation experiments
were performed using an anti-USP28 antibody (Figure 5.7.). However, no PP2AD
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was detected in this precipitate. This could be due to the antibody’s epitope being
masked by PP2A when it is in complex with USP28, therefore the anti-USP28
antibody would only precipitate other USP28 complexes not involving PP2A. Also,
in vitro translation binding studies in Figures 5.10. and 5.11. showed that translated
mouse PR65 and USP28 did not interact. This could be due to post-translational
modifications not occurring, probably on PR65, which allows the proteins to
complex. In addition, as PP2Ac is also co-precipitating with PR65 and USP28, IP
experiments were performed using a number of anti-PP2Ac antibodies that
recognised different areas of the PP2Ac sequence. This would determine whether
anti-PP2Ac antibodies could precipitate the PP2A-USP28 complex. No USP28 was
detected in the western blot of the IP eluates (Figure 5.8.). This is not surprising
when the amount of precipitated PP2Ac and PR65 is observed. Only two clones are
able  to  precipitate  PP2Ac  and  PR65,  the  latter  being  very  weak.  These  results
suggested that none of the PP2Ac antibodies precipitated the PP2A-USP28 complex
in a detectable amount.
In a complementary approach to the use of monoclonal antibodies in studying PP2A
complex composition, a novel TAP tagged PR65 was constructed and used to study a
wider  range  of  PP2A  complexes.  The  constructed  tag  consisted  of  a Strep-tag III
linked to the c-myc epitope and fused to the N-terminus of PR65 human sequence
(Figure 5.13.). Purification of this tag from cell lysate was accomplished initially on
StrepTactin, a specifically adapted form of streptavidin that has an increased peptide-
binding capacity. Elution of the native tagged proteins is achieved by addition of
biotin to the column. This eluate can be used in western blot analysis to identify
complex components or can be used in an IP experiment with amino-linked anti-c-
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myc antibody, as the second purification step. The tandemly purified complex can
then be separated by SDS-PAGE and visualised by western blot analysis, and
Coomassie blue and silver staining. The constructed Strep III- myc PR65 human
(SMPR65) tag has been transfected into Rat2 fibroblasts, the middle T expressing rat
fibroblast (C2 cells), Hela cells and an inducible rat fibroblast cell line, in which the
expression of polyoma ST can be switched on and off by the addition of Doxycycline.
A tag was also constructed in which the Rat sequence of PR65 fused to the Strep III-
myc tag (SMPR65r) was transfected into Rat 2 fibroblasts. The cell lines expressing
the tag were characterised and revealed to be located in the nucleus (Figure 5.16.).
Western blot analysis on the tagged lysate revealed that more tag is expressed when
the viral antigens are also expressed (Figure 5.15.), which is probably due to the T-
antigens up-regulating the CMV promoter on the pEXPR-IBA105 vector.
Purification of the Strep-tag III protein using the StrepTactin column was shown to
be  very  efficient  (Figure  5.17.)  and  the  elution  was  used  to  prove  that  the  tag
becomes incorporated into a PP2A holoenzyme complex, and a complex with the T-
antigens when they are expressed (Figure 5.18.-5.22.). Interestingly, the tags
associated with both the B subunits and MT and ST, which goes against the general
theory that the B subunits get out competed by the viral antigens.
To identify proteins in complex with tagged PR65, tandem purification can be
performed on the cell lysate and the eluted complexes separated by SDS-PAGE and
stained with Coomassie blue or silver. Proteins of interest can be excised and
identified by MS approaches. An example of the tag used in this application is shown
in Figure 5.26., in which SMPR65 in C2 cells has been purified using the StrepTactin
column and the tandem approach. This demonstrates how the constructed tag can be
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used in the future. Unfortunately, tagged PR65 could not be used to examine the
USP28-PP2A complex, because USP28 was not associated with any of the PR65 tags
(Figures 5.23.-5.25.). This could be due to the tag causing a slight change in PR65
conformation around the area of USP28 association.
To further examine USP28 complexes, Strep-tag III USP28 was constructed and
transfected into Rat2 and NIH 3T3 cells. The purified tag was analysed by western
blotting with anti-PR65 and anti-PP2Ac antibodies to look for an association of
PP2AD. PP2A could not be detected in purifications of tagged USP28 in Rat2 (Figure
5.29.) and NIH 3T3 (Figure 5.30.), suggesting that PP2A may not be associated with
Strep-tag III USP28 at a detectable amount. This eluted USP28 complex was used to
corroborate that the anti-PR65 antibodies did not directly recognising USP28. IPs
were performed with C5.3D10 on purified Strep-tag III USP28. C5.3D10 did not
precipitate Strep-tag III USP28, suggesting that the PR65 antibodies did not directly
interact with native USP28.
To examine the functional implications that the association of USP28 has on the
PP2AD complex, a Rat2 cell line was created using shRNA of USP28, to successfully
knock down USP28 cellular levels. This cell line was then used to observe possible
ubiquitination modifications of PP2AD complexes. The loss of USP28 had no affect
on the cellular levels of PR65 and PP2Ac levels, even when pre-treated with the
proteasome blocker, MG132 (Figure 5.33.). This was surprising as Trockenbacher et
al. [70] showed that the addition of a proteasome inhibitor to cells lead to an increase
in polyubiquitinated proteins, which is displayed by a smear higher up the western-
blots. A reason why the polyubiquitination of PP2Ac could not be detected here, may
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be due to the anti-PP2Ac antibodies not recognising this form. However, the total
levels of ubiquitinated proteins in the cell did slightly increase when USP28 is
knocked down, observed even under conditions when the proteasome is blocked.
This is perhaps expected as USP28 is a DUB, therefore it suggests that USP28
modulates the Ubiquitin status of a subset of cellular proteins in the Rat2 cell line.
In order to asses if USP28 plays a role in regulating ubiquitination of PR65-
complexes, PR65 immuno-precipitates were probed with anti-ubiquitin antibody.
Interestingly, changes in Ubiquitin levels of the PP2AD complex is observed in the
shRNA USP28 cells (Figure 5.34). One anti-ubiquitin and anti-PP2Ac immuno-
reactive species were lost upon USP28 knockdown. These bands were the same
molecular weight, suggesting it may represent an ubiquitinated form of PP2Ac in the
PP2A complex, which directly requires USP28 and not another DUB to modulate the
Ubiquitin status and consequently association of this protein in the PP2A complex.
USP28 knockdown also resulted in an increase in ubiquitin immuno-reactive bands
in the PR65 complex that may either represent polyubiquitinated forms of PP2A
subunits or, as yet unidentified proteins that accumulate in the absence of this DUB.
The viral T-Antigens are known to interact with, and modulate the activity of PP2A
[161, 162], therefore, the effects the T-antigens have on this novel PP2A-USP28
complex were then observed. Although the T-antigens did not effect the composition
of the PP2AD complex precipitated with any of the produced anti-PR65 antibodies,
these viral proteins did appear to affect the ubiquitin status of a PP2AD complex that
is associated with USP28 (Figure 5.35. and 5.36). An up-regulation in ubiquitin
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status of one of the proteins in the complex was observed when Polyoma ST and MT
were expressed. The biological significance of this will be discussed in Chapter 6.
In summary, USP28 has been identified as a novel interacting protein of PP2A that
may play a role in altering the ubiquitin levels of specific PR65α-associated subunits
or novel interacting proteins. Furthermore, useful tools have been established to
further investigate the cellular role of USP28. In addition, a novel tagged PR65
protein has been constructed which can be used to examine PP2A holoenzyme
complexes with and without expression of the T-antigens.
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CHAPTER 6: GENERAL DISCUSSION
Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase in
eukaryotic cells, that has been implicated in the regulation of many cellular processes
including metabolism, transcription and translation, DNA replication, cell-cycle
progression, cell growth, and apoptosis. The identification of PP2A as a critical
regulator of many cell signalling pathways has focused a great deal of attention on
understanding its activity. However, recent work has also shown that PP2A itself is
highly regulated, through observations that the active phosphatase can associate with
different regulatory or targeting proteins [4, 65], and also by post translational
modifications such as phosphorylation [73] and methylation [75]. Despite this, we
still understand little of how it is regulated, which sites it dephosphorylates in vivo,
and how viral proteins influence this activity. Furthermore, deregulation of PP2A is
implicated in; Alzheimer’s disease [213], increased susceptibility to pathogen
infection (in particular viral), and different types of cancers [200], with many
observations suggesting that PP2A acts as a tumour suppressor. For example, several
PP2A inhibitors are tumour promoters [199, 201]; PP2A is required for the full
transforming activity of viral proteins ST and MT, by forming a complex with
PP2AD without any regulatory B subunits [173]; and mutations in the genes
expressing PP2A subunits have been identified in numerous human cancers [202]. In
addition, PP2A activity and expression are decreased in drug-resistant breast cancer
cells [237]. These findings highlight the importance of dissecting PP2A functions
and how this is altered by interacting partners, to identify therapeutic targets for anti-
cancer drug intervention. Therefore, the aim of this project has been to identify novel
PP2A interacting proteins and examine their role on PP2A function, in particular its
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regulation. This has been achieved by generating a series of monoclonal antibodies
directed towards the structural subunit and two of the regulatory subunits of PP2A.
These antibodies have been characterised and used in immunoprecipitation
experiments and proteomics approaches to identify dynamic complexes that could
regulate PP2A. In a complementary approach, a TAP tagged PR65 was constructed
and used to identify proteins interacting with this structural subunit with and without
the expression of the viral T-antigens.
Monoclonal antibodies are useful tools for isolating antigens specifically, so it was
decided that producing our own mAbs would be advantageous as it would potentially
provide an unlimited supply of antibodies that would precipitate novel complexes
and  be  more  sensitive  than  the  commercially  available  antibodies.  This  was  a
challenging approach but was successful in the production of over a hundred
antibodies, of which 18 displayed a strong positive reaction against the fusion
proteins. At the beginning of this study, there were no commercial anti-B’ antibodies
available, which could successfully recognise its antigen and identify complexes in
cell lysate. This was a major driving force behind the aim of producing antibodies
towards these specific subunits. However, although the produced anti-B’ mAbs
reacted with their fusion protein in western blot experiments they did not recognise
the endogenous protein in total cell lysate, hence they were difficult to characterise.
This  may  be  due  to  a  lower  expression  of  each  of  the  B’  isoforms  in  cell  types
studied, but also the antibodies generated had difficult isotypes that may not have
had a strong affinity for their native antigen. This part of the project was not
continued.
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The antibodies produced against PR65α were successful in the fact that at least half
of them displayed a stronger specificity towards PR65 than the two widely used
commercial PP2A-Aα, antibodies, 6G3 and 6F9. As PR65 is well conserved between
species [238], it is not surprising that clones C5.1G7, C5.3D10, C5.3F8, C5.7A1,
C5.7F2, C5.12B12, G3.5F9, G3.8F11, R5.1A7, R5.8A4, R5.8F8 and R2.7E9 can be
used as tools to identify PR65 in human cells, the species the antibodies were raised
towards,  as  well  as  in  mouse,  rat,  hamster,  chicken  and  rabbit  cells.  C5.9E10
however, did not react with rabbit and chicken PR65, probably because the epitope
for this antibody is located in an area of sequence that is not so well conserved and
not present on these two sequences. The majority of the mAb clones precipitated
PP2Ac with PR65 but not with any of the B subunits. This suggested that these
antibodies recognised the PP2A core dimer (PP2AD) in the cells, the existence of
which was uncertain for a number of years. Therefore, this set of antibodies further
confirmed the presence of PP2AD and can be used to isolate it from cells.
Interestingly, clone R2.7E9 precipitated only its antigen and not PP2Ac or any B
subunits, and this raised the question whether free PR65 also exists in cells, or if it is
a result of complex breakdown during lysis and isolation. The data presented here
suggests that free PR65 is present in the cells for a few reasons. Firstly, the IP
experiments were performed under mild conditions to avoid proteolysis degradation
of  complexes;  the  protocol  was  performed at  4°C,  for  a  short  time (~2  hours)  and
effective protease inhibitors were used. This reduces the chance of any complexes
breaking down during lysis and isolation. Secondly, R2.7E9 recognised more PR65
in denatured lysate suggesting the epitope was not accessible when PR65 is present
in a complex form. The epitope for R2.7E9 was mapped to HEAT motif 11, the area
to which PP2Ac is known to associate, so it is suspected that this subunit masked the
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epitope. Thirdly, in the IP experiments using C5.1G7, C5.3D10, C5.9E10, C5.7F2,
C5.12B12, G3.5F9, G3.8F11, R5.1A7, R5.8A4 and R5.8F8 more PR65 is
precipitated  than  PP2Ac.  This  suggested  the  other  mAbs  also  recognise  free  PR65
because if only PP2AD was being precipitated, PR65 and PP2Ac would be present in
equal amounts in the elutions. One factor that has to be considered, is that the
presence of PP2AD and free PR65 could be due to break down of the complex during
the IP, potentially by the mAb competing for binding to PR65 with the other subunits,
especially if the antibody was present in excess amounts. However, when the amount
of lysate was increased compared to antibody amount, the results remained the same.
This argument along with the above points, suggests that PP2AD and free PR65 are
present  in  the  cells  and  therefore,  R2.7E9  can  be  used  to  isolate  PR65  complexes
occurring without the other PP2A subunits. As free PR65 has not been shown to exist
before, this raises the question as to the activity and biological role this could have.
Recruitable pools of the other subunits could exist, in particular B subunits. If this is
true, the binding of T-antigens to PP2AD could occur without displacement of B
subunits. This is not in full accordance with the generally accepted view of B subunit
displacement [173], because the T-antigen and B-subunit epitopes occur on non-
overlapping sites within the same region [28]. Recruitable pools of B subunits could
be up-regulated or down-regulated when required by specific cellular processes, and
these could target PP2A to the subcellular location to carry out its function. The
results  from  the  epitope  mapping  experiments  and  the  results  from  the  IP  western
experiments are consistent with the model of PP2A subunit composition (Figure 1.7.).
The B subunits and T-antigens associate with PR65 in the N-terminal half, the area
where the majority of the mAb epitopes are located, hence, a reason why none of the
mAbs precipitated the B-subunits and T-antigens with PP2AD. PP2Ac associates
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with PR65 in the C-terminal half, the area where R2.7E9s epitope is located; hence
this clone did not precipitate PP2Ac. Furthermore, the majority of the antibodies
performed well in immunofluorescence experiments. This along with the their ability
to perform well in western blots and immunoprecipitation experiments concludes
that the production of mAbs towards PR65 has been successful, and that the mAbs
can be used as tools to examine PR65 containing complexes in a wide range of
experiments.
With the PP2A subunit composition analysed in the immunoprecipitated complexes,
associated proteins were then examined by performing IP and MS experiments.
These results showed that the different antibodies precipitated different PP2A
complexes. Proteins were identified from IPs using different antibodies at molecular
weights: 130 kDa, 70 kDa, 50 kDa, 80 kDa, 40 kDa and 250 kDa as USP28, Hsp72,
tEF1α, Hsp90, GAPDH and Filamin, respectively. Unfortunately, the precipitation of
Hsp72, tEF1α, Hsp90, GAPDH and Filamin in IP western experiments were not
confirmed due to concerns that these interactions were non-specific. Hence, no
further experiments were performed. However, one can not rule out that some of
these proteins do form complexes with PP2A. For example, heat shock proteins and
protein phosphatases have been implicated together in platelet adhesion [239] and
Hsp90 does inhibit PP2A-mediated dephosphorylation of Akt [240], although a
direct interaction has not been confirmed. As already discussed, the IP experiments
were performed under mild conditions to avoid proteolysis degradation of complexes.
This does not reduce any non-specific interactions occurring through direct
interaction  with  the  matrix.  Increasing  the  concentration  of  detergents  in  the  wash
buffer could destroy non-covalent interactions but other true interacting proteins may
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have been lost. This highlights the first problem with using solely monoclonal
antibodies for the identification of associated proteins, especially when the target is a
phosphatase such as PP2A, which interacts with many proteins to generate a range of
holoenzymes with different specificities. This makes it difficult to distinguish
between specific, low abundance interacting proteins and low affinity, abundant,
contaminating proteins that are recovered non-specifically in immunoprecipitation
procedures. Therefore, it is important to perform these IP experiments in mild
conditions, and all identified interactions must be verified by additional complex
purification experiments.
In a complementary approach to the use of monoclonal antibodies, a novel TAP
tagged PR65 was constructed to purify PP2A complexes from Rat2 and Hela cells.
This tag consists of a Strep III tag linked to the c-myc epitope and fused to the N-
terminus of PR65, Strep III-myc–PR65 (SMPR65). SMPR65 was also expressed in
Rat cells that stably expressed MT or inducibly expressed polyoma ST. Therefore,
this tandem affinity purification system can be used to look at changes in PP2A
composition when the T-antigens are expressed. Tagged PR65 associated with
PP2Ac, and the B subunits and T-antigens, when they are expressed. No obvious
disruption in B subunit binding to the tag was detected when the T-antigens are
expressed. This was unexpected as the B subunits are thought to be outcompeted
from PP2AD by the T-antigens. These results potentially contradict this theory and
further highlight how it is probable that recruitable pools of B subunits exist within
cells, which can associate with PP2AD when required. This was described earlier in
this chapter. To identify proteins in complex with SMPR65, tandem purification has
been performed on cell lysates containing the tagged protein. Proteins of interest can
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be identified by MS. However, due to time constraints this has not been completed.
The purified tagged complexes appear to perform better than existing reported PR65
tags as there are less background bands, and because of this the eluted complexes
could also be subjected to non-gel based MS procedures. This would not only
identify the proteins present but could also be used to detect the phosphorylation
status of these proteins. This would be particularly useful to look at changes in PP2A
activity when the T-antigens are expressed.
IP western experiments confirmed that 3 of the mAbs, C5.1G7, C5.3D10 and
C5.12B12, precipitated Ubiquitin Specific Protease 28 (USP28) with PR65. USP28
is a deubiquitinating enzyme (DUB) that has an important regulatory role in the
dynamic ubiquitination process [225-227], and thus are integral components of a
number of fundamental cellular programs such as the core cell cycle machinery and
cell cycle checkpoints [241]. IP experiments performed in different denaturing
conditions indicated that the mAbs did not directly recognise denatured USP28. In
addition, alignment of PR65 and USP28 sequences showed only a very slight
homology which is unlikely to be sufficient to explain the large amount of USP28
that are precipitated in the native IP experiments. These experiments, therefore,
suggest that the presence of USP28 in the IP eluates was probably not due to any
unspecific interaction, but due to an association with PP2AD. Research into this fairly
recent  identified  DUB,  revealed  it  to  have  specific  roles  in  the  DNA  damage
response pathway, in part by associating with Claspin, and, in c-myc stabilisation.
Both of these proteins are known PP2A interactions, therefore, providing support for
a key biological role of a PP2A complex involving USP28.
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In an attempt to further elucidate the cellular role of USP28 in the PP2A complex, a
Rat  fibroblast  cell  line  was  created  in  which  the  USP28  gene  was  successfully
silenced. In these cells there was a slight increase in ubiquitinated proteins compared
to the parental cells, confirming that USP28 does act to remove ubiquitin from some
cellular  proteins.  However,  no  change  in  cellular  PR65  and  PP2Ac  levels  were
observed. Interestingly, a difference in Ubiquitin modification of a PP2AD complex
that co-precipitates with USP28 can be seen. It can be assumed that it is PP2Ac that
gets modified by the ubiquitination process because of the size of the band in the IP
corresponds closely to the size of PP2Ac in westerns, suggesting mono-
ubiquitination of PP2Ac. In addition, previous experiments performed by
Trockenbacher et al. [70] have already showed ubiquitination of PP2Ac. This
potential ubiquitinated PP2Ac form is observed in PR65 immunoprecipitates and not
in western blots of total cell lysates, which could be due to only a small amount of
total cellular PP2Ac being ubiquitinated that may be difficult to detect in whole cell
lysates. As blocking of the proteasome did not appear to affect the levels of the
putative ubiquitinated PP2Ac, or result in polyubiquitination of total PP2Ac, this
could suggests ubiquitin modification of the PP2A complex does not result in
targeting of this protein to the proteasome, but could lead to another outcome,
perhaps to an alteration in activity of PP2A. This would be in accordance with
experiments performed by Luo et al. [242] which showed that over-expression of
AtCHIP, an E3 Ubiquitin ligase, leads to an increase in PP2A activity, as a result of
an increase in ubiquitination, and this does not lead to degradation. Therefore, as this
Ubiquitin modification is only observed on complexes co-precipitated with USP28,
the role of PP2AD-USP28 interaction could represent a mechanism for tight
regulation of PP2A activity. Future work could entail looking at phosphatase activity
252
of the PP2AD-USP28 complex compared with other PP2AD complexes. In addition,
the phosphorylation status of any cellular proteins could be analysed, between the
knockdown and wild type cells, and whether these proteins are targets of PP2A.
Another way the addition of ubiquitin to PP2Ac could affect PP2A function, is to
enable association with other proteins, e.g. proteins containing the Ubiquitin-
interacting motif (UIM). UIM containing proteins are involved in functions such as
trafficking of membrane-associated proteins and their cargo from the plasma
membrane, or Golgi, for destruction in the lysosome or proteasome [243]. Generally,
monoubiquitination, and not polyubiquitination, is required to ‘mark’ proteins for
endocytosis and lysosomal trafficking [244, 245]. UIMs are required for trafficking
of receptor ligand complexes, for example the EGFR (epidermal growth factor
receptor) [246, 247]. PP2A has multiple roles down-stream of signal transduction
cascades as well as at the level of the receptor such as EGFR [109] suggesting that
the PP2AD-USP28 interaction may be important for receptor systems that are
regulated by both phosphorylation and ubiquitination. Of additional technical note,
these ubiquitin studies also help to explain why PR65 and USP28 were not observed
to interact in vitro, because the reticulocyte used in the translation kit does not
support post-translational modifications, for example ubiquitination, or contain
proteins, such as UIM proteins that may be required for complex assembly. Future
experiments that could be undertaken to explore the direct interaction of PP2AD-
USP28 in real time, in intact cells, might include resonance energy transfer methods
such as BRET [248] or FRET [249].
Interestingly, the PP2AD-USP28 complex appears to be modulated by expression of
the viral T-antigens. Although the exact composition of this complex is not altered,
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greater ubiquitination levels of a protein, expected to be PP2Ac, is observed when
PyST and MT are expressed. This could act to increase the activity of PP2A towards
specific substrates. For example, SV40 ST has been reported to increase the activity
of PP2A towards the androgen receptor [178, 179]. It is now becoming apparent that
‘hijacking’ of the Ubiquitin system by viruses, in particular DNA tumour viruses, is
important to enable their own replication [250]. SV40 LT has been shown to bind to
the SCFFbw7 ubiquitin ligase complex to inhibit degradation of cyclin E [251]. It has
also been suggested that LT may induce the ubiquitination of new substrates not
normally  targeted  by  the  SCF  complex.  Also,  SV40  has  been  implicated  in
manipulating the DNA damage response pathway to reprogram the cell for viral
DNA replication [252], as both USP28 and PP2A are involved in this process, and
the PP2AD-USP28 complex may be located in the nucleus (based on
immunofluorescence studies performed in chapter 5), suggests a possible mechanism
behind the alteration of the PP2AD-USP28 complex by the T-antigens.
In summary, different methods for studying PP2A have been produced. With these a
novel PP2AD-USP28 complex has been identified, which probably plays a key role
in regulating the activity of PP2A by ubiquitination. The ubiquitination status of this
complex appears to be affected by the expression of the T-antigens, although the
precise biological impact of this has not been elucidated. However, this data along
with the association of both USP28 and PP2A with the tumour promoter c-myc,
indicates that PP2AD-USP28 could represent an important interaction that may
provide a potential therapeutic target for anti-cancer therapies.
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a b s t r a c t
Polyoma virus and SV40 are the founding members of the Polyomaviridae. They are small viruses, with a
genome consisting of around 5.3 kbases of closed circular, double-stranded DNA. This simplicity, the ease
with which they can be grown, and their capacity to cause cancers in newborn rodents has made them
popular models for studying the molecular basis of cancer formation. As a consequence, many of the
underlying principles involved in tumorigenesis have been uncovered during the study of these viruses.
For instance, the discovery of p53, Rb protein function, tyrosine kinases and PI3 kinases were all made
when examining polyoma virus and SV40. Here we review how these discoveries were made, and the
inﬂuence they have had on our understanding of cancer development.
© 2009 Elsevier Ltd. All rights reserved.
1. Introduction
The genes and gene products responsible for initiating tumori-
genesis arenowunderstood indetail (especially thosemalignancies
where an infectious agent can be identiﬁed as an essential compo-
nent) and this is having a signiﬁcant impact on how these cancers
are treated. The early stages of gaining this knowledge relied heav-
ily on work using cancer causing viruses and animal models. Fifty
years ago,weknew little of oncogenes and tumour suppressors, and
the techniques used to study cancers in the laboratory were prim-
itive in comparison to today. The discovery of a number of viruses
with small DNA, or RNA, genomes that could induce tumours in
animals ﬁrst raised the possibility that deciphering at least one
tumour forming process might be feasible, and stimulated a great
deal of work. The ﬁndings made in these model systems were also
directly relevant to human cancer formation, so underpin much
of our understanding of tumorigenesis. It has taken time, but the
real beneﬁts of this work are now being seen in the clinic, with
rational drug design inﬂuencing many aspects of cancer treatment.
Two of the most signiﬁcant DNA viruses in this history, the mouse
polyoma virus and the simian virus 40, belong to the same family.
Work on these viruses has provided us with many of the impor-
tant paradigms in our understanding of normal and tumour cell
biology, which we review here. The number of papers published in
this ﬁeld is enormous and we cannot accommodate all of them. We
apologize to those who made contributions to the ﬁeld that are not
referenced. The early work (pre 1980) has been reviewed in detail
in [1], and the other chapters in this volume bring this up to date.
∗ Corresponding author. Tel.: +44 20 7594 2127.
E-mail address: s.dilworth@imperial.ac.uk (S.M. Dilworth).
2. Discovery of polyoma and SV40
Murine polyoma virus (MPyV) and simian virus 40 (SV40) were
two of the ﬁrst DNA tumour viruses to be discovered. In 1953, Lud-
wik Gross working on the cell free transmission of leukaemia in
newborn mice ﬁrst reported the existence of another component
in ﬁltrates that promoted the formation of salivary gland carci-
nomas [2]. This work was followed up by Stewart and Eddy who
developed procedures to grow the virus using mouse embryo cells,
thus enabling them to isolate, characterise, and study its prop-
erties. They proposed the name polyoma virus [3] because of its
ability to induce a variety of tumour types when inoculated into
newborn mice, hamsters or rats. Shortly after this, tissue culture
methods were developed for measuring the ability of polyoma to
alter, or transform, cells into a state that resembled closely theprop-
erties of tumour cells isolated directly from the animal [4,5]. These
proceduresusedprimary embryonicﬁbroblasts, but the later devel-
opment of transformable clonal cell lines made the assays more
reliable and reproducible. Cell culture assays enabled the tumori-
genic properties of the virus to be studied outside the animal for
the ﬁrst time, and allowed the phenotypic changes to be exam-
ined at the molecular level. Cell transformation in vitro, including
foci formation or growth in semi-solidmedia, provided the basis for
futuremethods formeasuring the activity of oncogenes and tumour
suppressors.
SV40, isolated from monkey kidney cell lines being used in the
late 1950s to produce polio vaccines, was ﬁrst reported as a new
virus by Sweet in 1960 [6]. The observation that this virus could
induce tumours in hamsters and transform human cells in culture
became a cause for much concern when it was discovered that
potential contamination of simian cell lines used tomake polio vac-
cine might have resulted in up to 98million children and adults in
1044-579X/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
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theUSAbeing exposed to SV40. Further studies on this topic remain
controversial (reviewed in [7]) and it is still not clear if it has a
role in forming human malignancies. The vacuolated appearance
of infected cells led to the virus being designated as ‘vacuolating
agent’, but this soon became simian virus (SV) 40. As the virus
closely resembled MPyV (by electron microscopy it had compa-
rable size and shape, and its genome had very similar properties),
initially both were placed in the broad papovavirus family. This was
later reorganised into the polyomaviridae and papillomaviridae.
Both MPyV and SV40 rarely caused any deleterious effects to their
host populations in the wild, instead persisting as endemic, harm-
less passengers. Generally, tumour induction in animals occurred
only when large amounts of virus were inoculated into newborns,
or the animals were immunocompromised.
2.1. Development of genetic engineering
The close similarity betweenMPyVandSV40allowedearlywork
on them to progress in parallel, with ﬁndings in one quickly being
conﬁrmed in the other. Propagation of both viruses in cultured cells
provided sufﬁcient material for biochemical studies, leading to the
discovery that their virions contain only protein and DNA, and the
genomes consist of closed, double-stranded (ds)DNAcircles. Danna
and Nathans in 1971 ﬁrst had the idea that the recently identiﬁed
bacterial restrictionendonucleases [8] shouldproducespeciﬁc frag-
ments of SV40 DNA that could be used to develop a physical map
of the genome [9]. Their map, and the one subsequently produced
for MPyV [10], made it possible to localise speciﬁc biological func-
tions onto the DNA genomes through complementation between
deﬁned pieces of DNA and viral mutants, producing a novel form of
‘advanced genetics’. Characterisation of the viral genomes contin-
ued rapidly until the complete nucleotide sequence of SV40 DNA
was determined in 1978 [11,12] and that of MPyV about a year later
[13–15] using DNA sequencing technology facilitated by the use of
restriction enzyme fragments. This use of restriction enzymes to
generate precise DNA fragments, and so map functions to speciﬁc
sequences, has been used extensively by molecular biologists ever
since.
Following on from the development of the viral physical maps,
another landmark achievement in molecular biology was made
when Paul Berg’s group realised that SV40 might be used as a
vehicle to carry genes from other organisms into mammalian cells.
Buildingonexisting techniques to insert bacterial [16], theneukary-
otic genes, into restriction sites in SV40, they then exploited the
‘recombinant’ viral genomes to introduce these ‘foreign’ pieces of
DNA into cells in culture [17,18]. This work marked the beginning
of the ﬁeld of genetic engineering as the techniques were quickly
adapted and improved elsewhere. In particular, the ligation tech-
nique was used to insert DNA fragments into bacterial plasmids for
production of unlimited amounts of speciﬁc DNA for a variety of
purposes, one of the key technologies of current molecular biology.
The use of viruses to carry genetic information into cells has also
become one of the main approaches being explored for medical
purposes in the gene therapy ﬁeld.
3. Viral life cycle
3.1. Virion composition
The protein components of SV40 and MPyV consist of the virus-
encoded structural polypeptides synthesised during their late lytic
cycle phase (see below), and histones derived from the infected
cell. The major protein of each virion, denoted VP1, is a polypeptide
about 40–45kDa in size which accounts for almost three quarters
of the total virion protein content. Electron microscopy and X-ray
crystallography have shown that the viral capsids are made up of
360 copies of VP1, arranged in a simple icosahedron, and 72 copies
of the minor polypeptides (VP2 and VP3), probably located inside
the core and coordinating interactions between the outer VP1 shell
and the genome chromatin. The virions also contain cellular core
histones H2A, H2B, H3 and H4 associated with the viral genome
to assemble a chromatin structure similar to that of their hosts.
Interestingly, there appears to be no H1 present and the H3 and H4
are highly acetylated. The signiﬁcance of these two observations
are not clear, though recent studies of chromatin acetylation and
gene transcription control suggests theymayplay a part in ensuring
high levels of transcription from the viral genome, or have a role in
assembly of the chromatin and/or virion.
3.2. Lytic infection versus transformation
Once in vitro systems were established that allowed MPyV and
SV40 to replicate or transformcultured cells itwas possible to study
the lytic cycle and transformation indetail. Theﬁrstﬁndingwas that
not all cells support a replicative cycle; cells could be divided into
‘permissive’ and ‘non’, or ‘semi’, permissive hosts. For MPyV, many
mouse cells are permissive and support a lytic infection, making
it difﬁcult to establish transformed murine cells. However, ham-
ster and rat cells are semi-permissive and survive in high numbers
after infection. A signiﬁcant number of these surviving cells have
stably acquired an altered phenotype, designated as ‘transformed’.
For SV40, many simian cell lines are permissive, whereas mouse,
rat, and hamster cells are non-permissive. Permissivity is a dom-
inant trait, that is, a non-permissive cell fused with a permissive
cell supports a lytic cycle. It is possible, though very rare, to isolate
transformed cells frompermissive cultures, indicating the ability to
transform is not restricted to non-permissive cells. Transformation
appears to be a characteristic of a failed lytic infection, either asso-
ciated with the properties of the host cell, or the defective nature
of the virus used.
In the lytic cycle, virus absorbs onto the cell surface probably
via receptor/VP1 interactions allowing it to enter the cell by invagi-
nation, subsequently to be transported to the nucleus (reviewed in
[19]). The genome is then uncoated and RNA transcription of one
half, the so-called ‘early’ region, of the genome begins. This is fol-
lowed by translation of these RNAs to produce ‘early’ proteins, one
of which is large T-antigen (LT; see T-antigen section below). LT
binds to a speciﬁc region of the viral genome, where it promotes
the initiation of DNA synthesis thus deﬁning the area as the ‘origin
of replication’. LT binding to the genome also promotes a transcrip-
tional switch from the early to late promoter, both of which lie in
close proximity to the viral replication origin. The switch initiates
RNA synthesis from the other, ‘late’, DNA strand, which then acts as
mRNA for translation of the late proteins. These include the three
virion proteins that self assemble around the replicated genome
to form new mature virions, which are released by a mechanism
involving cell lysis. MPyV and SV40 replicate their genomes by a
similar mechanism to that used by the host cell, and for many years
have provided model systems for research into DNA replication
[20–22]. These studies led to the characterisation of many of the
key mechanisms involved in eukaryotic DNA replication, includ-
ing the discovery of eukaryotic ‘DNA untwisting enzyme’ or DNA
topoisomerase [23], now a target of a number of anti-cancer drugs.
MPyV and SV40 have proved easy to propagate in tissue culture
cells, but cannot be isolated from tumour material, thus raising
an important early question. Does the viral-induced neoplasia
require the incorporation of viral genes into the cellular genome
and continued expression as a provirus, or does the virus alter the
cell, and then disappear by a process called “hit and run”? This
question was answered deﬁnitively for MPyV when viral RNA was
detected in transformed cells and continued viral gene expression
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demonstrated. Later experiments showed that the viral DNA was
integrated into the host genome, ﬁrmly establishing a provirus
mechanism. A similar conclusion was reached for SV40 when
fusing a virus-transformed cell with a permissive cell was shown
to result in a productive infection, demonstrating clearly that the
intact SV40 viral information had remainedwithin the transformed
cell. Later experiments on digests of the host DNA containing inte-
grated provirus showed that there was little, if any, speciﬁcity in
the site of integration of the virus. Instead, viral integration into
the host genome appeared to be essentially random.
4. Genetics and RNA splicing
The small size of the viral genome raised hopes that genetic
methodologies could be used to identify the viral genes required
for both lytic infections and tumour induction, and to deﬁne their
actions. Temperature sensitive A (tsA) mutants of MPyV were the
ﬁrst tobe isolated [24]; thesemutantspromoteda full lytic infection
at 32 ◦C, but not at 39 ◦C. Infection at the higher, non-permissive,
temperatureproduced early proteins, but failed to initiate viralDNA
synthesis, late gene transcription and capsid protein production.
The mutants were shown to be temperature sensitive for the initi-
ation of transformation, but not for its maintenance. Temperature
sensitivemutantsof SV40werealso isolatedand fell intoﬁvegroups
A, B, C, BC and D based on their complementation properties. The
A group are analogous to the MPyV A mutants, so fail to initiate
viral DNA replication and transformation at 39 ◦C. Unlike MPyV
tsA, SV40 tsA mutants were also unable to maintain transforma-
tion at the restrictive temperature. The B and C groups were late
mutants defective in viral structural proteins, and had no effect on
transformation. Data derived from studies on ts mutants showed
clearly that the transformation defective mutants all mapped onto
the early regions of both viruses, indicating that the late region was
not involved in tumour formation.
As an alternative to the temperature sensitive approach used for
earlier mutant studies, a host range strategy was next employed
to select for MPyV mutants with separate growth properties in
different types of cells. Host range transformation defective (hr-t)
mutants [25] grew in MPyV transformed 3T3 mouse cells but not in
normal 3T3 cells, and could be complemented in a lytic infection by
the tsA mutants, thus suggesting a separate gene. The hr-t mutants
failed to transform cells in culture, or induce tumours in animals,
and mapped again to the early region of the virus. No analogous
mutations could be found in SV40, one of the ﬁrst indications that
there was a fundamental mechanistic difference between the two
viruses. A third group of MPyV mutants to be isolated contained
alterations in another region of the viral genome [26]. These were
designated mlt mutants after the effect they had on the size of the
viral early proteins (the T-antigens). These mutants varied in their
transforming and lytic growth properties, and were characterised
by size and biological property alterations in the middle T and large
T-antigens. Again, no analogous mutants were found for SV40.
At this stage, it was beginning to become apparent that classi-
cal explanations and assumptions were inadequate to explain the
genetic results coming from these modiﬁed viruses. There simply
was not enough DNA to encode the number and/or variety of pro-
teins predicted. An explanation for the data became clearer when
work in another DNA tumour virus, adenovirus 5, demonstrated
that mRNA need not be contiguous with DNA, but could be com-
posed of ‘spliced’ pieces [27]. This was quickly shown to apply to
the genes from other viruses, including SV40 [28] and MPyV, and
to cellular genes. This suggested how multiple, related, but func-
tionally separate, proteins could be generated from a small piece
of DNA. Much of what we know of the existence and mechanisms
involved in RNA splicing has come from original work on the DNA
tumour viruses.
5. T-antigens and associated proteins
Shortly after MPyV was discovered, two groups demonstrated
that an immune reaction could be mounted against cells it had
transformed, which could prevent the development of MPyV
induced cancer. They identiﬁed a new antigen on the surface of
the transformed cells which could prevent transplantation of cells
into syngeneic animals, and so was designated TSTA (tumour spe-
ciﬁc transplantation antigen). TSTA was speciﬁc for MPyV induced
tumours, suggesting a response directed against the proteins that
were foreign to the host, hence, viral in origin. Later, complementa-
tion ﬁxation and immunoﬂuorescence studies demonstrated that
sera from tumour bearing animals recognised another antigen in
bothSV40andpolyomatransformedcells. This tumour, orT, antigen
[29,30]was nuclear in location and again speciﬁc for the virus used;
there was no cross reaction between SV40 and MPyV transformed
cells. T-antigen reactivity appeared in lytically infected cells of both
viruses soonafter infection,whether permissive or non-permissive,
and before viral DNA synthesis started.
Over the next few years, procedures were established for using
the sera from tumour bearing animals to immunoprecipitate pro-
teins from virally infected or transformed cells for further analysis.
Cells infected by both SV40 and MPyV contained a protein with a
molecular weight of 90–100kDa, which was nuclear in location.
This protein was determined to be thermolabile when a tsA mutant
virus was used at the non-permissive temperature, and could be
synthesised in in vitro translation systems using viral cRNA or
infected cell mRNA selected by hybridisation to viral DNA, demon-
strating T-antigen to be virally encoded. Closer analysis of gels from
in vitro translation and immunoprecipitation approaches showed
that both viruses also express a smaller, and related, 17–22kDa
polypeptide, leading to the heavier protein being designated large
T (LT) and the lighter one, small T (ST, or t) antigen.
5.1. Discovery of middle T and p53
Other polypeptides were also observed to be precipitated by
tumour sera from tumour cell lysates, most notably a protein
approximately 55kDa in size [31]. All other MPyV and SV40 protein
comparisons to this point had shown similar results, so it was sur-
prising when the results obtained on this polypeptide conﬂicted.
Peptide mapping experiments showed that the 55kDa protein in
MPyV-infected cells was virus-encoded, and related to the other
two T-antigens; it was thus designated middle T-antigen (MT)
[32–34]. The 53kDa protein identiﬁed by Lane (in the Crawford
laboratory) and Linzer (in the Levine group) in immunoprecipitates
from SV40 infected cells did not share peptides with the other T-
antigens, however, and proved to be cell derived [35,36]. Initially, it
was called nvt (non-viral T-antigen), but once it was realised that
the protein was present as a consequence of its association with
SV40LT, itwas renamedp53. Studyof thisproteinhasdemonstrated
that it plays a major role in preventing human cancer formation
by acting as a tumour suppressor. Two methods of p53 inactiva-
tion have been found in viral systems: SV40 LT stabilised p53, but
inactivated it; adenovirus E1B and human papillomavirus (HPV)
E6 target p53 for ubiquitinylation, and hence, degradation. Despite
the almost opposite effects on p53 levels, all three viruses lead to
the same consequences, that is, inactivation of the cell cycle checks
and the induction of apoptosis normally induced by p53. MPyV LT
has never been shown to bind p53 nor transform cells, and appears
unique among theDNA tumour viruses in not targeting p53 directly
[37].
The identiﬁcation of MT accounted for the diverse transform-
ing properties of SV40 and MPyV, both in vitro and in vivo, and the
discrepancies in genetic data noted above. Consequently, work on
MPyV and SV40 diverged from this time onwards, but perhaps this
Author's personal copy
214 S.J.L. Atkin et al. / Seminars in Cancer Biology 19 (2009) 211–217
could have been predicated. Pontén as early as 1971 [38] had noted
that the phenotypes of MPyV and SV40 transformed cells were
very different. Whereas MPyV transformed cells had an irregular
growth pattern, SV40 transformed cells appeared to be deregu-
lated with regard to cell division. His conclusion was that the two
viruses probably transform cells by completely different mecha-
nisms, MPyV through alterations to the membranes of cells, SV40
through changes to the control of the cell cycle, a remarkable con-
clusion that eventually was proven by and large to be correct.
5.2. T-antigen sequences and co-operating oncogenes
Numerous strands of research merged in the early 1980s to pro-
vide a comprehensive understanding of the molecular biology of
these viruses. These approaches included: the sequencing of the
viralDNAs that identiﬁedopen reading frames andalloweddetailed
mapping of the viral transcription start, stop and splice points; pep-
tide mapping studies, which showed that each SV40 and MPyV
T-antigen shared N-terminal amino acid sequences; and character-
isation of the T-antigen alterations caused by a number of deﬁned
deletionmutants. Combining thesedata generated a codingmap for
each virus, and hence, the amino acid sequences of the T-antigens
(see Fig. 1).
cDNAs encoding each T-antigen were then cloned, which
provided tools to explore and deﬁne roles for each individual
polypeptide. For SV40, only the LT appeared tobe required for trans-
formation both in culture and animals, although ST augmented this
activity. InMPyV, expressing individual cDNAs showedconclusively
thatMTwas a potent oncogene as suspected from the geneticwork,
Fig. 1. The polyoma virus genome. The closed circular, double-stranded DNA of
mouse polyoma virus is shown with the original HpaII restriction map divisions,
and gene locations (with the later nucleotide numberings in kbase on the inside)
noted. Regions transcribed into mRNA are indicated with the sequences removed by
splicing designated by broken lines, mRNA non-coding regions by solid lines, and
coding regions by boxes with adopted protein designations used. Also noted is the
position of the bi-directional origin of DNA replication. The regions transcribed and
direction of transcription for early and late RNAs is noted by heavy solid lines to
the outside. A similar map drawn for SV40, would omit the middle T-antigen. Minor
RNAs and proteins are omitted here for simplicity.
and on its own could transform established cell lines [39]. Using
individualMPyV cDNAs in a novel series of experiments, the groups
of Kamen and Cuzin showed that MPyV LT and MT performed quite
different roles in altering the phenotype of cells [40,41]: LT altered
the life span of primary rodent cells, converting them into an estab-
lished cell line that, although having altered properties, was not
tumorigenic; MT, on the other hand, was unable to transform pri-
mary cells, but could effectively convert “immortal cells” into a
fully tumorigenic cell. This “dual oncogene” effect was taken up by
others [42,43], setting the stage for future work on the nature of co-
operating oncogenes. Surprisingly, the combination of LT and MT is
still not sufﬁcient to turn primary rodent cells into tumour cells,
ST is also required, and human systems seem to need even more
oncogenes to become fully transformed. Currently, four separate
activities seem to be a minimum requirement for transformation
of human BJ foreskin ﬁbroblasts or early passage HEK cells; these
are SV40 LT, SV40 ST, an activated RAS, and telomerase [44]. The
ability of SV40 LT to immortalise primarymammalian cells has pro-
vided unique reagents that have also added to our knowledge of cell
function and senescence [45]. Thus the viruses and their encoded
proteins continue toprovide insights intohumancell behaviour and
its regulation, or dysregulation.
5.3. Large T-antigen and the function of retinoblastoma proteins
The conclusion drawn from cDNA expression studies that the
T-antigens were solely responsible for the tumour inducing prop-
erties of the viruses concentrated efforts on working out how they
achieved this. The initial search for functional properties of the T-
antigens focussed on direct enzymatic activities. Puriﬁcation of an
SV40 LT–Adenovirus hybrid polypeptide, and material from other
sources, showed LT had speciﬁc DNA binding activity for sequences
at thevirusoriginofDNAreplication.Manypreparationsalsohadan
ATPase activity, shown later tobe associatedwith aDNAunwinding,
or helicase, action. Mapping studies located the sequences respon-
sible for these activities, and mutations demonstrated that DNA
binding and the helicase activity were essential for the replicative
activity of LT, but not for its transforming action. Binding to p53,
however, did correlate with the transforming function of SV40 LT
in most cell types.
Other SV40 LT functions were identiﬁed as a result of experi-
mentsperformed in conjunctionwithadenovirus5. SV40andMPyV
studies suggested that transformation required the formation of
stable complexes between the viral polypeptides and host proteins.
This led to a search for adenovirus E1A binding partners, and the
identiﬁcation of a polypeptide co-immunoprecipitated by anti-E1A
monoclonal antibodies as the product of the retinoblastoma sus-
ceptibility gene, p105Rb [46]. E1A contains two conserved regions
that are essential for its transforming activity. One of these, con-
served region2 (cr2) showsconsiderablehomologywithasequence
in theN-terminal regionofbothSV40andMPyVLT. This SV40region
is required for SV40 LT induced transformation [47], and could func-
tionally replace cr2 when inserted into E1A [48]. E1A cr2 was then
found to be required for interaction with p105Rb, leading to the
demonstration that SV40 and MPyV LT could also bind p105Rb. In
all three cases, interaction required an LXCXE motif present in the
viral proteins. Two other polypeptides found associated with the
same region of E1A, p107 and p130, were subsequently shown to
be closely related to Rb and to interact with both SV40 and MPyV
LTs. Using SV40 LT and E1A as tools, the principles involved in the
control of E2F transcription factor activity by the Rb family of pro-
teins, a primary mechanism in the control of cell cycle entry, have
been determined.
The identiﬁcation of two proteins interacting with LT at
sequences required for its transforming properties centred atten-
tion on ﬁnding other binding partners. To date, SV40 LT has been
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found to associate with p300/CBP, Hsc70, Cul7, Bub1, TEF-1, Nbs1
and Fbw7. A role for LT binding to Rb and p53 in transformation
is clear, but the function of these other proteins is less certain and
requires further substantiation, even in the cases where mutations
that affect binding of a protein reduce the transforming potential
of SV40 LT. Whereas expression of MPyV MT is almost always asso-
ciated with a transformed phenotype, SV40 LT transformation is
much less efﬁcient and is dependent on the cell origin. Conse-
quently, while Rb family and p53 binding by SV40 LT have been
shown tobe sufﬁcient to contribute to transformation in at least one
system [44], the precise number of factors involved in SV40 induced
transformation in vitro, and tumorigenesis in vivo remain unclear.
5.4. Middle T and tyrosine kinases
Interest in the MPyV T-antigens switched focus to the activ-
ity of MT when its potent transforming properties were realised
(reviewed in [49]). MT was ﬁrst found in cell membrane fractions,
notably the plasma membrane, although further work has shown it
to be present inmost other cellmembranes aswell. The demonstra-
tion that the retroviral oncogene v-SRC was associated with kinase
activity, and localisedat theplasmamembrane,promptedanumber
ofMPyV groups to address the question ofwhether therewas also a
kinase present in MT precipitates. An activity that phosphorylated
bothMT itself, and associated immunoprecipitating immunoglobu-
lins, and correlated closely with the transforming ability of MT, was
found [50–52]. In a unique series of experiments [50], the Eckhart
and Hunter laboratory showed that this phosphorylation occurred
on tyrosine residues, and that the kinase activity associated with
v-SRC and many other cellular oncogenes was also speciﬁc for tyro-
sine. This was the ﬁrst time this modiﬁcation had been observed
in mammalian cells, and tyrosine kinases have subsequently been
shown to play a major part in the signalling pathways involved in
regulating cell growth, differentiation, and cancer formation.
Later, it was shown that the kinase activity present in MT
immunoprecipitates was not intrinsic to MT, but instead was a
property of an association between MT and c-SRC [53]. As hap-
pened with the LT and p53 interaction, this result directed the ﬁeld
into searching for polypeptides interacting with MT rather than
ﬁnding intrinsic activities. Over the years, the number of LT and
MT associated molecules has expanded dramatically. It has also
become clear that this is mimicry of the processes by which the
cell itself functions. Most cell signalling and growth control mech-
anisms involve the stimulation of protein–protein interactions to
formmulti-protein complexes that achieve thenecessary signalling
responses. Again, through their copying of normal cell processes,
the viruses have provided insights into the way cells control their
major signalling activities, and how this can malfunction to cause
malignancies.
5.5. PI3K discovery
The development of new anti-peptide andmonoclonal antibody
approaches aided the search for interacting proteins. MT immuno-
precipitates were next found to contain a tyrosine phosphorylated
85kDa polypeptide [54] that correlated with the presence of a lipid
kinase activity and transformation [55,56]. This novel lipid kinase
was shown to phosphorylate the 3′ OH position on phosphatidyl
inositol by the Cantley laboratory [57], sowas designated PI3 kinase
(PI3K). Interestingly, the same molecule was observed associated
with activated growth factor receptors. Interaction between the
85kDa component of PI3K and MT occurred through a tyrosine
site in MT phosphorylated by the associated c-SRC [58], and the
SH2 domain in p85 [59]. This report came at the same time that
other groups were realising that the SH2 domains of p85 were
also involved in binding to phosphorylated growth factor receptors.
Thus, it had an important part in the discovery that SH2 domains
interact with phosphorylated tyrosine motifs, which was found to
be a fundamental component in the mechanisms by which growth
factor receptor signalling occurswithin cells.Work on PI3Khas pro-
gressed rapidly since its discovery, and the pathways initiated by
its action have been shown to play a major role in the tumorigenic
process.
Following on from this, another growth factor receptor associ-
ated polypeptide, ShcA, was identiﬁed in MT immunoprecipitates
[60,61]. MT bound ShcA then interacts with the adapter molecule
Grb2 that, via its associated guanine nucleotide exchange factor,
Sos1, activates Ras. These results supplied a direct link between MT
and the MAP kinase pathway and started to develop our realisa-
tion that MT functions as a permanently active viral homologue
of a growth factor receptor. Based on this conclusion, PLC-1 was
also found to associate with MT [62], although, in this case, disrup-
tion of the binding site had only a small effect on its transforming
properties. Other, unidentiﬁed, polypeptides are observed in MT
immunoprecipitates, indicating this is still an open ﬁeld.
5.6. Middle T, small T and PP2A
Another signiﬁcant advance in identifying T-antigen interact-
ing proteins came when MT and the STs of MPyV and SV40 were
shown to bind to polypeptides with reported molecular weights of
55–65kDa and 30–35kDa [63], which were then identiﬁed as the
PR65 (A) and PR35 (C) subunits of the core dimer of protein phos-
phatase 2A (PP2A) [64,65]. It is still not clear how this interaction
functions to inﬂuence cell activity at the molecular level, but all of
the phenotypic properties induced by ST seem to depend on it. The
general consensus now is that tight binding of ST andMT to the core
dimer displaces some of the regulatory B subunits normally part of
PP2A, changing its substrate speciﬁcity. The exact nature of these
substrates remains elusive, though c-myc stability and Akt activ-
ity are suggested targets. Interestingly, in MT the interaction with
PP2A has also been found to be required for the subsequent associ-
ation with c-SRC, although it is not clear why [66]. The requirement
for ST in augmenting tumour formation by LT, as a component of
transforming human primary cells, and that PP2A is targeted by
many tumour viruses, suggests that alterations in PP2Aactivitymay
be a key event in human carcinogenesis [67]. Whether alterations
in PP2A activity are eventually recognised to be as signiﬁcant in
tumour formation as p53 and PI3K remains to be determined.
6. Concluding remarks
To replicate in the normally quiescent cells of a multicellular
organism, all viruses must ﬁnd ways of stimulating the infected
cell to enter the cell cycle in order to provide the appropriate cell
environment for replication of the viral genome. This they achieve
by expressing a mitogenic protein early in the lytic cycle. As the cell
normally dies as a consequence of infection, these proteins have
no further affect. However, should expression of the early proteins
become uncoupled from the normal lytic events, continued expres-
sion of a mitogenic protein has the potential to cause uncontrolled
cell proliferation, and eventually, tumorigenesis. The potential for
tumour induction by a normally lytic virus is simply related to how
often during an infection expression of the mitogenic proteins can
be maintained and uncoupled from the remaining parts of the lytic
cycle. The small, simple nature of the polyoma viruses makes them
heavily dependent on interactions with the infected cell, making
errors in the lytic process, and hence prolonged expression of the T-
antigens, relatively frequent. This simplicity also makes MPyV and
SV40 easy to study, so providing us with nearly ideal models for
exploring mammalian cell behaviour.
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This short journey through the history of MPyV and SV40
research has concentrated on seminal experiments and discoveries,
focussing on those that inﬂuenced work outside the viral studies.
These viruses are limited in coding potential, which means they
must precisely target the regulatory processes that control the cell
cycle. It is this aspect that has made them such important tools in
our efforts to understand these control mechanisms. Evolution of
these viruseshas identiﬁed thekeyevents controlling cell growth in
mammalian cells, to determine what these are, and how they work,
we simply have to study the proteins targeted by the virus. This
explains why MPyV and SV40 have had such a major impact on the
study of the molecular mechanisms underlying cancer formation.
Thegenerationof transgenic animals expressingvariousT-antigens,
particularly SV40 LT and MPyV MT, in speciﬁc tissue locations, are
still providing major insights into processes required for tumori-
genesis, indicating that this work is far from over. Although the
pace of discoveriesmade using these small viruses has slowed, they
still have a vital role to play in our attempts to understand, and
eventually overcome, cancer.
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